6	CIMZIA.xml:S1:4:1	O
ADVERSE	CIMZIA.xml:S1:6:7	O
REACTIONS	CIMZIA.xml:S1:14:9	O

EXCERPT	CIMZIA.xml:S1:27:7	O
:	CIMZIA.xml:S1:34:1	O
The	CIMZIA.xml:S1:38:3	O
most	CIMZIA.xml:S1:42:4	O
common	CIMZIA.xml:S1:47:6	O
adverse	CIMZIA.xml:S1:54:7	O
reactions	CIMZIA.xml:S1:62:9	O
(	CIMZIA.xml:S1:72:1	O
incidence	CIMZIA.xml:S1:73:9	O
7%	CIMZIA.xml:S1:85:2	O
and	CIMZIA.xml:S1:88:3	O
higher	CIMZIA.xml:S1:92:6	O
than	CIMZIA.xml:S1:99:4	O
placebo	CIMZIA.xml:S1:104:7	O
)	CIMZIA.xml:S1:111:1	O
:	CIMZIA.xml:S1:112:1	O
upper	CIMZIA.xml:S1:114:5	B-AdverseReaction
respiratory	CIMZIA.xml:S1:120:11	I-AdverseReaction
tract	CIMZIA.xml:S1:132:5	I-AdverseReaction
infection	CIMZIA.xml:S1:138:9	I-AdverseReaction
,	CIMZIA.xml:S1:147:1	O
rash	CIMZIA.xml:S1:149:4	B-AdverseReaction
,	CIMZIA.xml:S1:153:1	O
and	CIMZIA.xml:S1:155:3	O
urinary	CIMZIA.xml:S1:159:7	B-AdverseReaction
tract	CIMZIA.xml:S1:167:5	I-AdverseReaction
infection	CIMZIA.xml:S1:173:9	I-AdverseReaction
(	CIMZIA.xml:S1:183:1	O
6.1	CIMZIA.xml:S1:186:3	O
)	CIMZIA.xml:S1:191:1	O
To	CIMZIA.xml:S1:194:2	O
report	CIMZIA.xml:S1:197:6	O
SUSPECTED	CIMZIA.xml:S1:204:9	O
ADVERSE	CIMZIA.xml:S1:214:7	O
REACTIONS	CIMZIA.xml:S1:222:9	O
,	CIMZIA.xml:S1:231:1	O
contact	CIMZIA.xml:S1:233:7	O
UCB	CIMZIA.xml:S1:241:3	O
,	CIMZIA.xml:S1:244:1	O
Inc	CIMZIA.xml:S1:246:3	O
.	CIMZIA.xml:S1:249:1	O

at	CIMZIA.xml:S1:251:2	O
1	CIMZIA.xml:S1:254:1	O
-	CIMZIA.xml:S1:255:1	O
866	CIMZIA.xml:S1:256:3	O
-	CIMZIA.xml:S1:259:1	O
822	CIMZIA.xml:S1:260:3	O
-	CIMZIA.xml:S1:263:1	O
0068	CIMZIA.xml:S1:264:4	O
or	CIMZIA.xml:S1:269:2	O
FDA	CIMZIA.xml:S1:272:3	O
at	CIMZIA.xml:S1:276:2	O
1	CIMZIA.xml:S1:279:1	O
-	CIMZIA.xml:S1:280:1	O
800	CIMZIA.xml:S1:281:3	O
-	CIMZIA.xml:S1:284:1	O
FDA	CIMZIA.xml:S1:285:3	O
-	CIMZIA.xml:S1:288:1	O
1088	CIMZIA.xml:S1:289:4	O
or	CIMZIA.xml:S1:294:2	O
www	CIMZIA.xml:S1:297:3	O
.	CIMZIA.xml:S1:300:1	O
fda	CIMZIA.xml:S1:301:3	O
.	CIMZIA.xml:S1:304:1	O
gov	CIMZIA.xml:S1:305:3	O
medwatch	CIMZIA.xml:S1:309:8	O
.	CIMZIA.xml:S1:317:1	O

6.1	CIMZIA.xml:S1:329:3	O

Clinical	CIMZIA.xml:S1:333:8	O
Trials	CIMZIA.xml:S1:342:6	O
Experience	CIMZIA.xml:S1:349:10	O

The	CIMZIA.xml:S1:363:3	O
most	CIMZIA.xml:S1:367:4	O
serious	CIMZIA.xml:S1:372:7	O
adverse	CIMZIA.xml:S1:380:7	O
reactions	CIMZIA.xml:S1:388:9	O
were	CIMZIA.xml:S1:398:4	O
:	CIMZIA.xml:S1:402:1	O

Serious	CIMZIA.xml:S1:411:7	B-Severity
Infections	CIMZIA.xml:S1:419:10	B-AdverseReaction
[	CIMZIA.xml:S1:430:1	O
see	CIMZIA.xml:S1:431:3	O
Warnings	CIMZIA.xml:S1:436:8	O
and	CIMZIA.xml:S1:445:3	O
Precautions	CIMZIA.xml:S1:449:11	O
(	CIMZIA.xml:S1:461:1	O
5.1	CIMZIA.xml:S1:462:3	O
)	CIMZIA.xml:S1:465:1	O
]	CIMZIA.xml:S1:468:1	O

Malignancies	CIMZIA.xml:S1:476:12	B-AdverseReaction
[	CIMZIA.xml:S1:489:1	O
see	CIMZIA.xml:S1:490:3	O
Warnings	CIMZIA.xml:S1:495:8	O
and	CIMZIA.xml:S1:504:3	O
Precautions	CIMZIA.xml:S1:508:11	O
(	CIMZIA.xml:S1:520:1	O
5.2	CIMZIA.xml:S1:521:3	O
)	CIMZIA.xml:S1:524:1	O
]	CIMZIA.xml:S1:527:1	O

Heart	CIMZIA.xml:S1:535:5	B-AdverseReaction
Failure	CIMZIA.xml:S1:541:7	I-AdverseReaction
[	CIMZIA.xml:S1:549:1	O
see	CIMZIA.xml:S1:550:3	O
Warnings	CIMZIA.xml:S1:555:8	O
and	CIMZIA.xml:S1:564:3	O
Precautions	CIMZIA.xml:S1:568:11	O
(	CIMZIA.xml:S1:580:1	O
5.3	CIMZIA.xml:S1:581:3	O
)	CIMZIA.xml:S1:584:1	O
]	CIMZIA.xml:S1:587:1	O

Because	CIMZIA.xml:S1:595:7	O
clinical	CIMZIA.xml:S1:603:8	O
studies	CIMZIA.xml:S1:612:7	O
are	CIMZIA.xml:S1:620:3	O
conducted	CIMZIA.xml:S1:624:9	O
under	CIMZIA.xml:S1:634:5	O
widely	CIMZIA.xml:S1:640:6	O
varying	CIMZIA.xml:S1:647:7	O
and	CIMZIA.xml:S1:655:3	O
controlled	CIMZIA.xml:S1:659:10	O
conditions	CIMZIA.xml:S1:670:10	O
,	CIMZIA.xml:S1:680:1	O
adverse	CIMZIA.xml:S1:682:7	O
reaction	CIMZIA.xml:S1:690:8	O
rates	CIMZIA.xml:S1:699:5	O
observed	CIMZIA.xml:S1:705:8	O
in	CIMZIA.xml:S1:714:2	O
clinical	CIMZIA.xml:S1:717:8	O
studies	CIMZIA.xml:S1:726:7	O
of	CIMZIA.xml:S1:734:2	O
a	CIMZIA.xml:S1:737:1	O
drug	CIMZIA.xml:S1:739:4	O
cannot	CIMZIA.xml:S1:744:6	O
be	CIMZIA.xml:S1:751:2	O
directly	CIMZIA.xml:S1:754:8	O
compared	CIMZIA.xml:S1:763:8	O
to	CIMZIA.xml:S1:772:2	O
rates	CIMZIA.xml:S1:775:5	O
in	CIMZIA.xml:S1:781:2	O
the	CIMZIA.xml:S1:784:3	O
clinical	CIMZIA.xml:S1:788:8	O
studies	CIMZIA.xml:S1:797:7	O
of	CIMZIA.xml:S1:805:2	O
another	CIMZIA.xml:S1:808:7	O
drug	CIMZIA.xml:S1:816:4	O
,	CIMZIA.xml:S1:820:1	O
and	CIMZIA.xml:S1:822:3	O
may	CIMZIA.xml:S1:826:3	O
not	CIMZIA.xml:S1:830:3	O
predict	CIMZIA.xml:S1:834:7	O
the	CIMZIA.xml:S1:842:3	O
rates	CIMZIA.xml:S1:846:5	O
observed	CIMZIA.xml:S1:852:8	O
in	CIMZIA.xml:S1:861:2	O
a	CIMZIA.xml:S1:864:1	O
broader	CIMZIA.xml:S1:866:7	O
patient	CIMZIA.xml:S1:874:7	O
population	CIMZIA.xml:S1:882:10	O
in	CIMZIA.xml:S1:893:2	O
clinical	CIMZIA.xml:S1:896:8	O
practice	CIMZIA.xml:S1:905:8	O
.	CIMZIA.xml:S1:913:1	O

In	CIMZIA.xml:S1:919:2	O

premarketing	CIMZIA.xml:S1:922:12	O
controlled	CIMZIA.xml:S1:935:10	O
trials	CIMZIA.xml:S1:946:6	O
of	CIMZIA.xml:S1:953:2	O
all	CIMZIA.xml:S1:956:3	O
patient	CIMZIA.xml:S1:960:7	O
populations	CIMZIA.xml:S1:968:11	O
combined	CIMZIA.xml:S1:980:8	O
the	CIMZIA.xml:S1:989:3	O
most	CIMZIA.xml:S1:993:4	O
common	CIMZIA.xml:S1:998:6	O
adverse	CIMZIA.xml:S1:1005:7	O
reactions	CIMZIA.xml:S1:1013:9	O
(	CIMZIA.xml:S1:1023:1	O
8%	CIMZIA.xml:S1:1027:2	O
)	CIMZIA.xml:S1:1029:1	O
were	CIMZIA.xml:S1:1031:4	O
upper	CIMZIA.xml:S1:1036:5	B-AdverseReaction
respiratory	CIMZIA.xml:S1:1042:11	I-AdverseReaction
infections	CIMZIA.xml:S1:1054:10	I-AdverseReaction
(	CIMZIA.xml:S1:1065:1	O
18%	CIMZIA.xml:S1:1066:3	O
)	CIMZIA.xml:S1:1069:1	O
,	CIMZIA.xml:S1:1070:1	O
rash	CIMZIA.xml:S1:1072:4	B-AdverseReaction
(	CIMZIA.xml:S1:1077:1	O
9%	CIMZIA.xml:S1:1078:2	O
)	CIMZIA.xml:S1:1080:1	O
and	CIMZIA.xml:S1:1082:3	O
urinary	CIMZIA.xml:S1:1086:7	B-AdverseReaction
tract	CIMZIA.xml:S1:1094:5	I-AdverseReaction
infections	CIMZIA.xml:S1:1100:10	I-AdverseReaction
(	CIMZIA.xml:S1:1111:1	O
8%	CIMZIA.xml:S1:1112:2	O
)	CIMZIA.xml:S1:1114:1	O
.	CIMZIA.xml:S1:1115:1	O

Adverse	CIMZIA.xml:S1:1125:7	O
Reactions	CIMZIA.xml:S1:1133:9	O
Most	CIMZIA.xml:S1:1143:4	O
Commonly	CIMZIA.xml:S1:1148:8	O
Leading	CIMZIA.xml:S1:1157:7	O
to	CIMZIA.xml:S1:1165:2	O
Discontinuation	CIMZIA.xml:S1:1168:15	O
of	CIMZIA.xml:S1:1184:2	O
Treatment	CIMZIA.xml:S1:1187:9	O
in	CIMZIA.xml:S1:1197:2	O
Premarketing	CIMZIA.xml:S1:1200:12	O
Controlled	CIMZIA.xml:S1:1213:10	O
Trials	CIMZIA.xml:S1:1224:6	O

The	CIMZIA.xml:S1:1237:3	O
proportion	CIMZIA.xml:S1:1241:10	O
of	CIMZIA.xml:S1:1252:2	O
patients	CIMZIA.xml:S1:1255:8	O
with	CIMZIA.xml:S1:1264:4	O
Crohn	CIMZIA.xml:S1:1269:5	O
's	CIMZIA.xml:S1:1274:2	O
disease	CIMZIA.xml:S1:1277:7	O
who	CIMZIA.xml:S1:1285:3	O
discontinued	CIMZIA.xml:S1:1289:12	O
treatment	CIMZIA.xml:S1:1302:9	O
due	CIMZIA.xml:S1:1312:3	O
to	CIMZIA.xml:S1:1316:2	O
adverse	CIMZIA.xml:S1:1319:7	O
reactions	CIMZIA.xml:S1:1327:9	O
in	CIMZIA.xml:S1:1337:2	O
the	CIMZIA.xml:S1:1340:3	O
controlled	CIMZIA.xml:S1:1344:10	O
clinical	CIMZIA.xml:S1:1355:8	O
studies	CIMZIA.xml:S1:1364:7	O
was	CIMZIA.xml:S1:1372:3	O
8%	CIMZIA.xml:S1:1376:2	O
for	CIMZIA.xml:S1:1379:3	O
CIMZIA	CIMZIA.xml:S1:1383:6	O
and	CIMZIA.xml:S1:1390:3	O
7%	CIMZIA.xml:S1:1394:2	O
for	CIMZIA.xml:S1:1397:3	O
placebo	CIMZIA.xml:S1:1401:7	O
.	CIMZIA.xml:S1:1408:1	O

The	CIMZIA.xml:S1:1410:3	O
most	CIMZIA.xml:S1:1414:4	O
common	CIMZIA.xml:S1:1419:6	O
adverse	CIMZIA.xml:S1:1426:7	O
reactions	CIMZIA.xml:S1:1434:9	O
leading	CIMZIA.xml:S1:1444:7	O
to	CIMZIA.xml:S1:1452:2	O
the	CIMZIA.xml:S1:1455:3	O
discontinuation	CIMZIA.xml:S1:1459:15	O
of	CIMZIA.xml:S1:1475:2	O
CIMZIA	CIMZIA.xml:S1:1478:6	O
(	CIMZIA.xml:S1:1485:1	O
for	CIMZIA.xml:S1:1486:3	O
at	CIMZIA.xml:S1:1490:2	O
least	CIMZIA.xml:S1:1493:5	O
2	CIMZIA.xml:S1:1499:1	O
patients	CIMZIA.xml:S1:1501:8	O
and	CIMZIA.xml:S1:1510:3	O
with	CIMZIA.xml:S1:1514:4	O
a	CIMZIA.xml:S1:1519:1	O
higher	CIMZIA.xml:S1:1521:6	O
incidence	CIMZIA.xml:S1:1528:9	O
than	CIMZIA.xml:S1:1538:4	O
placebo	CIMZIA.xml:S1:1543:7	O
)	CIMZIA.xml:S1:1550:1	O
were	CIMZIA.xml:S1:1552:4	O
abdominal	CIMZIA.xml:S1:1557:9	B-AdverseReaction
pain	CIMZIA.xml:S1:1567:4	I-AdverseReaction
(	CIMZIA.xml:S1:1572:1	O
0.4%	CIMZIA.xml:S1:1573:4	O
CIMZIA	CIMZIA.xml:S1:1578:6	O
,	CIMZIA.xml:S1:1584:1	O
0.2%	CIMZIA.xml:S1:1586:4	O
placebo	CIMZIA.xml:S1:1591:7	O
)	CIMZIA.xml:S1:1598:1	O
,	CIMZIA.xml:S1:1599:1	O
diarrhea	CIMZIA.xml:S1:1601:8	B-AdverseReaction
(	CIMZIA.xml:S1:1610:1	O
0.4%	CIMZIA.xml:S1:1611:4	O
CIMZIA	CIMZIA.xml:S1:1616:6	O
,	CIMZIA.xml:S1:1622:1	O
0%	CIMZIA.xml:S1:1624:2	O
placebo	CIMZIA.xml:S1:1627:7	O
)	CIMZIA.xml:S1:1634:1	O
,	CIMZIA.xml:S1:1635:1	O
and	CIMZIA.xml:S1:1637:3	O
intestinal	CIMZIA.xml:S1:1641:10	B-AdverseReaction
obstruction	CIMZIA.xml:S1:1652:11	I-AdverseReaction
(	CIMZIA.xml:S1:1664:1	O
0.4%	CIMZIA.xml:S1:1665:4	O
CIMZIA	CIMZIA.xml:S1:1670:6	O
,	CIMZIA.xml:S1:1676:1	O
0%	CIMZIA.xml:S1:1678:2	O
placebo	CIMZIA.xml:S1:1681:7	O
)	CIMZIA.xml:S1:1688:1	O
.	CIMZIA.xml:S1:1689:1	O

The	CIMZIA.xml:S1:1695:3	O
proportion	CIMZIA.xml:S1:1699:10	O
of	CIMZIA.xml:S1:1710:2	O
patients	CIMZIA.xml:S1:1713:8	O
with	CIMZIA.xml:S1:1722:4	O
rheumatoid	CIMZIA.xml:S1:1727:10	O
arthritis	CIMZIA.xml:S1:1738:9	O
who	CIMZIA.xml:S1:1748:3	O
discontinued	CIMZIA.xml:S1:1752:12	O
treatment	CIMZIA.xml:S1:1765:9	O
due	CIMZIA.xml:S1:1775:3	O
to	CIMZIA.xml:S1:1779:2	O
adverse	CIMZIA.xml:S1:1782:7	O
reactions	CIMZIA.xml:S1:1790:9	O
in	CIMZIA.xml:S1:1800:2	O
the	CIMZIA.xml:S1:1803:3	O
controlled	CIMZIA.xml:S1:1807:10	O
clinical	CIMZIA.xml:S1:1818:8	O
studies	CIMZIA.xml:S1:1827:7	O
was	CIMZIA.xml:S1:1835:3	O
5%	CIMZIA.xml:S1:1839:2	O
for	CIMZIA.xml:S1:1842:3	O
CIMZIA	CIMZIA.xml:S1:1846:6	O
and	CIMZIA.xml:S1:1853:3	O
2.5%	CIMZIA.xml:S1:1857:4	O
for	CIMZIA.xml:S1:1862:3	O
placebo	CIMZIA.xml:S1:1866:7	O
.	CIMZIA.xml:S1:1873:1	O

The	CIMZIA.xml:S1:1875:3	O
most	CIMZIA.xml:S1:1879:4	O
common	CIMZIA.xml:S1:1884:6	O
adverse	CIMZIA.xml:S1:1891:7	O
reactions	CIMZIA.xml:S1:1899:9	O
leading	CIMZIA.xml:S1:1909:7	O
to	CIMZIA.xml:S1:1917:2	O
discontinuation	CIMZIA.xml:S1:1920:15	O
of	CIMZIA.xml:S1:1936:2	O
CIMZIA	CIMZIA.xml:S1:1939:6	O
were	CIMZIA.xml:S1:1946:4	O
tuberculosis	CIMZIA.xml:S1:1951:12	B-AdverseReaction
infections	CIMZIA.xml:S1:1964:10	I-AdverseReaction
(	CIMZIA.xml:S1:1975:1	O
0.5%	CIMZIA.xml:S1:1976:4	O
)	CIMZIA.xml:S1:1980:1	O
;	CIMZIA.xml:S1:1981:1	O
and	CIMZIA.xml:S1:1983:3	O
pyrexia	CIMZIA.xml:S1:1987:7	B-AdverseReaction
,	CIMZIA.xml:S1:1994:1	O
urticaria	CIMZIA.xml:S1:1996:9	B-AdverseReaction
,	CIMZIA.xml:S1:2005:1	O
pneumonia	CIMZIA.xml:S1:2007:9	B-AdverseReaction
,	CIMZIA.xml:S1:2016:1	O
and	CIMZIA.xml:S1:2018:3	O
rash	CIMZIA.xml:S1:2022:4	B-AdverseReaction
(	CIMZIA.xml:S1:2027:1	O
0.3%	CIMZIA.xml:S1:2028:4	O
)	CIMZIA.xml:S1:2032:1	O
.	CIMZIA.xml:S1:2033:1	O

Controlled	CIMZIA.xml:S1:2043:10	O
Studies	CIMZIA.xml:S1:2054:7	O
with	CIMZIA.xml:S1:2062:4	O
Crohn	CIMZIA.xml:S1:2067:5	O
's	CIMZIA.xml:S1:2072:2	O
Disease	CIMZIA.xml:S1:2075:7	O

The	CIMZIA.xml:S1:2089:3	O
data	CIMZIA.xml:S1:2093:4	O
described	CIMZIA.xml:S1:2098:9	O
below	CIMZIA.xml:S1:2108:5	O
reflect	CIMZIA.xml:S1:2114:7	O
exposure	CIMZIA.xml:S1:2122:8	O
to	CIMZIA.xml:S1:2131:2	O
CIMZIA	CIMZIA.xml:S1:2134:6	O
at	CIMZIA.xml:S1:2141:2	O
400	CIMZIA.xml:S1:2144:3	O
mg	CIMZIA.xml:S1:2148:2	O
subcutaneous	CIMZIA.xml:S1:2151:12	O
dosing	CIMZIA.xml:S1:2164:6	O
in	CIMZIA.xml:S1:2171:2	O
studies	CIMZIA.xml:S1:2174:7	O
of	CIMZIA.xml:S1:2182:2	O
patients	CIMZIA.xml:S1:2185:8	O
with	CIMZIA.xml:S1:2194:4	O
Crohn	CIMZIA.xml:S1:2199:5	O
's	CIMZIA.xml:S1:2204:2	O
disease	CIMZIA.xml:S1:2207:7	O
.	CIMZIA.xml:S1:2214:1	O

In	CIMZIA.xml:S1:2216:2	O
the	CIMZIA.xml:S1:2219:3	O
safety	CIMZIA.xml:S1:2223:6	O
population	CIMZIA.xml:S1:2230:10	O
in	CIMZIA.xml:S1:2241:2	O
controlled	CIMZIA.xml:S1:2244:10	O
studies	CIMZIA.xml:S1:2255:7	O
,	CIMZIA.xml:S1:2262:1	O
a	CIMZIA.xml:S1:2264:1	O
total	CIMZIA.xml:S1:2266:5	O
of	CIMZIA.xml:S1:2272:2	O
620	CIMZIA.xml:S1:2275:3	O
patients	CIMZIA.xml:S1:2279:8	O
with	CIMZIA.xml:S1:2288:4	O
Crohn	CIMZIA.xml:S1:2293:5	O
's	CIMZIA.xml:S1:2298:2	O
disease	CIMZIA.xml:S1:2301:7	O
received	CIMZIA.xml:S1:2309:8	O
CIMZIA	CIMZIA.xml:S1:2318:6	O
at	CIMZIA.xml:S1:2325:2	O
a	CIMZIA.xml:S1:2328:1	O
dose	CIMZIA.xml:S1:2330:4	O
of	CIMZIA.xml:S1:2335:2	O
400	CIMZIA.xml:S1:2338:3	O
mg	CIMZIA.xml:S1:2342:2	O
,	CIMZIA.xml:S1:2344:1	O
and	CIMZIA.xml:S1:2346:3	O
614	CIMZIA.xml:S1:2350:3	O
subjects	CIMZIA.xml:S1:2354:8	O
received	CIMZIA.xml:S1:2363:8	O
placebo	CIMZIA.xml:S1:2372:7	O
(	CIMZIA.xml:S1:2380:1	O
including	CIMZIA.xml:S1:2381:9	O
subjects	CIMZIA.xml:S1:2391:8	O
randomized	CIMZIA.xml:S1:2400:10	O
to	CIMZIA.xml:S1:2411:2	O
placebo	CIMZIA.xml:S1:2414:7	O
in	CIMZIA.xml:S1:2422:2	O
Study	CIMZIA.xml:S1:2425:5	O
CD2	CIMZIA.xml:S1:2431:3	O
following	CIMZIA.xml:S1:2435:9	O
open	CIMZIA.xml:S1:2445:4	O
label	CIMZIA.xml:S1:2450:5	O
dosing	CIMZIA.xml:S1:2456:6	O
of	CIMZIA.xml:S1:2463:2	O
CIMZIA	CIMZIA.xml:S1:2466:6	O
at	CIMZIA.xml:S1:2473:2	O
Weeks	CIMZIA.xml:S1:2476:5	O
0	CIMZIA.xml:S1:2482:1	O
,	CIMZIA.xml:S1:2483:1	O
2	CIMZIA.xml:S1:2485:1	O
,	CIMZIA.xml:S1:2486:1	O
4	CIMZIA.xml:S1:2488:1	O
)	CIMZIA.xml:S1:2489:1	O
.	CIMZIA.xml:S1:2490:1	O

In	CIMZIA.xml:S1:2492:2	O
controlled	CIMZIA.xml:S1:2495:10	O
and	CIMZIA.xml:S1:2506:3	O
uncontrolled	CIMZIA.xml:S1:2510:12	O
studies	CIMZIA.xml:S1:2523:7	O
,	CIMZIA.xml:S1:2530:1	O
1	CIMZIA.xml:S1:2532:1	O
,	CIMZIA.xml:S1:2533:1	O
564	CIMZIA.xml:S1:2534:3	O
patients	CIMZIA.xml:S1:2538:8	O
received	CIMZIA.xml:S1:2547:8	O
CIMZIA	CIMZIA.xml:S1:2556:6	O
at	CIMZIA.xml:S1:2563:2	O
some	CIMZIA.xml:S1:2566:4	O
dose	CIMZIA.xml:S1:2571:4	O
level	CIMZIA.xml:S1:2576:5	O
,	CIMZIA.xml:S1:2581:1	O
of	CIMZIA.xml:S1:2583:2	O
whom	CIMZIA.xml:S1:2586:4	O
1	CIMZIA.xml:S1:2591:1	O
,	CIMZIA.xml:S1:2592:1	O
350	CIMZIA.xml:S1:2593:3	O
patients	CIMZIA.xml:S1:2597:8	O
received	CIMZIA.xml:S1:2606:8	O
400	CIMZIA.xml:S1:2615:3	O
mg	CIMZIA.xml:S1:2619:2	O
CIMZIA	CIMZIA.xml:S1:2622:6	O
.	CIMZIA.xml:S1:2628:1	O

Approximately	CIMZIA.xml:S1:2630:13	O
55%	CIMZIA.xml:S1:2644:3	O
of	CIMZIA.xml:S1:2648:2	O
subjects	CIMZIA.xml:S1:2651:8	O
were	CIMZIA.xml:S1:2660:4	O
female	CIMZIA.xml:S1:2665:6	O
,	CIMZIA.xml:S1:2671:1	O
45%	CIMZIA.xml:S1:2673:3	O
were	CIMZIA.xml:S1:2677:4	O
male	CIMZIA.xml:S1:2682:4	O
,	CIMZIA.xml:S1:2686:1	O
and	CIMZIA.xml:S1:2688:3	O
94%	CIMZIA.xml:S1:2692:3	O
were	CIMZIA.xml:S1:2696:4	O
Caucasian	CIMZIA.xml:S1:2701:9	O
.	CIMZIA.xml:S1:2710:1	O

The	CIMZIA.xml:S1:2712:3	O
majority	CIMZIA.xml:S1:2716:8	O
of	CIMZIA.xml:S1:2725:2	O
patients	CIMZIA.xml:S1:2728:8	O
in	CIMZIA.xml:S1:2737:2	O
the	CIMZIA.xml:S1:2740:3	O
active	CIMZIA.xml:S1:2744:6	O
group	CIMZIA.xml:S1:2751:5	O
were	CIMZIA.xml:S1:2757:4	O
between	CIMZIA.xml:S1:2762:7	O
the	CIMZIA.xml:S1:2770:3	O
ages	CIMZIA.xml:S1:2774:4	O
of	CIMZIA.xml:S1:2779:2	O
18	CIMZIA.xml:S1:2782:2	O
and	CIMZIA.xml:S1:2785:3	O
64	CIMZIA.xml:S1:2789:2	O
.	CIMZIA.xml:S1:2791:1	O

During	CIMZIA.xml:S1:2797:6	O
controlled	CIMZIA.xml:S1:2804:10	O
clinical	CIMZIA.xml:S1:2815:8	O
studies	CIMZIA.xml:S1:2824:7	O
,	CIMZIA.xml:S1:2831:1	O
the	CIMZIA.xml:S1:2833:3	O
proportion	CIMZIA.xml:S1:2837:10	O
of	CIMZIA.xml:S1:2848:2	O
patients	CIMZIA.xml:S1:2851:8	O
with	CIMZIA.xml:S1:2860:4	O
serious	CIMZIA.xml:S1:2865:7	O
adverse	CIMZIA.xml:S1:2873:7	O
reactions	CIMZIA.xml:S1:2881:9	O
was	CIMZIA.xml:S1:2891:3	O
10%	CIMZIA.xml:S1:2895:3	O
for	CIMZIA.xml:S1:2899:3	O
CIMZIA	CIMZIA.xml:S1:2903:6	O
and	CIMZIA.xml:S1:2910:3	O
9%	CIMZIA.xml:S1:2914:2	O
for	CIMZIA.xml:S1:2917:3	O
placebo	CIMZIA.xml:S1:2921:7	O
.	CIMZIA.xml:S1:2928:1	O

The	CIMZIA.xml:S1:2930:3	O
most	CIMZIA.xml:S1:2934:4	O
common	CIMZIA.xml:S1:2939:6	O
adverse	CIMZIA.xml:S1:2946:7	O
reactions	CIMZIA.xml:S1:2954:9	O
(	CIMZIA.xml:S1:2964:1	O
occurring	CIMZIA.xml:S1:2965:9	O
in	CIMZIA.xml:S1:2975:2	O
5%	CIMZIA.xml:S1:2981:2	O
of	CIMZIA.xml:S1:2984:2	O
CIMZIA	CIMZIA.xml:S1:2987:6	O
-	CIMZIA.xml:S1:2993:1	O
treated	CIMZIA.xml:S1:2994:7	O
patients	CIMZIA.xml:S1:3002:8	O
,	CIMZIA.xml:S1:3010:1	O
and	CIMZIA.xml:S1:3012:3	O
with	CIMZIA.xml:S1:3016:4	O
a	CIMZIA.xml:S1:3021:1	O
higher	CIMZIA.xml:S1:3023:6	O
incidence	CIMZIA.xml:S1:3030:9	O
compared	CIMZIA.xml:S1:3040:8	O
to	CIMZIA.xml:S1:3049:2	O
placebo	CIMZIA.xml:S1:3052:7	O
)	CIMZIA.xml:S1:3059:1	O
in	CIMZIA.xml:S1:3061:2	O
controlled	CIMZIA.xml:S1:3064:10	O
clinical	CIMZIA.xml:S1:3075:8	O
studies	CIMZIA.xml:S1:3084:7	O
with	CIMZIA.xml:S1:3092:4	O
CIMZIA	CIMZIA.xml:S1:3097:6	O
were	CIMZIA.xml:S1:3104:4	O
upper	CIMZIA.xml:S1:3109:5	B-AdverseReaction
respiratory	CIMZIA.xml:S1:3115:11	I-AdverseReaction
infections	CIMZIA.xml:S1:3127:10	I-AdverseReaction
(	CIMZIA.xml:S1:3138:1	O
e	CIMZIA.xml:S1:3139:1	O
.	CIMZIA.xml:S1:3140:1	O
g	CIMZIA.xml:S1:3141:1	O
.	CIMZIA.xml:S1:3142:1	O

nasopharyngitis	CIMZIA.xml:S1:3144:15	B-AdverseReaction
,	CIMZIA.xml:S1:3159:1	O
laryngitis	CIMZIA.xml:S1:3161:10	B-AdverseReaction
,	CIMZIA.xml:S1:3171:1	O
viral	CIMZIA.xml:S1:3173:5	B-AdverseReaction
infection	CIMZIA.xml:S1:3179:9	I-AdverseReaction
)	CIMZIA.xml:S1:3188:1	O
in	CIMZIA.xml:S1:3190:2	O
20%	CIMZIA.xml:S1:3193:3	O
of	CIMZIA.xml:S1:3197:2	O
CIMZIA	CIMZIA.xml:S1:3200:6	O
-	CIMZIA.xml:S1:3206:1	O
treated	CIMZIA.xml:S1:3207:7	O
patients	CIMZIA.xml:S1:3215:8	O
and	CIMZIA.xml:S1:3224:3	O
13%	CIMZIA.xml:S1:3228:3	O
of	CIMZIA.xml:S1:3232:2	O
placebo	CIMZIA.xml:S1:3235:7	O
-	CIMZIA.xml:S1:3242:1	O
treated	CIMZIA.xml:S1:3243:7	O
patients	CIMZIA.xml:S1:3251:8	O
,	CIMZIA.xml:S1:3259:1	O
urinary	CIMZIA.xml:S1:3261:7	B-AdverseReaction
tract	CIMZIA.xml:S1:3269:5	I-AdverseReaction
infections	CIMZIA.xml:S1:3275:10	I-AdverseReaction
(	CIMZIA.xml:S1:3286:1	O
e	CIMZIA.xml:S1:3287:1	O
.	CIMZIA.xml:S1:3288:1	O
g	CIMZIA.xml:S1:3289:1	O
.	CIMZIA.xml:S1:3290:1	O

bladder	CIMZIA.xml:S1:3292:7	B-AdverseReaction
infection	CIMZIA.xml:S1:3300:9	I-AdverseReaction
,	CIMZIA.xml:S1:3309:1	O
bacteriuria	CIMZIA.xml:S1:3311:11	B-AdverseReaction
,	CIMZIA.xml:S1:3322:1	O
cystitis	CIMZIA.xml:S1:3324:8	B-AdverseReaction
)	CIMZIA.xml:S1:3332:1	O
in	CIMZIA.xml:S1:3334:2	O
7%	CIMZIA.xml:S1:3337:2	O
of	CIMZIA.xml:S1:3340:2	O
CIMZIA	CIMZIA.xml:S1:3343:6	O
-	CIMZIA.xml:S1:3349:1	O
treated	CIMZIA.xml:S1:3350:7	O
patients	CIMZIA.xml:S1:3358:8	O
and	CIMZIA.xml:S1:3367:3	O
in	CIMZIA.xml:S1:3371:2	O
6%	CIMZIA.xml:S1:3374:2	O
of	CIMZIA.xml:S1:3377:2	O
placebo	CIMZIA.xml:S1:3380:7	O
-	CIMZIA.xml:S1:3387:1	O
treated	CIMZIA.xml:S1:3388:7	O
patients	CIMZIA.xml:S1:3396:8	O
,	CIMZIA.xml:S1:3404:1	O
and	CIMZIA.xml:S1:3406:3	O
arthralgia	CIMZIA.xml:S1:3410:10	B-AdverseReaction
(	CIMZIA.xml:S1:3421:1	O
6%	CIMZIA.xml:S1:3422:2	O
CIMZIA	CIMZIA.xml:S1:3425:6	O
,	CIMZIA.xml:S1:3431:1	O
4%	CIMZIA.xml:S1:3433:2	O
placebo	CIMZIA.xml:S1:3436:7	O
)	CIMZIA.xml:S1:3443:1	O
.	CIMZIA.xml:S1:3444:1	O

Other	CIMZIA.xml:S1:3456:5	O
Adverse	CIMZIA.xml:S1:3462:7	O
Reactions	CIMZIA.xml:S1:3470:9	O

The	CIMZIA.xml:S1:3488:3	O
most	CIMZIA.xml:S1:3492:4	O
commonly	CIMZIA.xml:S1:3497:8	O
occurring	CIMZIA.xml:S1:3506:9	O
adverse	CIMZIA.xml:S1:3516:7	O
reactions	CIMZIA.xml:S1:3524:9	O
in	CIMZIA.xml:S1:3534:2	O
controlled	CIMZIA.xml:S1:3537:10	O
trials	CIMZIA.xml:S1:3548:6	O
of	CIMZIA.xml:S1:3555:2	O
Crohn	CIMZIA.xml:S1:3558:5	O
's	CIMZIA.xml:S1:3563:2	O
disease	CIMZIA.xml:S1:3566:7	O
were	CIMZIA.xml:S1:3574:4	O
described	CIMZIA.xml:S1:3579:9	O
above	CIMZIA.xml:S1:3589:5	O
.	CIMZIA.xml:S1:3594:1	O

Other	CIMZIA.xml:S1:3596:5	O
serious	CIMZIA.xml:S1:3602:7	O
or	CIMZIA.xml:S1:3610:2	O
significant	CIMZIA.xml:S1:3613:11	O
adverse	CIMZIA.xml:S1:3625:7	O
reactions	CIMZIA.xml:S1:3633:9	O
reported	CIMZIA.xml:S1:3643:8	O
in	CIMZIA.xml:S1:3652:2	O
controlled	CIMZIA.xml:S1:3655:10	O
and	CIMZIA.xml:S1:3666:3	O
uncontrolled	CIMZIA.xml:S1:3670:12	O
studies	CIMZIA.xml:S1:3683:7	O
in	CIMZIA.xml:S1:3691:2	O
Crohn	CIMZIA.xml:S1:3694:5	O
's	CIMZIA.xml:S1:3699:2	O
disease	CIMZIA.xml:S1:3702:7	O
and	CIMZIA.xml:S1:3710:3	O
other	CIMZIA.xml:S1:3714:5	O
diseases	CIMZIA.xml:S1:3720:8	O
,	CIMZIA.xml:S1:3728:1	O
occurring	CIMZIA.xml:S1:3730:9	O
in	CIMZIA.xml:S1:3740:2	O
patients	CIMZIA.xml:S1:3743:8	O
receiving	CIMZIA.xml:S1:3752:9	O
CIMZIA	CIMZIA.xml:S1:3762:6	O
at	CIMZIA.xml:S1:3769:2	O
doses	CIMZIA.xml:S1:3772:5	O
of	CIMZIA.xml:S1:3778:2	O
400	CIMZIA.xml:S1:3781:3	O
mg	CIMZIA.xml:S1:3785:2	O
or	CIMZIA.xml:S1:3788:2	O
other	CIMZIA.xml:S1:3791:5	O
doses	CIMZIA.xml:S1:3797:5	O
include	CIMZIA.xml:S1:3803:7	O
:	CIMZIA.xml:S1:3810:1	O

Blood	CIMZIA.xml:S1:3818:5	O
and	CIMZIA.xml:S1:3824:3	O
lymphatic	CIMZIA.xml:S1:3828:9	O
system	CIMZIA.xml:S1:3838:6	O
disorders	CIMZIA.xml:S1:3845:9	O
:	CIMZIA.xml:S1:3854:1	O
Anemia	CIMZIA.xml:S1:3857:6	B-AdverseReaction
,	CIMZIA.xml:S1:3863:1	O
leukopenia	CIMZIA.xml:S1:3865:10	B-AdverseReaction
,	CIMZIA.xml:S1:3875:1	O
lymphadenopathy	CIMZIA.xml:S1:3877:15	B-AdverseReaction
,	CIMZIA.xml:S1:3892:1	O
pancytopenia	CIMZIA.xml:S1:3894:12	B-AdverseReaction
,	CIMZIA.xml:S1:3906:1	O
and	CIMZIA.xml:S1:3908:3	O
thrombophilia	CIMZIA.xml:S1:3912:13	B-AdverseReaction
.	CIMZIA.xml:S1:3925:1	O

Cardiac	CIMZIA.xml:S1:3933:7	O
disorders	CIMZIA.xml:S1:3941:9	O
:	CIMZIA.xml:S1:3950:1	O
Angina	CIMZIA.xml:S1:3953:6	B-AdverseReaction
pectoris	CIMZIA.xml:S1:3960:8	I-AdverseReaction
,	CIMZIA.xml:S1:3968:1	O
arrhythmias	CIMZIA.xml:S1:3970:11	B-AdverseReaction
,	CIMZIA.xml:S1:3981:1	O
atrial	CIMZIA.xml:S1:3983:6	B-AdverseReaction
fibrillation	CIMZIA.xml:S1:3990:12	I-AdverseReaction
,	CIMZIA.xml:S1:4002:1	O
cardiac	CIMZIA.xml:S1:4004:7	B-AdverseReaction
failure	CIMZIA.xml:S1:4012:7	I-AdverseReaction
,	CIMZIA.xml:S1:4019:1	O
hypertensive	CIMZIA.xml:S1:4021:12	B-AdverseReaction
heart	CIMZIA.xml:S1:4034:5	I-AdverseReaction
disease	CIMZIA.xml:S1:4040:7	I-AdverseReaction
,	CIMZIA.xml:S1:4047:1	O
myocardial	CIMZIA.xml:S1:4049:10	B-AdverseReaction
infarction	CIMZIA.xml:S1:4060:10	I-AdverseReaction
,	CIMZIA.xml:S1:4070:1	O
myocardial	CIMZIA.xml:S1:4072:10	B-AdverseReaction
ischemia	CIMZIA.xml:S1:4083:8	I-AdverseReaction
,	CIMZIA.xml:S1:4091:1	O
pericardial	CIMZIA.xml:S1:4093:11	B-AdverseReaction
effusion	CIMZIA.xml:S1:4105:8	I-AdverseReaction
,	CIMZIA.xml:S1:4113:1	O
pericarditis	CIMZIA.xml:S1:4115:12	B-AdverseReaction
,	CIMZIA.xml:S1:4127:1	O
stroke	CIMZIA.xml:S1:4129:6	B-AdverseReaction
and	CIMZIA.xml:S1:4136:3	O
transient	CIMZIA.xml:S1:4140:9	B-AdverseReaction
ischemic	CIMZIA.xml:S1:4150:8	I-AdverseReaction
attack	CIMZIA.xml:S1:4159:6	I-AdverseReaction
.	CIMZIA.xml:S1:4165:1	O

Eye	CIMZIA.xml:S1:4173:3	O
disorders	CIMZIA.xml:S1:4177:9	O
:	CIMZIA.xml:S1:4186:1	O
Optic	CIMZIA.xml:S1:4189:5	B-AdverseReaction
neuritis	CIMZIA.xml:S1:4195:8	I-AdverseReaction
,	CIMZIA.xml:S1:4203:1	O
retinal	CIMZIA.xml:S1:4205:7	B-AdverseReaction
hemorrhage	CIMZIA.xml:S1:4213:10	I-AdverseReaction
,	CIMZIA.xml:S1:4223:1	O
and	CIMZIA.xml:S1:4225:3	O
uveitis	CIMZIA.xml:S1:4229:7	B-AdverseReaction
.	CIMZIA.xml:S1:4236:1	O

General	CIMZIA.xml:S1:4244:7	O
disorders	CIMZIA.xml:S1:4252:9	O
and	CIMZIA.xml:S1:4262:3	O
administration	CIMZIA.xml:S1:4266:14	O
site	CIMZIA.xml:S1:4281:4	O
conditions	CIMZIA.xml:S1:4286:10	O
:	CIMZIA.xml:S1:4296:1	O
Bleeding	CIMZIA.xml:S1:4299:8	B-AdverseReaction
and	CIMZIA.xml:S1:4308:3	O
injection	CIMZIA.xml:S1:4312:9	B-AdverseReaction
site	CIMZIA.xml:S1:4322:4	I-AdverseReaction
reactions	CIMZIA.xml:S1:4327:9	I-AdverseReaction
.	CIMZIA.xml:S1:4336:1	O

Hepatobiliary	CIMZIA.xml:S1:4344:13	O
disorders	CIMZIA.xml:S1:4358:9	O
:	CIMZIA.xml:S1:4369:1	O
Elevated	CIMZIA.xml:S1:4371:8	B-AdverseReaction
liver	CIMZIA.xml:S1:4380:5	I-AdverseReaction
enzymes	CIMZIA.xml:S1:4386:7	I-AdverseReaction
and	CIMZIA.xml:S1:4394:3	O
hepatitis	CIMZIA.xml:S1:4398:9	B-AdverseReaction
.	CIMZIA.xml:S1:4407:1	O

Immune	CIMZIA.xml:S1:4415:6	O
system	CIMZIA.xml:S1:4422:6	O
disorders	CIMZIA.xml:S1:4429:9	O
:	CIMZIA.xml:S1:4440:1	O
Alopecia	CIMZIA.xml:S1:4442:8	B-AdverseReaction
totalis	CIMZIA.xml:S1:4451:7	I-AdverseReaction
.	CIMZIA.xml:S1:4458:1	O

Psychiatric	CIMZIA.xml:S1:4466:11	O
disorders	CIMZIA.xml:S1:4478:9	O
:	CIMZIA.xml:S1:4487:1	O
Anxiety	CIMZIA.xml:S1:4490:7	B-AdverseReaction
,	CIMZIA.xml:S1:4497:1	O
bipolar	CIMZIA.xml:S1:4499:7	B-AdverseReaction
disorder	CIMZIA.xml:S1:4507:8	I-AdverseReaction
,	CIMZIA.xml:S1:4515:1	O
and	CIMZIA.xml:S1:4517:3	O
suicide	CIMZIA.xml:S1:4521:7	B-AdverseReaction
attempt	CIMZIA.xml:S1:4529:7	I-AdverseReaction
.	CIMZIA.xml:S1:4536:1	O

Renal	CIMZIA.xml:S1:4544:5	O
and	CIMZIA.xml:S1:4550:3	O
urinary	CIMZIA.xml:S1:4554:7	O
disorders	CIMZIA.xml:S1:4562:9	O
:	CIMZIA.xml:S1:4571:1	O
Nephrotic	CIMZIA.xml:S1:4574:9	B-AdverseReaction
syndrome	CIMZIA.xml:S1:4584:8	I-AdverseReaction
and	CIMZIA.xml:S1:4593:3	O
renal	CIMZIA.xml:S1:4597:5	B-AdverseReaction
failure	CIMZIA.xml:S1:4603:7	I-AdverseReaction
.	CIMZIA.xml:S1:4610:1	O

Reproductive	CIMZIA.xml:S1:4618:12	O
system	CIMZIA.xml:S1:4631:6	O
and	CIMZIA.xml:S1:4638:3	O
breast	CIMZIA.xml:S1:4642:6	O
disorders	CIMZIA.xml:S1:4649:9	O
:	CIMZIA.xml:S1:4658:1	O
Menstrual	CIMZIA.xml:S1:4661:9	B-AdverseReaction
disorder	CIMZIA.xml:S1:4671:8	I-AdverseReaction
.	CIMZIA.xml:S1:4679:1	O

Skin	CIMZIA.xml:S1:4687:4	O
and	CIMZIA.xml:S1:4692:3	O
subcutaneous	CIMZIA.xml:S1:4696:12	O
tissue	CIMZIA.xml:S1:4709:6	O
disorders	CIMZIA.xml:S1:4716:9	O
:	CIMZIA.xml:S1:4725:1	O
Dermatitis	CIMZIA.xml:S1:4728:10	B-AdverseReaction
,	CIMZIA.xml:S1:4738:1	O
erythema	CIMZIA.xml:S1:4740:8	B-AdverseReaction
nodosum	CIMZIA.xml:S1:4749:7	I-AdverseReaction
,	CIMZIA.xml:S1:4756:1	O
and	CIMZIA.xml:S1:4758:3	O
urticaria	CIMZIA.xml:S1:4762:9	B-AdverseReaction
.	CIMZIA.xml:S1:4771:1	O

Vascular	CIMZIA.xml:S1:4779:8	O
disorders	CIMZIA.xml:S1:4788:9	O
:	CIMZIA.xml:S1:4797:1	O
Thrombophlebitis	CIMZIA.xml:S1:4800:16	B-AdverseReaction
,	CIMZIA.xml:S1:4816:1	O
vasculitis	CIMZIA.xml:S1:4818:10	B-AdverseReaction
.	CIMZIA.xml:S1:4828:1	O

Controlled	CIMZIA.xml:S1:4838:10	O
Studies	CIMZIA.xml:S1:4849:7	O
with	CIMZIA.xml:S1:4857:4	O
Rheumatoid	CIMZIA.xml:S1:4862:10	O
Arthritis	CIMZIA.xml:S1:4873:9	O

CIMZIA	CIMZIA.xml:S1:4889:6	O
was	CIMZIA.xml:S1:4896:3	O
studied	CIMZIA.xml:S1:4900:7	O
primarily	CIMZIA.xml:S1:4908:9	O
in	CIMZIA.xml:S1:4918:2	O
placebo	CIMZIA.xml:S1:4921:7	O
-	CIMZIA.xml:S1:4928:1	O
controlled	CIMZIA.xml:S1:4929:10	O
trials	CIMZIA.xml:S1:4940:6	O
and	CIMZIA.xml:S1:4947:3	O
in	CIMZIA.xml:S1:4951:2	O
long	CIMZIA.xml:S1:4954:4	O
-	CIMZIA.xml:S1:4958:1	O
term	CIMZIA.xml:S1:4959:4	O
follow	CIMZIA.xml:S1:4964:6	O
-	CIMZIA.xml:S1:4970:1	O
up	CIMZIA.xml:S1:4971:2	O
studies	CIMZIA.xml:S1:4974:7	O
.	CIMZIA.xml:S1:4981:1	O

The	CIMZIA.xml:S1:4983:3	O
data	CIMZIA.xml:S1:4987:4	O
described	CIMZIA.xml:S1:4992:9	O
below	CIMZIA.xml:S1:5002:5	O
reflect	CIMZIA.xml:S1:5008:7	O
the	CIMZIA.xml:S1:5016:3	O
exposure	CIMZIA.xml:S1:5020:8	O
to	CIMZIA.xml:S1:5029:2	O
CIMZIA	CIMZIA.xml:S1:5032:6	O
in	CIMZIA.xml:S1:5039:2	O
2	CIMZIA.xml:S1:5042:1	O
,	CIMZIA.xml:S1:5043:1	O
367	CIMZIA.xml:S1:5044:3	O
RA	CIMZIA.xml:S1:5048:2	O
patients	CIMZIA.xml:S1:5051:8	O
,	CIMZIA.xml:S1:5059:1	O
including	CIMZIA.xml:S1:5061:9	O
2	CIMZIA.xml:S1:5071:1	O
,	CIMZIA.xml:S1:5072:1	O
030	CIMZIA.xml:S1:5073:3	O
exposed	CIMZIA.xml:S1:5077:7	O
for	CIMZIA.xml:S1:5085:3	O
at	CIMZIA.xml:S1:5089:2	O
least	CIMZIA.xml:S1:5092:5	O
6	CIMZIA.xml:S1:5098:1	O
months	CIMZIA.xml:S1:5100:6	O
,	CIMZIA.xml:S1:5106:1	O
1	CIMZIA.xml:S1:5108:1	O
,	CIMZIA.xml:S1:5109:1	O
663	CIMZIA.xml:S1:5110:3	O
exposed	CIMZIA.xml:S1:5114:7	O
for	CIMZIA.xml:S1:5122:3	O
at	CIMZIA.xml:S1:5126:2	O
least	CIMZIA.xml:S1:5129:5	O
one	CIMZIA.xml:S1:5135:3	O
year	CIMZIA.xml:S1:5139:4	O
and	CIMZIA.xml:S1:5144:3	O
282	CIMZIA.xml:S1:5148:3	O
for	CIMZIA.xml:S1:5152:3	O
at	CIMZIA.xml:S1:5156:2	O
least	CIMZIA.xml:S1:5159:5	O
2	CIMZIA.xml:S1:5165:1	O
years	CIMZIA.xml:S1:5167:5	O
;	CIMZIA.xml:S1:5172:1	O
and	CIMZIA.xml:S1:5174:3	O
1	CIMZIA.xml:S1:5178:1	O
,	CIMZIA.xml:S1:5179:1	O
774	CIMZIA.xml:S1:5180:3	O
in	CIMZIA.xml:S1:5184:2	O
adequate	CIMZIA.xml:S1:5187:8	O
and	CIMZIA.xml:S1:5196:3	O
well	CIMZIA.xml:S1:5200:4	O
-	CIMZIA.xml:S1:5204:1	O
controlled	CIMZIA.xml:S1:5205:10	O
studies	CIMZIA.xml:S1:5216:7	O
.	CIMZIA.xml:S1:5223:1	O

In	CIMZIA.xml:S1:5225:2	O
placebo	CIMZIA.xml:S1:5228:7	O
-	CIMZIA.xml:S1:5235:1	O
controlled	CIMZIA.xml:S1:5236:10	O
studies	CIMZIA.xml:S1:5247:7	O
,	CIMZIA.xml:S1:5254:1	O
the	CIMZIA.xml:S1:5256:3	O
population	CIMZIA.xml:S1:5260:10	O
had	CIMZIA.xml:S1:5271:3	O
a	CIMZIA.xml:S1:5275:1	O
median	CIMZIA.xml:S1:5277:6	O
age	CIMZIA.xml:S1:5284:3	O
of	CIMZIA.xml:S1:5288:2	O
53	CIMZIA.xml:S1:5291:2	O
years	CIMZIA.xml:S1:5294:5	O
at	CIMZIA.xml:S1:5300:2	O
entry	CIMZIA.xml:S1:5303:5	O
;	CIMZIA.xml:S1:5308:1	O
approximately	CIMZIA.xml:S1:5310:13	O
80%	CIMZIA.xml:S1:5324:3	O
were	CIMZIA.xml:S1:5328:4	O
females	CIMZIA.xml:S1:5333:7	O
,	CIMZIA.xml:S1:5340:1	O
93%	CIMZIA.xml:S1:5342:3	O
were	CIMZIA.xml:S1:5346:4	O
Caucasian	CIMZIA.xml:S1:5351:9	O
and	CIMZIA.xml:S1:5361:3	O
all	CIMZIA.xml:S1:5365:3	O
patients	CIMZIA.xml:S1:5369:8	O
were	CIMZIA.xml:S1:5378:4	O
suffering	CIMZIA.xml:S1:5383:9	O
from	CIMZIA.xml:S1:5393:4	O
active	CIMZIA.xml:S1:5398:6	O
rheumatoid	CIMZIA.xml:S1:5405:10	O
arthritis	CIMZIA.xml:S1:5416:9	O
,	CIMZIA.xml:S1:5425:1	O
with	CIMZIA.xml:S1:5427:4	O
a	CIMZIA.xml:S1:5432:1	O
median	CIMZIA.xml:S1:5434:6	O
disease	CIMZIA.xml:S1:5441:7	O
duration	CIMZIA.xml:S1:5449:8	O
of	CIMZIA.xml:S1:5458:2	O
6.2	CIMZIA.xml:S1:5461:3	O
years	CIMZIA.xml:S1:5465:5	O
.	CIMZIA.xml:S1:5470:1	O

Most	CIMZIA.xml:S1:5472:4	O
patients	CIMZIA.xml:S1:5477:8	O
received	CIMZIA.xml:S1:5486:8	O
the	CIMZIA.xml:S1:5495:3	O
recommended	CIMZIA.xml:S1:5499:11	O
dose	CIMZIA.xml:S1:5511:4	O
of	CIMZIA.xml:S1:5516:2	O
CIMZIA	CIMZIA.xml:S1:5519:6	O
or	CIMZIA.xml:S1:5526:2	O
higher	CIMZIA.xml:S1:5529:6	O
.	CIMZIA.xml:S1:5535:1	O

Table	CIMZIA.xml:S1:5541:5	O
1	CIMZIA.xml:S1:5547:1	O
summarizes	CIMZIA.xml:S1:5549:10	O
the	CIMZIA.xml:S1:5560:3	O
reactions	CIMZIA.xml:S1:5564:9	O
reported	CIMZIA.xml:S1:5574:8	O
at	CIMZIA.xml:S1:5583:2	O
a	CIMZIA.xml:S1:5586:1	O
rate	CIMZIA.xml:S1:5588:4	O
of	CIMZIA.xml:S1:5593:2	O
at	CIMZIA.xml:S1:5596:2	O
least	CIMZIA.xml:S1:5599:5	O
3%	CIMZIA.xml:S1:5605:2	O
in	CIMZIA.xml:S1:5608:2	O
patients	CIMZIA.xml:S1:5611:8	O
treated	CIMZIA.xml:S1:5620:7	O
with	CIMZIA.xml:S1:5628:4	O
CIMZIA	CIMZIA.xml:S1:5633:6	O
200	CIMZIA.xml:S1:5640:3	O
mg	CIMZIA.xml:S1:5644:2	O
every	CIMZIA.xml:S1:5647:5	O
other	CIMZIA.xml:S1:5653:5	O
week	CIMZIA.xml:S1:5659:4	O
compared	CIMZIA.xml:S1:5664:8	O
to	CIMZIA.xml:S1:5673:2	O
placebo	CIMZIA.xml:S1:5676:7	O
(	CIMZIA.xml:S1:5684:1	O
saline	CIMZIA.xml:S1:5685:6	O
formulation	CIMZIA.xml:S1:5692:11	O
)	CIMZIA.xml:S1:5703:1	O
,	CIMZIA.xml:S1:5704:1	O
given	CIMZIA.xml:S1:5706:5	O
concomitantly	CIMZIA.xml:S1:5712:13	O
with	CIMZIA.xml:S1:5726:4	O
methotrexate	CIMZIA.xml:S1:5731:12	O
.	CIMZIA.xml:S1:5743:1	O

Table	CIMZIA.xml:S1:5749:5	O
1	CIMZIA.xml:S1:5755:1	O
:	CIMZIA.xml:S1:5756:1	O
Adverse	CIMZIA.xml:S1:5758:7	O
Reactions	CIMZIA.xml:S1:5766:9	O
Reported	CIMZIA.xml:S1:5776:8	O
by	CIMZIA.xml:S1:5785:2	O
3%	CIMZIA.xml:S1:5790:2	O
of	CIMZIA.xml:S1:5793:2	O
Patients	CIMZIA.xml:S1:5796:8	O
Treated	CIMZIA.xml:S1:5805:7	O
with	CIMZIA.xml:S1:5813:4	O
CIMZIA	CIMZIA.xml:S1:5818:6	O
Dosed	CIMZIA.xml:S1:5825:5	O
Every	CIMZIA.xml:S1:5831:5	O
Other	CIMZIA.xml:S1:5837:5	O
Week	CIMZIA.xml:S1:5843:4	O
during	CIMZIA.xml:S1:5848:6	O
Placebo	CIMZIA.xml:S1:5855:7	O
-	CIMZIA.xml:S1:5862:1	O
Controlled	CIMZIA.xml:S1:5863:10	O
Period	CIMZIA.xml:S1:5874:6	O
of	CIMZIA.xml:S1:5881:2	O
Rheumatoid	CIMZIA.xml:S1:5884:10	O
Arthritis	CIMZIA.xml:S1:5895:9	O
Studies	CIMZIA.xml:S1:5905:7	O
,	CIMZIA.xml:S1:5912:1	O
with	CIMZIA.xml:S1:5914:4	O
Concomitant	CIMZIA.xml:S1:5919:11	O
Methotrexate	CIMZIA.xml:S1:5931:12	O
.	CIMZIA.xml:S1:5943:1	O

Adverse	CIMZIA.xml:S1:5947:7	O
Reaction	CIMZIA.xml:S1:5955:8	O
(	CIMZIA.xml:S1:5963:1	O
Preferred	CIMZIA.xml:S1:5964:9	O
Term	CIMZIA.xml:S1:5974:4	O
)	CIMZIA.xml:S1:5978:1	O
Placebo	CIMZIA.xml:S1:5990:7	O
MTX	CIMZIA.xml:S1:5999:3	O
(	CIMZIA.xml:S1:6002:1	O
)	CIMZIA.xml:S1:6004:1	O
N	CIMZIA.xml:S1:6005:1	O
324	CIMZIA.xml:S1:6008:3	O
CIMZIA	CIMZIA.xml:S1:6018:6	O
200	CIMZIA.xml:S1:6025:3	O
mg	CIMZIA.xml:S1:6029:2	O
EOW	CIMZIA.xml:S1:6032:3	O
MTX	CIMZIA.xml:S1:6038:3	O
(	CIMZIA.xml:S1:6041:1	O
)	CIMZIA.xml:S1:6043:1	O
N	CIMZIA.xml:S1:6044:1	O
640	CIMZIA.xml:S1:6047:3	O

Upper	CIMZIA.xml:S1:6059:5	B-AdverseReaction

respiratory	CIMZIA.xml:S1:6065:11	I-AdverseReaction
tract	CIMZIA.xml:S1:6077:5	I-AdverseReaction
infection	CIMZIA.xml:S1:6083:9	I-AdverseReaction
2	CIMZIA.xml:S1:6112:1	O
6	CIMZIA.xml:S1:6146:1	O

Headache	CIMZIA.xml:S1:6168:8	B-AdverseReaction
4	CIMZIA.xml:S1:6221:1	O
5	CIMZIA.xml:S1:6255:1	O

Hypertension	CIMZIA.xml:S1:6277:12	B-AdverseReaction
2	CIMZIA.xml:S1:6330:1	O
5	CIMZIA.xml:S1:6364:1	O

Nasopharyngitis	CIMZIA.xml:S1:6386:15	B-AdverseReaction
1	CIMZIA.xml:S1:6439:1	O
5	CIMZIA.xml:S1:6473:1	O

Back	CIMZIA.xml:S1:6495:4	B-AdverseReaction
pain	CIMZIA.xml:S1:6500:4	I-AdverseReaction
1	CIMZIA.xml:S1:6548:1	O
4	CIMZIA.xml:S1:6582:1	O

Pyrexia	CIMZIA.xml:S1:6604:7	B-AdverseReaction
2	CIMZIA.xml:S1:6657:1	O
3	CIMZIA.xml:S1:6691:1	O

Pharyngitis	CIMZIA.xml:S1:6713:11	B-AdverseReaction
1	CIMZIA.xml:S1:6766:1	O
3	CIMZIA.xml:S1:6800:1	O

Rash	CIMZIA.xml:S1:6822:4	B-AdverseReaction
1	CIMZIA.xml:S1:6875:1	O
3	CIMZIA.xml:S1:6909:1	O

Acute	CIMZIA.xml:S1:6931:5	B-AdverseReaction
bronchitis	CIMZIA.xml:S1:6937:10	I-AdverseReaction
1	CIMZIA.xml:S1:6984:1	O
3	CIMZIA.xml:S1:7018:1	O

Fatigue	CIMZIA.xml:S1:7040:7	B-AdverseReaction
2	CIMZIA.xml:S1:7093:1	O
3	CIMZIA.xml:S1:7127:1	O

Hypertensive	CIMZIA.xml:S1:7157:12	B-AdverseReaction
adverse	CIMZIA.xml:S1:7170:7	I-AdverseReaction
reactions	CIMZIA.xml:S1:7178:9	I-AdverseReaction
were	CIMZIA.xml:S1:7188:4	O
observed	CIMZIA.xml:S1:7193:8	O
more	CIMZIA.xml:S1:7202:4	O
frequently	CIMZIA.xml:S1:7207:10	O
in	CIMZIA.xml:S1:7218:2	O
patients	CIMZIA.xml:S1:7221:8	O
receiving	CIMZIA.xml:S1:7230:9	O
CIMZIA	CIMZIA.xml:S1:7240:6	O
than	CIMZIA.xml:S1:7247:4	O
in	CIMZIA.xml:S1:7252:2	O
controls	CIMZIA.xml:S1:7255:8	O
.	CIMZIA.xml:S1:7263:1	O

These	CIMZIA.xml:S1:7265:5	O
adverse	CIMZIA.xml:S1:7271:7	O
reactions	CIMZIA.xml:S1:7279:9	O
occurred	CIMZIA.xml:S1:7289:8	O
more	CIMZIA.xml:S1:7298:4	O
frequently	CIMZIA.xml:S1:7303:10	O
among	CIMZIA.xml:S1:7314:5	O
patients	CIMZIA.xml:S1:7320:8	O
with	CIMZIA.xml:S1:7329:4	O
a	CIMZIA.xml:S1:7334:1	O
baseline	CIMZIA.xml:S1:7336:8	O
history	CIMZIA.xml:S1:7345:7	O
of	CIMZIA.xml:S1:7353:2	O
hypertension	CIMZIA.xml:S1:7356:12	O
and	CIMZIA.xml:S1:7369:3	O
among	CIMZIA.xml:S1:7373:5	O
patients	CIMZIA.xml:S1:7379:8	O
receiving	CIMZIA.xml:S1:7388:9	O
concomitant	CIMZIA.xml:S1:7398:11	O
corticosteroids	CIMZIA.xml:S1:7410:15	O
and	CIMZIA.xml:S1:7426:3	O
non	CIMZIA.xml:S1:7430:3	O
-	CIMZIA.xml:S1:7433:1	O
steroidal	CIMZIA.xml:S1:7434:9	O
anti	CIMZIA.xml:S1:7444:4	O
-	CIMZIA.xml:S1:7448:1	O
inflammatory	CIMZIA.xml:S1:7449:12	O
drugs	CIMZIA.xml:S1:7462:5	O
.	CIMZIA.xml:S1:7467:1	O

Patients	CIMZIA.xml:S1:7473:8	O

receiving	CIMZIA.xml:S1:7482:9	O
CIMZIA	CIMZIA.xml:S1:7492:6	O
400	CIMZIA.xml:S1:7499:3	O
mg	CIMZIA.xml:S1:7503:2	O
as	CIMZIA.xml:S1:7506:2	O
monotherapy	CIMZIA.xml:S1:7509:11	O
every	CIMZIA.xml:S1:7521:5	O
4	CIMZIA.xml:S1:7527:1	O
weeks	CIMZIA.xml:S1:7529:5	O
in	CIMZIA.xml:S1:7535:2	O
rheumatoid	CIMZIA.xml:S1:7538:10	O
arthritis	CIMZIA.xml:S1:7549:9	O
controlled	CIMZIA.xml:S1:7559:10	O
clinical	CIMZIA.xml:S1:7570:8	O
trials	CIMZIA.xml:S1:7579:6	O
had	CIMZIA.xml:S1:7586:3	O
similar	CIMZIA.xml:S1:7590:7	O
adverse	CIMZIA.xml:S1:7598:7	O
reactions	CIMZIA.xml:S1:7606:9	O
to	CIMZIA.xml:S1:7616:2	O
those	CIMZIA.xml:S1:7619:5	O
patients	CIMZIA.xml:S1:7625:8	O
receiving	CIMZIA.xml:S1:7634:9	O
CIMZIA	CIMZIA.xml:S1:7644:6	O
200	CIMZIA.xml:S1:7651:3	O
mg	CIMZIA.xml:S1:7655:2	O
every	CIMZIA.xml:S1:7658:5	O
other	CIMZIA.xml:S1:7664:5	O
week	CIMZIA.xml:S1:7670:4	O
.	CIMZIA.xml:S1:7674:1	O

Other	CIMZIA.xml:S1:7686:5	O
Adverse	CIMZIA.xml:S1:7692:7	O
Reactions	CIMZIA.xml:S1:7700:9	O

Other	CIMZIA.xml:S1:7718:5	O
infrequent	CIMZIA.xml:S1:7724:10	O
adverse	CIMZIA.xml:S1:7735:7	O
reactions	CIMZIA.xml:S1:7743:9	O
(	CIMZIA.xml:S1:7753:1	O
occurring	CIMZIA.xml:S1:7754:9	O
in	CIMZIA.xml:S1:7764:2	O
less	CIMZIA.xml:S1:7767:4	O
than	CIMZIA.xml:S1:7772:4	O
3%	CIMZIA.xml:S1:7777:2	O
of	CIMZIA.xml:S1:7780:2	O
RA	CIMZIA.xml:S1:7783:2	O
patients	CIMZIA.xml:S1:7786:8	O
)	CIMZIA.xml:S1:7794:1	O
were	CIMZIA.xml:S1:7796:4	O
similar	CIMZIA.xml:S1:7801:7	O
to	CIMZIA.xml:S1:7809:2	O
those	CIMZIA.xml:S1:7812:5	O
seen	CIMZIA.xml:S1:7818:4	O
in	CIMZIA.xml:S1:7823:2	O
Crohn	CIMZIA.xml:S1:7826:5	O
's	CIMZIA.xml:S1:7831:2	O
disease	CIMZIA.xml:S1:7834:7	O
patients	CIMZIA.xml:S1:7842:8	O
.	CIMZIA.xml:S1:7850:1	O

Psoriatic	CIMZIA.xml:S1:7860:9	O
Arthritis	CIMZIA.xml:S1:7870:9	O
Clinical	CIMZIA.xml:S1:7880:8	O
Study	CIMZIA.xml:S1:7889:5	O

CIMZIA	CIMZIA.xml:S1:7901:6	O
has	CIMZIA.xml:S1:7908:3	O
been	CIMZIA.xml:S1:7912:4	O
studied	CIMZIA.xml:S1:7917:7	O
in	CIMZIA.xml:S1:7925:2	O
409	CIMZIA.xml:S1:7928:3	O
patients	CIMZIA.xml:S1:7932:8	O
with	CIMZIA.xml:S1:7941:4	O
psoriatic	CIMZIA.xml:S1:7946:9	O
arthritis	CIMZIA.xml:S1:7956:9	O
(	CIMZIA.xml:S1:7966:1	O
PsA	CIMZIA.xml:S1:7967:3	O
)	CIMZIA.xml:S1:7970:1	O
in	CIMZIA.xml:S1:7972:2	O
a	CIMZIA.xml:S1:7975:1	O
placebo	CIMZIA.xml:S1:7977:7	O
-	CIMZIA.xml:S1:7984:1	O
controlled	CIMZIA.xml:S1:7985:10	O
trial	CIMZIA.xml:S1:7996:5	O
.	CIMZIA.xml:S1:8001:1	O

The	CIMZIA.xml:S1:8003:3	O
safety	CIMZIA.xml:S1:8007:6	O
profile	CIMZIA.xml:S1:8014:7	O
for	CIMZIA.xml:S1:8022:3	O
patients	CIMZIA.xml:S1:8026:8	O
with	CIMZIA.xml:S1:8035:4	O
PsA	CIMZIA.xml:S1:8040:3	O
treated	CIMZIA.xml:S1:8044:7	O
with	CIMZIA.xml:S1:8052:4	O
CIMZIA	CIMZIA.xml:S1:8057:6	O
was	CIMZIA.xml:S1:8064:3	O
similar	CIMZIA.xml:S1:8068:7	O
to	CIMZIA.xml:S1:8076:2	O
the	CIMZIA.xml:S1:8079:3	O
safety	CIMZIA.xml:S1:8083:6	O
profile	CIMZIA.xml:S1:8090:7	O
seen	CIMZIA.xml:S1:8098:4	O
in	CIMZIA.xml:S1:8103:2	O
patients	CIMZIA.xml:S1:8106:8	O
with	CIMZIA.xml:S1:8115:4	O
RA	CIMZIA.xml:S1:8120:2	O
and	CIMZIA.xml:S1:8123:3	O
previous	CIMZIA.xml:S1:8127:8	O
experience	CIMZIA.xml:S1:8136:10	O
with	CIMZIA.xml:S1:8147:4	O
CIMZIA	CIMZIA.xml:S1:8152:6	O
.	CIMZIA.xml:S1:8160:1	O

Ankylosing	CIMZIA.xml:S1:8172:10	O
Spondylitis	CIMZIA.xml:S1:8183:11	O
Clinical	CIMZIA.xml:S1:8195:8	O
Study	CIMZIA.xml:S1:8204:5	O

CIMZIA	CIMZIA.xml:S1:8216:6	O
has	CIMZIA.xml:S1:8223:3	O
been	CIMZIA.xml:S1:8227:4	O
studied	CIMZIA.xml:S1:8232:7	O
in	CIMZIA.xml:S1:8240:2	O
325	CIMZIA.xml:S1:8243:3	O
patients	CIMZIA.xml:S1:8247:8	O
with	CIMZIA.xml:S1:8256:4	O
axial	CIMZIA.xml:S1:8261:5	O
spondyloarthritis	CIMZIA.xml:S1:8267:17	O
of	CIMZIA.xml:S1:8285:2	O
whom	CIMZIA.xml:S1:8288:4	O
the	CIMZIA.xml:S1:8293:3	O
majority	CIMZIA.xml:S1:8297:8	O
had	CIMZIA.xml:S1:8306:3	O
ankylosing	CIMZIA.xml:S1:8310:10	O
spondylitis	CIMZIA.xml:S1:8321:11	O
(	CIMZIA.xml:S1:8333:1	O
AS	CIMZIA.xml:S1:8334:2	O
)	CIMZIA.xml:S1:8336:1	O
in	CIMZIA.xml:S1:8338:2	O
a	CIMZIA.xml:S1:8341:1	O
placebo	CIMZIA.xml:S1:8343:7	O
-	CIMZIA.xml:S1:8350:1	O
controlled	CIMZIA.xml:S1:8351:10	O
study	CIMZIA.xml:S1:8362:5	O
(	CIMZIA.xml:S1:8368:1	O
AS	CIMZIA.xml:S1:8369:2	O
-	CIMZIA.xml:S1:8371:1	O
1	CIMZIA.xml:S1:8372:1	O
)	CIMZIA.xml:S1:8373:1	O
.	CIMZIA.xml:S1:8374:1	O

The	CIMZIA.xml:S1:8376:3	O
safety	CIMZIA.xml:S1:8380:6	O
profile	CIMZIA.xml:S1:8387:7	O
for	CIMZIA.xml:S1:8395:3	O
patients	CIMZIA.xml:S1:8399:8	O
in	CIMZIA.xml:S1:8408:2	O
study	CIMZIA.xml:S1:8411:5	O
AS	CIMZIA.xml:S1:8417:2	O
-	CIMZIA.xml:S1:8419:1	O
1	CIMZIA.xml:S1:8420:1	O
treated	CIMZIA.xml:S1:8422:7	O
with	CIMZIA.xml:S1:8430:4	O
CIMZIA	CIMZIA.xml:S1:8435:6	O
was	CIMZIA.xml:S1:8442:3	O
similar	CIMZIA.xml:S1:8446:7	O
to	CIMZIA.xml:S1:8454:2	O
the	CIMZIA.xml:S1:8457:3	O
safety	CIMZIA.xml:S1:8461:6	O
profile	CIMZIA.xml:S1:8468:7	O
seen	CIMZIA.xml:S1:8476:4	O
in	CIMZIA.xml:S1:8481:2	O
patients	CIMZIA.xml:S1:8484:8	O
with	CIMZIA.xml:S1:8493:4	O
RA	CIMZIA.xml:S1:8498:2	O
.	CIMZIA.xml:S1:8500:1	O

Infections	CIMZIA.xml:S1:8512:10	O

The	CIMZIA.xml:S1:8531:3	O
incidence	CIMZIA.xml:S1:8535:9	O
of	CIMZIA.xml:S1:8545:2	O
infections	CIMZIA.xml:S1:8548:10	B-AdverseReaction
in	CIMZIA.xml:S1:8559:2	O
controlled	CIMZIA.xml:S1:8562:10	O
studies	CIMZIA.xml:S1:8573:7	O
in	CIMZIA.xml:S1:8581:2	O
Crohn	CIMZIA.xml:S1:8584:5	O
's	CIMZIA.xml:S1:8589:2	O
disease	CIMZIA.xml:S1:8592:7	O
was	CIMZIA.xml:S1:8600:3	O
38%	CIMZIA.xml:S1:8604:3	O
for	CIMZIA.xml:S1:8608:3	O
CIMZIA	CIMZIA.xml:S1:8612:6	O
-	CIMZIA.xml:S1:8618:1	O
treated	CIMZIA.xml:S1:8619:7	O
patients	CIMZIA.xml:S1:8627:8	O
and	CIMZIA.xml:S1:8636:3	O
30%	CIMZIA.xml:S1:8640:3	O
for	CIMZIA.xml:S1:8644:3	O
placebo	CIMZIA.xml:S1:8648:7	O
-	CIMZIA.xml:S1:8655:1	O
treated	CIMZIA.xml:S1:8656:7	O
patients	CIMZIA.xml:S1:8664:8	O
.	CIMZIA.xml:S1:8672:1	O

The	CIMZIA.xml:S1:8674:3	O
infections	CIMZIA.xml:S1:8678:10	B-AdverseReaction
consisted	CIMZIA.xml:S1:8689:9	O
primarily	CIMZIA.xml:S1:8699:9	O
of	CIMZIA.xml:S1:8709:2	O
upper	CIMZIA.xml:S1:8712:5	B-AdverseReaction
respiratory	CIMZIA.xml:S1:8718:11	I-AdverseReaction
infections	CIMZIA.xml:S1:8730:10	I-AdverseReaction
(	CIMZIA.xml:S1:8741:1	O
20%	CIMZIA.xml:S1:8742:3	O
for	CIMZIA.xml:S1:8746:3	O
CIMZIA	CIMZIA.xml:S1:8750:6	O
,	CIMZIA.xml:S1:8756:1	O
13%	CIMZIA.xml:S1:8758:3	O
for	CIMZIA.xml:S1:8762:3	O
placebo	CIMZIA.xml:S1:8766:7	O
)	CIMZIA.xml:S1:8773:1	O
.	CIMZIA.xml:S1:8774:1	O

The	CIMZIA.xml:S1:8776:3	O
incidence	CIMZIA.xml:S1:8780:9	O
of	CIMZIA.xml:S1:8790:2	O
serious	CIMZIA.xml:S1:8793:7	B-Severity
infections	CIMZIA.xml:S1:8801:10	B-AdverseReaction
during	CIMZIA.xml:S1:8812:6	O
the	CIMZIA.xml:S1:8819:3	O
controlled	CIMZIA.xml:S1:8823:10	O
clinical	CIMZIA.xml:S1:8834:8	O
studies	CIMZIA.xml:S1:8843:7	O
was	CIMZIA.xml:S1:8851:3	O
3%	CIMZIA.xml:S1:8855:2	O
per	CIMZIA.xml:S1:8858:3	O
patient	CIMZIA.xml:S1:8862:7	O
-	CIMZIA.xml:S1:8869:1	O
year	CIMZIA.xml:S1:8870:4	O
for	CIMZIA.xml:S1:8875:3	O
CIMZIA	CIMZIA.xml:S1:8879:6	O
-	CIMZIA.xml:S1:8885:1	O
treated	CIMZIA.xml:S1:8886:7	O
patients	CIMZIA.xml:S1:8894:8	O
and	CIMZIA.xml:S1:8903:3	O
1%	CIMZIA.xml:S1:8907:2	O
for	CIMZIA.xml:S1:8910:3	O
placebo	CIMZIA.xml:S1:8914:7	O
-	CIMZIA.xml:S1:8921:1	O
treated	CIMZIA.xml:S1:8922:7	O
patients	CIMZIA.xml:S1:8930:8	O
.	CIMZIA.xml:S1:8938:1	O

Serious	CIMZIA.xml:S1:8940:7	B-Severity
infections	CIMZIA.xml:S1:8948:10	B-AdverseReaction
observed	CIMZIA.xml:S1:8959:8	O
included	CIMZIA.xml:S1:8968:8	O
bacterial	CIMZIA.xml:S1:8977:9	B-AdverseReaction
and	CIMZIA.xml:S1:8987:3	O
viral	CIMZIA.xml:S1:8991:5	B-AdverseReaction
infections	CIMZIA.xml:S1:8997:10	I-AdverseReaction
,	CIMZIA.xml:S1:9007:1	O
pneumonia	CIMZIA.xml:S1:9009:9	B-AdverseReaction
,	CIMZIA.xml:S1:9018:1	O
and	CIMZIA.xml:S1:9020:3	O
pyelonephritis	CIMZIA.xml:S1:9024:14	B-AdverseReaction
.	CIMZIA.xml:S1:9038:1	O

The	CIMZIA.xml:S1:9044:3	O
incidence	CIMZIA.xml:S1:9048:9	O
of	CIMZIA.xml:S1:9058:2	O
new	CIMZIA.xml:S1:9061:3	O
cases	CIMZIA.xml:S1:9065:5	O
of	CIMZIA.xml:S1:9071:2	O
infections	CIMZIA.xml:S1:9074:10	B-AdverseReaction
in	CIMZIA.xml:S1:9085:2	O
controlled	CIMZIA.xml:S1:9088:10	O
clinical	CIMZIA.xml:S1:9099:8	O
studies	CIMZIA.xml:S1:9108:7	O
in	CIMZIA.xml:S1:9116:2	O
rheumatoid	CIMZIA.xml:S1:9119:10	O
arthritis	CIMZIA.xml:S1:9130:9	O
was	CIMZIA.xml:S1:9140:3	O
0.91	CIMZIA.xml:S1:9144:4	O
per	CIMZIA.xml:S1:9149:3	O
patient	CIMZIA.xml:S1:9153:7	O
-	CIMZIA.xml:S1:9160:1	O
year	CIMZIA.xml:S1:9161:4	O
for	CIMZIA.xml:S1:9166:3	O
all	CIMZIA.xml:S1:9170:3	O
CIMZIA	CIMZIA.xml:S1:9174:6	O
-	CIMZIA.xml:S1:9180:1	O
treated	CIMZIA.xml:S1:9181:7	O
patients	CIMZIA.xml:S1:9189:8	O
and	CIMZIA.xml:S1:9198:3	O
0.72	CIMZIA.xml:S1:9202:4	O
per	CIMZIA.xml:S1:9207:3	O
patient	CIMZIA.xml:S1:9211:7	O
-	CIMZIA.xml:S1:9218:1	O
year	CIMZIA.xml:S1:9219:4	O
for	CIMZIA.xml:S1:9224:3	O
placebo	CIMZIA.xml:S1:9228:7	O
-	CIMZIA.xml:S1:9235:1	O
treated	CIMZIA.xml:S1:9236:7	O
patients	CIMZIA.xml:S1:9244:8	O
.	CIMZIA.xml:S1:9252:1	O

The	CIMZIA.xml:S1:9254:3	O
infections	CIMZIA.xml:S1:9258:10	B-AdverseReaction
consisted	CIMZIA.xml:S1:9269:9	O
primarily	CIMZIA.xml:S1:9279:9	O
of	CIMZIA.xml:S1:9289:2	O
upper	CIMZIA.xml:S1:9292:5	B-AdverseReaction
respiratory	CIMZIA.xml:S1:9298:11	I-AdverseReaction
tract	CIMZIA.xml:S1:9310:5	I-AdverseReaction
infections	CIMZIA.xml:S1:9316:10	I-AdverseReaction
,	CIMZIA.xml:S1:9326:1	O
herpes	CIMZIA.xml:S1:9328:6	B-AdverseReaction
infections	CIMZIA.xml:S1:9335:10	I-AdverseReaction
,	CIMZIA.xml:S1:9345:1	O
urinary	CIMZIA.xml:S1:9347:7	B-AdverseReaction
tract	CIMZIA.xml:S1:9355:5	I-AdverseReaction
infections	CIMZIA.xml:S1:9361:10	I-AdverseReaction
,	CIMZIA.xml:S1:9371:1	O
and	CIMZIA.xml:S1:9373:3	O
lower	CIMZIA.xml:S1:9377:5	B-AdverseReaction
respiratory	CIMZIA.xml:S1:9383:11	I-AdverseReaction
tract	CIMZIA.xml:S1:9395:5	I-AdverseReaction
infections	CIMZIA.xml:S1:9401:10	I-AdverseReaction
.	CIMZIA.xml:S1:9411:1	O

In	CIMZIA.xml:S1:9413:2	O
the	CIMZIA.xml:S1:9416:3	O
controlled	CIMZIA.xml:S1:9420:10	O
rheumatoid	CIMZIA.xml:S1:9431:10	O
arthritis	CIMZIA.xml:S1:9442:9	O
studies	CIMZIA.xml:S1:9452:7	O
,	CIMZIA.xml:S1:9459:1	O
there	CIMZIA.xml:S1:9461:5	O
were	CIMZIA.xml:S1:9467:4	O
more	CIMZIA.xml:S1:9472:4	O
new	CIMZIA.xml:S1:9477:3	O
cases	CIMZIA.xml:S1:9481:5	O
of	CIMZIA.xml:S1:9487:2	O
serious	CIMZIA.xml:S1:9490:7	B-Severity
infection	CIMZIA.xml:S1:9498:9	B-AdverseReaction
adverse	CIMZIA.xml:S1:9508:7	O
reactions	CIMZIA.xml:S1:9516:9	O
in	CIMZIA.xml:S1:9526:2	O
the	CIMZIA.xml:S1:9529:3	O
CIMZIA	CIMZIA.xml:S1:9533:6	O
treatment	CIMZIA.xml:S1:9540:9	O
groups	CIMZIA.xml:S1:9550:6	O
,	CIMZIA.xml:S1:9556:1	O
compared	CIMZIA.xml:S1:9558:8	O
to	CIMZIA.xml:S1:9567:2	O
the	CIMZIA.xml:S1:9570:3	O
placebo	CIMZIA.xml:S1:9574:7	O
groups	CIMZIA.xml:S1:9582:6	O
(	CIMZIA.xml:S1:9589:1	O
0.06	CIMZIA.xml:S1:9590:4	O
per	CIMZIA.xml:S1:9595:3	O
patient	CIMZIA.xml:S1:9599:7	O
-	CIMZIA.xml:S1:9606:1	O
year	CIMZIA.xml:S1:9607:4	O
for	CIMZIA.xml:S1:9612:3	O
all	CIMZIA.xml:S1:9616:3	O
CIMZIA	CIMZIA.xml:S1:9620:6	O
doses	CIMZIA.xml:S1:9627:5	O
vs	CIMZIA.xml:S1:9633:2	O
.	CIMZIA.xml:S1:9635:1	O

0.02	CIMZIA.xml:S1:9637:4	O
per	CIMZIA.xml:S1:9642:3	O
patient	CIMZIA.xml:S1:9646:7	O
-	CIMZIA.xml:S1:9653:1	O
year	CIMZIA.xml:S1:9654:4	O
for	CIMZIA.xml:S1:9659:3	O
placebo	CIMZIA.xml:S1:9663:7	O
)	CIMZIA.xml:S1:9670:1	O
.	CIMZIA.xml:S1:9671:1	O

Rates	CIMZIA.xml:S1:9673:5	O
of	CIMZIA.xml:S1:9679:2	O
serious	CIMZIA.xml:S1:9682:7	B-Severity
infections	CIMZIA.xml:S1:9690:10	B-AdverseReaction
in	CIMZIA.xml:S1:9701:2	O
the	CIMZIA.xml:S1:9704:3	O
200	CIMZIA.xml:S1:9708:3	O
mg	CIMZIA.xml:S1:9712:2	O
every	CIMZIA.xml:S1:9715:5	O
other	CIMZIA.xml:S1:9721:5	O
week	CIMZIA.xml:S1:9727:4	O
dose	CIMZIA.xml:S1:9732:4	O
group	CIMZIA.xml:S1:9737:5	O
were	CIMZIA.xml:S1:9743:4	O
0.06	CIMZIA.xml:S1:9748:4	O
per	CIMZIA.xml:S1:9753:3	O
patient	CIMZIA.xml:S1:9757:7	O
-	CIMZIA.xml:S1:9764:1	O
year	CIMZIA.xml:S1:9765:4	O
and	CIMZIA.xml:S1:9770:3	O
in	CIMZIA.xml:S1:9774:2	O
the	CIMZIA.xml:S1:9777:3	O
400	CIMZIA.xml:S1:9781:3	O
mg	CIMZIA.xml:S1:9785:2	O
every	CIMZIA.xml:S1:9788:5	O
4	CIMZIA.xml:S1:9794:1	O
weeks	CIMZIA.xml:S1:9796:5	O
dose	CIMZIA.xml:S1:9802:4	O
group	CIMZIA.xml:S1:9807:5	O
were	CIMZIA.xml:S1:9813:4	O
0.04	CIMZIA.xml:S1:9818:4	O
per	CIMZIA.xml:S1:9823:3	O
patient	CIMZIA.xml:S1:9827:7	O
-	CIMZIA.xml:S1:9834:1	O
year	CIMZIA.xml:S1:9835:4	O
.	CIMZIA.xml:S1:9839:1	O

Serious	CIMZIA.xml:S1:9841:7	B-Severity
infections	CIMZIA.xml:S1:9849:10	B-AdverseReaction
included	CIMZIA.xml:S1:9860:8	O
tuberculosis	CIMZIA.xml:S1:9869:12	B-AdverseReaction
,	CIMZIA.xml:S1:9881:1	O
pneumonia	CIMZIA.xml:S1:9883:9	B-AdverseReaction
,	CIMZIA.xml:S1:9892:1	O
cellulitis	CIMZIA.xml:S1:9894:10	B-AdverseReaction
,	CIMZIA.xml:S1:9904:1	O
and	CIMZIA.xml:S1:9906:3	O
pyelonephritis	CIMZIA.xml:S1:9910:14	B-AdverseReaction
.	CIMZIA.xml:S1:9924:1	O

In	CIMZIA.xml:S1:9926:2	O
the	CIMZIA.xml:S1:9929:3	O
placebo	CIMZIA.xml:S1:9933:7	B-Factor
group	CIMZIA.xml:S1:9941:5	O
,	CIMZIA.xml:S1:9946:1	O
no	CIMZIA.xml:S1:9948:2	O
serious	CIMZIA.xml:S1:9951:7	B-Severity
infection	CIMZIA.xml:S1:9959:9	B-AdverseReaction
occurred	CIMZIA.xml:S1:9969:8	O
in	CIMZIA.xml:S1:9978:2	O
more	CIMZIA.xml:S1:9981:4	O
than	CIMZIA.xml:S1:9986:4	O
one	CIMZIA.xml:S1:9991:3	O
subject	CIMZIA.xml:S1:9995:7	O
.	CIMZIA.xml:S1:10002:1	O

There	CIMZIA.xml:S1:10004:5	O
is	CIMZIA.xml:S1:10010:2	O
no	CIMZIA.xml:S1:10013:2	O
evidence	CIMZIA.xml:S1:10016:8	O
of	CIMZIA.xml:S1:10025:2	O
increased	CIMZIA.xml:S1:10028:9	O
risk	CIMZIA.xml:S1:10038:4	O
of	CIMZIA.xml:S1:10043:2	O
infections	CIMZIA.xml:S1:10046:10	O
with	CIMZIA.xml:S1:10057:4	O
continued	CIMZIA.xml:S1:10062:9	O
exposure	CIMZIA.xml:S1:10072:8	O
over	CIMZIA.xml:S1:10081:4	O
time	CIMZIA.xml:S1:10086:4	O
[	CIMZIA.xml:S1:10092:1	O
see	CIMZIA.xml:S1:10093:3	O
Warnings	CIMZIA.xml:S1:10098:8	O
and	CIMZIA.xml:S1:10107:3	O
Precautions	CIMZIA.xml:S1:10111:11	O
(	CIMZIA.xml:S1:10123:1	O
5.1	CIMZIA.xml:S1:10124:3	O
)	CIMZIA.xml:S1:10127:1	O
]	CIMZIA.xml:S1:10130:1	O
.	CIMZIA.xml:S1:10133:1	O

Tuberculosis	CIMZIA.xml:S1:10145:12	O
and	CIMZIA.xml:S1:10158:3	O
Opportunistic	CIMZIA.xml:S1:10162:13	O
Infections	CIMZIA.xml:S1:10176:10	O

In	CIMZIA.xml:S1:10195:2	O
completed	CIMZIA.xml:S1:10198:9	O
and	CIMZIA.xml:S1:10208:3	O
ongoing	CIMZIA.xml:S1:10212:7	O
global	CIMZIA.xml:S1:10220:6	O
clinical	CIMZIA.xml:S1:10227:8	O
studies	CIMZIA.xml:S1:10236:7	O
in	CIMZIA.xml:S1:10244:2	O
all	CIMZIA.xml:S1:10247:3	O
indications	CIMZIA.xml:S1:10251:11	O
including	CIMZIA.xml:S1:10263:9	O
5	CIMZIA.xml:S1:10273:1	O
,	CIMZIA.xml:S1:10274:1	O
118	CIMZIA.xml:S1:10275:3	O
CIMZIA	CIMZIA.xml:S1:10279:6	O
-	CIMZIA.xml:S1:10285:1	O
treated	CIMZIA.xml:S1:10286:7	O
patients	CIMZIA.xml:S1:10294:8	O
,	CIMZIA.xml:S1:10302:1	O
the	CIMZIA.xml:S1:10304:3	O
overall	CIMZIA.xml:S1:10308:7	O
rate	CIMZIA.xml:S1:10316:4	O
of	CIMZIA.xml:S1:10321:2	O
tuberculosis	CIMZIA.xml:S1:10324:12	B-AdverseReaction
is	CIMZIA.xml:S1:10337:2	O
approximately	CIMZIA.xml:S1:10340:13	O
0.61	CIMZIA.xml:S1:10354:4	O
per	CIMZIA.xml:S1:10359:3	O
100	CIMZIA.xml:S1:10363:3	O
patient	CIMZIA.xml:S1:10367:7	O
-	CIMZIA.xml:S1:10374:1	O
years	CIMZIA.xml:S1:10375:5	O
across	CIMZIA.xml:S1:10381:6	O
all	CIMZIA.xml:S1:10388:3	O
indications	CIMZIA.xml:S1:10392:11	O
.	CIMZIA.xml:S1:10403:1	O

The	CIMZIA.xml:S1:10409:3	O
majority	CIMZIA.xml:S1:10413:8	O
of	CIMZIA.xml:S1:10422:2	O
cases	CIMZIA.xml:S1:10425:5	O
occurred	CIMZIA.xml:S1:10431:8	O
in	CIMZIA.xml:S1:10440:2	O
countries	CIMZIA.xml:S1:10443:9	O
with	CIMZIA.xml:S1:10453:4	O
high	CIMZIA.xml:S1:10458:4	O
endemic	CIMZIA.xml:S1:10463:7	O
rates	CIMZIA.xml:S1:10471:5	O
of	CIMZIA.xml:S1:10477:2	O
TB	CIMZIA.xml:S1:10480:2	B-AdverseReaction
.	CIMZIA.xml:S1:10482:1	O

Reports	CIMZIA.xml:S1:10484:7	O
include	CIMZIA.xml:S1:10492:7	O
cases	CIMZIA.xml:S1:10500:5	O
of	CIMZIA.xml:S1:10506:2	O
miliary	CIMZIA.xml:S1:10509:7	B-AdverseReaction
,	CIMZIA.xml:S1:10516:1	O
lymphatic	CIMZIA.xml:S1:10518:9	B-AdverseReaction
,	CIMZIA.xml:S1:10527:1	O
peritoneal	CIMZIA.xml:S1:10529:10	B-AdverseReaction
,	CIMZIA.xml:S1:10539:1	O
as	CIMZIA.xml:S1:10541:2	O
well	CIMZIA.xml:S1:10544:4	O
as	CIMZIA.xml:S1:10549:2	O
pulmonary	CIMZIA.xml:S1:10552:9	B-AdverseReaction
TB	CIMZIA.xml:S1:10562:2	I-AdverseReaction
.	CIMZIA.xml:S1:10564:1	O

The	CIMZIA.xml:S1:10566:3	O
median	CIMZIA.xml:S1:10570:6	O
time	CIMZIA.xml:S1:10577:4	O
to	CIMZIA.xml:S1:10582:2	O
onset	CIMZIA.xml:S1:10585:5	O
of	CIMZIA.xml:S1:10591:2	O
TB	CIMZIA.xml:S1:10594:2	B-AdverseReaction
for	CIMZIA.xml:S1:10597:3	O
all	CIMZIA.xml:S1:10601:3	O
patients	CIMZIA.xml:S1:10605:8	O
exposed	CIMZIA.xml:S1:10614:7	O
to	CIMZIA.xml:S1:10622:2	O
CIMZIA	CIMZIA.xml:S1:10625:6	O
across	CIMZIA.xml:S1:10632:6	O
all	CIMZIA.xml:S1:10639:3	O
indications	CIMZIA.xml:S1:10643:11	O
was	CIMZIA.xml:S1:10655:3	O
345	CIMZIA.xml:S1:10659:3	O
days	CIMZIA.xml:S1:10663:4	O
.	CIMZIA.xml:S1:10667:1	O

In	CIMZIA.xml:S1:10669:2	O
the	CIMZIA.xml:S1:10672:3	O
studies	CIMZIA.xml:S1:10676:7	O
with	CIMZIA.xml:S1:10684:4	O
CIMZIA	CIMZIA.xml:S1:10689:6	O
in	CIMZIA.xml:S1:10696:2	O
RA	CIMZIA.xml:S1:10699:2	O
,	CIMZIA.xml:S1:10701:1	O
there	CIMZIA.xml:S1:10703:5	O
were	CIMZIA.xml:S1:10709:4	O
36	CIMZIA.xml:S1:10714:2	O
cases	CIMZIA.xml:S1:10717:5	O
of	CIMZIA.xml:S1:10723:2	O
TB	CIMZIA.xml:S1:10726:2	B-AdverseReaction
among	CIMZIA.xml:S1:10729:5	O
2	CIMZIA.xml:S1:10735:1	O
,	CIMZIA.xml:S1:10736:1	O
367	CIMZIA.xml:S1:10737:3	O
exposed	CIMZIA.xml:S1:10741:7	O
patients	CIMZIA.xml:S1:10749:8	O
,	CIMZIA.xml:S1:10757:1	O
including	CIMZIA.xml:S1:10759:9	O
some	CIMZIA.xml:S1:10769:4	O
fatal	CIMZIA.xml:S1:10774:5	B-AdverseReaction
cases	CIMZIA.xml:S1:10780:5	O
.	CIMZIA.xml:S1:10785:1	O

Rare	CIMZIA.xml:S1:10787:4	O
cases	CIMZIA.xml:S1:10792:5	O
of	CIMZIA.xml:S1:10798:2	O
opportunistic	CIMZIA.xml:S1:10801:13	B-AdverseReaction
infections	CIMZIA.xml:S1:10815:10	I-AdverseReaction
have	CIMZIA.xml:S1:10826:4	O
also	CIMZIA.xml:S1:10831:4	O
been	CIMZIA.xml:S1:10836:4	O
reported	CIMZIA.xml:S1:10841:8	O
in	CIMZIA.xml:S1:10850:2	O
these	CIMZIA.xml:S1:10853:5	O
clinical	CIMZIA.xml:S1:10859:8	O
trials	CIMZIA.xml:S1:10868:6	O
.	CIMZIA.xml:S1:10874:1	O

[	CIMZIA.xml:S1:10877:1	O
see	CIMZIA.xml:S1:10878:3	O
Warnings	CIMZIA.xml:S1:10883:8	O
and	CIMZIA.xml:S1:10892:3	O
Precautions	CIMZIA.xml:S1:10896:11	O
(	CIMZIA.xml:S1:10908:1	O
5.1	CIMZIA.xml:S1:10909:3	O
)	CIMZIA.xml:S1:10912:1	O
]	CIMZIA.xml:S1:10915:1	O
.	CIMZIA.xml:S1:10916:1	O

Malignancies	CIMZIA.xml:S1:10930:12	O

In	CIMZIA.xml:S1:10951:2	O
clinical	CIMZIA.xml:S1:10954:8	O
studies	CIMZIA.xml:S1:10963:7	O
of	CIMZIA.xml:S1:10971:2	O
CIMZIA	CIMZIA.xml:S1:10974:6	O
,	CIMZIA.xml:S1:10980:1	O
the	CIMZIA.xml:S1:10982:3	O
overall	CIMZIA.xml:S1:10986:7	O
incidence	CIMZIA.xml:S1:10994:9	O
rate	CIMZIA.xml:S1:11004:4	O
of	CIMZIA.xml:S1:11009:2	O
malignancies	CIMZIA.xml:S1:11012:12	B-AdverseReaction
was	CIMZIA.xml:S1:11025:3	O
similar	CIMZIA.xml:S1:11029:7	O
for	CIMZIA.xml:S1:11037:3	O
CIMZIA	CIMZIA.xml:S1:11041:6	O
-	CIMZIA.xml:S1:11047:1	O
treated	CIMZIA.xml:S1:11048:7	O
and	CIMZIA.xml:S1:11056:3	O
control	CIMZIA.xml:S1:11060:7	O
patients	CIMZIA.xml:S1:11068:8	O
.	CIMZIA.xml:S1:11076:1	O

For	CIMZIA.xml:S1:11078:3	O
some	CIMZIA.xml:S1:11082:4	O
TNF	CIMZIA.xml:S1:11087:3	O
blockers	CIMZIA.xml:S1:11091:8	O
,	CIMZIA.xml:S1:11099:1	O
more	CIMZIA.xml:S1:11101:4	O
cases	CIMZIA.xml:S1:11106:5	O
of	CIMZIA.xml:S1:11112:2	O
malignancies	CIMZIA.xml:S1:11115:12	B-AdverseReaction
have	CIMZIA.xml:S1:11128:4	O
been	CIMZIA.xml:S1:11133:4	O
observed	CIMZIA.xml:S1:11138:8	O
among	CIMZIA.xml:S1:11147:5	O
patients	CIMZIA.xml:S1:11153:8	O
receiving	CIMZIA.xml:S1:11162:9	O
those	CIMZIA.xml:S1:11172:5	O
TNF	CIMZIA.xml:S1:11178:3	B-DrugClass
blockers	CIMZIA.xml:S1:11182:8	I-DrugClass
compared	CIMZIA.xml:S1:11191:8	O
to	CIMZIA.xml:S1:11200:2	O
control	CIMZIA.xml:S1:11203:7	O
patients	CIMZIA.xml:S1:11211:8	O
.	CIMZIA.xml:S1:11221:1	O

[	CIMZIA.xml:S1:11226:1	O
see	CIMZIA.xml:S1:11227:3	O
Warnings	CIMZIA.xml:S1:11232:8	O
and	CIMZIA.xml:S1:11241:3	O
Precautions	CIMZIA.xml:S1:11245:11	O
(	CIMZIA.xml:S1:11257:1	O
5.2	CIMZIA.xml:S1:11258:3	O
)	CIMZIA.xml:S1:11261:1	O
]	CIMZIA.xml:S1:11264:1	O

Heart	CIMZIA.xml:S1:11278:5	O
Failure	CIMZIA.xml:S1:11284:7	O

In	CIMZIA.xml:S1:11300:2	O
placebo	CIMZIA.xml:S1:11303:7	O
-	CIMZIA.xml:S1:11310:1	O
controlled	CIMZIA.xml:S1:11311:10	O
and	CIMZIA.xml:S1:11322:3	O
open	CIMZIA.xml:S1:11326:4	O
-	CIMZIA.xml:S1:11330:1	O
label	CIMZIA.xml:S1:11331:5	O
rheumatoid	CIMZIA.xml:S1:11337:10	O
arthritis	CIMZIA.xml:S1:11348:9	O
studies	CIMZIA.xml:S1:11358:7	O
,	CIMZIA.xml:S1:11365:1	O
cases	CIMZIA.xml:S1:11367:5	O
of	CIMZIA.xml:S1:11373:2	O
new	CIMZIA.xml:S1:11376:3	B-AdverseReaction
or	CIMZIA.xml:S1:11380:2	O
worsening	CIMZIA.xml:S1:11383:9	B-AdverseReaction
heart	CIMZIA.xml:S1:11393:5	I-AdverseReaction
failure	CIMZIA.xml:S1:11399:7	I-AdverseReaction
have	CIMZIA.xml:S1:11407:4	O
been	CIMZIA.xml:S1:11412:4	O
reported	CIMZIA.xml:S1:11417:8	O
for	CIMZIA.xml:S1:11426:3	O
CIMZIA	CIMZIA.xml:S1:11430:6	O
-	CIMZIA.xml:S1:11436:1	O
treated	CIMZIA.xml:S1:11437:7	O
patients	CIMZIA.xml:S1:11445:8	O
.	CIMZIA.xml:S1:11453:1	O

The	CIMZIA.xml:S1:11455:3	O
majority	CIMZIA.xml:S1:11459:8	O
of	CIMZIA.xml:S1:11468:2	O
these	CIMZIA.xml:S1:11471:5	O
cases	CIMZIA.xml:S1:11477:5	O
were	CIMZIA.xml:S1:11483:4	O
mild	CIMZIA.xml:S1:11488:4	O
to	CIMZIA.xml:S1:11493:2	O
moderate	CIMZIA.xml:S1:11496:8	O
and	CIMZIA.xml:S1:11505:3	O
occurred	CIMZIA.xml:S1:11509:8	O
during	CIMZIA.xml:S1:11518:6	O
the	CIMZIA.xml:S1:11525:3	O
first	CIMZIA.xml:S1:11529:5	O
year	CIMZIA.xml:S1:11535:4	O
of	CIMZIA.xml:S1:11540:2	O
exposure	CIMZIA.xml:S1:11543:8	O
.	CIMZIA.xml:S1:11551:1	O

[	CIMZIA.xml:S1:11554:1	O
see	CIMZIA.xml:S1:11555:3	O
Warnings	CIMZIA.xml:S1:11560:8	O
and	CIMZIA.xml:S1:11569:3	O
Precautions	CIMZIA.xml:S1:11573:11	O
(	CIMZIA.xml:S1:11585:1	O
5.3	CIMZIA.xml:S1:11586:3	O
)	CIMZIA.xml:S1:11589:1	O
]	CIMZIA.xml:S1:11592:1	O
.	CIMZIA.xml:S1:11593:1	O

Autoantibodies	CIMZIA.xml:S1:11607:14	O

In	CIMZIA.xml:S1:11630:2	O
clinical	CIMZIA.xml:S1:11633:8	O
studies	CIMZIA.xml:S1:11642:7	O
in	CIMZIA.xml:S1:11650:2	O
Crohn	CIMZIA.xml:S1:11653:5	O
's	CIMZIA.xml:S1:11658:2	O
disease	CIMZIA.xml:S1:11661:7	O
,	CIMZIA.xml:S1:11668:1	O
4%	CIMZIA.xml:S1:11670:2	O
of	CIMZIA.xml:S1:11673:2	O
patients	CIMZIA.xml:S1:11676:8	O
treated	CIMZIA.xml:S1:11685:7	O
with	CIMZIA.xml:S1:11693:4	O
CIMZIA	CIMZIA.xml:S1:11698:6	O
and	CIMZIA.xml:S1:11705:3	O
2%	CIMZIA.xml:S1:11709:2	O
of	CIMZIA.xml:S1:11712:2	O
patients	CIMZIA.xml:S1:11715:8	O
treated	CIMZIA.xml:S1:11724:7	O
with	CIMZIA.xml:S1:11732:4	O
placebo	CIMZIA.xml:S1:11737:7	O
that	CIMZIA.xml:S1:11745:4	O
had	CIMZIA.xml:S1:11750:3	O
negative	CIMZIA.xml:S1:11754:8	O
baseline	CIMZIA.xml:S1:11763:8	O
ANA	CIMZIA.xml:S1:11772:3	B-AdverseReaction
titers	CIMZIA.xml:S1:11776:6	I-AdverseReaction
developed	CIMZIA.xml:S1:11783:9	O
positive	CIMZIA.xml:S1:11793:8	I-AdverseReaction
titers	CIMZIA.xml:S1:11802:6	O
during	CIMZIA.xml:S1:11809:6	O
the	CIMZIA.xml:S1:11816:3	O
studies	CIMZIA.xml:S1:11820:7	O
.	CIMZIA.xml:S1:11827:1	O

One	CIMZIA.xml:S1:11829:3	O
of	CIMZIA.xml:S1:11833:2	O
the	CIMZIA.xml:S1:11836:3	O
1	CIMZIA.xml:S1:11840:1	O
,	CIMZIA.xml:S1:11841:1	O
564	CIMZIA.xml:S1:11842:3	O
Crohn	CIMZIA.xml:S1:11846:5	O
's	CIMZIA.xml:S1:11851:2	O
disease	CIMZIA.xml:S1:11854:7	O
patients	CIMZIA.xml:S1:11862:8	O
treated	CIMZIA.xml:S1:11871:7	O
with	CIMZIA.xml:S1:11879:4	O
CIMZIA	CIMZIA.xml:S1:11884:6	O
developed	CIMZIA.xml:S1:11891:9	O
symptoms	CIMZIA.xml:S1:11901:8	O
of	CIMZIA.xml:S1:11910:2	O
a	CIMZIA.xml:S1:11913:1	O
lupus	CIMZIA.xml:S1:11915:5	B-AdverseReaction
-	CIMZIA.xml:S1:11920:1	I-AdverseReaction
like	CIMZIA.xml:S1:11921:4	I-AdverseReaction
syndrome	CIMZIA.xml:S1:11926:8	I-AdverseReaction
.	CIMZIA.xml:S1:11934:1	O

In	CIMZIA.xml:S1:11940:2	O
clinical	CIMZIA.xml:S1:11943:8	O
trials	CIMZIA.xml:S1:11952:6	O
of	CIMZIA.xml:S1:11959:2	O
TNF	CIMZIA.xml:S1:11962:3	O
blockers	CIMZIA.xml:S1:11966:8	O
,	CIMZIA.xml:S1:11974:1	O
including	CIMZIA.xml:S1:11976:9	O
CIMZIA	CIMZIA.xml:S1:11986:6	O
,	CIMZIA.xml:S1:11992:1	O
in	CIMZIA.xml:S1:11994:2	O
patients	CIMZIA.xml:S1:11997:8	O
with	CIMZIA.xml:S1:12006:4	O
RA	CIMZIA.xml:S1:12011:2	O
,	CIMZIA.xml:S1:12013:1	O
some	CIMZIA.xml:S1:12015:4	O
patients	CIMZIA.xml:S1:12020:8	O
have	CIMZIA.xml:S1:12029:4	O
developed	CIMZIA.xml:S1:12034:9	O
ANA	CIMZIA.xml:S1:12044:3	B-AdverseReaction
.	CIMZIA.xml:S1:12047:1	O

Four	CIMZIA.xml:S1:12049:4	O
patients	CIMZIA.xml:S1:12054:8	O
out	CIMZIA.xml:S1:12063:3	O
of	CIMZIA.xml:S1:12067:2	O
2	CIMZIA.xml:S1:12070:1	O
,	CIMZIA.xml:S1:12071:1	O
367	CIMZIA.xml:S1:12072:3	O
patients	CIMZIA.xml:S1:12076:8	O
treated	CIMZIA.xml:S1:12085:7	O
with	CIMZIA.xml:S1:12093:4	O
CIMZIA	CIMZIA.xml:S1:12098:6	O
in	CIMZIA.xml:S1:12105:2	O
RA	CIMZIA.xml:S1:12108:2	O
clinical	CIMZIA.xml:S1:12111:8	O
studies	CIMZIA.xml:S1:12120:7	O
developed	CIMZIA.xml:S1:12128:9	O
clinical	CIMZIA.xml:S1:12138:8	O
signs	CIMZIA.xml:S1:12147:5	O
suggestive	CIMZIA.xml:S1:12153:10	O
of	CIMZIA.xml:S1:12164:2	O
a	CIMZIA.xml:S1:12167:1	O
lupus	CIMZIA.xml:S1:12169:5	B-AdverseReaction
-	CIMZIA.xml:S1:12174:1	I-AdverseReaction
like	CIMZIA.xml:S1:12175:4	I-AdverseReaction
syndrome	CIMZIA.xml:S1:12180:8	I-AdverseReaction
.	CIMZIA.xml:S1:12188:1	O

The	CIMZIA.xml:S1:12190:3	O
impact	CIMZIA.xml:S1:12194:6	O
of	CIMZIA.xml:S1:12201:2	O
long	CIMZIA.xml:S1:12204:4	O
-	CIMZIA.xml:S1:12208:1	O
term	CIMZIA.xml:S1:12209:4	O
treatment	CIMZIA.xml:S1:12214:9	O
with	CIMZIA.xml:S1:12224:4	O
CIMZIA	CIMZIA.xml:S1:12229:6	O
on	CIMZIA.xml:S1:12236:2	O
the	CIMZIA.xml:S1:12239:3	O
development	CIMZIA.xml:S1:12243:11	O
of	CIMZIA.xml:S1:12255:2	O
autoimmune	CIMZIA.xml:S1:12258:10	O
diseases	CIMZIA.xml:S1:12269:8	O
is	CIMZIA.xml:S1:12278:2	O
unknown	CIMZIA.xml:S1:12281:7	O
[	CIMZIA.xml:S1:12290:1	O
see	CIMZIA.xml:S1:12291:3	O
Warnings	CIMZIA.xml:S1:12296:8	O
and	CIMZIA.xml:S1:12305:3	O
Precautions	CIMZIA.xml:S1:12309:11	O
(	CIMZIA.xml:S1:12321:1	O
5.9	CIMZIA.xml:S1:12322:3	O
)	CIMZIA.xml:S1:12325:1	O
]	CIMZIA.xml:S1:12328:1	O
.	CIMZIA.xml:S1:12329:1	O

Immunogenicity	CIMZIA.xml:S1:12343:14	O

Patients	CIMZIA.xml:S1:12366:8	O
were	CIMZIA.xml:S1:12375:4	O
tested	CIMZIA.xml:S1:12380:6	O
at	CIMZIA.xml:S1:12387:2	O
multiple	CIMZIA.xml:S1:12390:8	O
time	CIMZIA.xml:S1:12399:4	O
points	CIMZIA.xml:S1:12404:6	O
for	CIMZIA.xml:S1:12411:3	O
antibodies	CIMZIA.xml:S1:12415:10	O
to	CIMZIA.xml:S1:12426:2	O
certolizumab	CIMZIA.xml:S1:12429:12	O
pegol	CIMZIA.xml:S1:12442:5	O
during	CIMZIA.xml:S1:12448:6	O
Studies	CIMZIA.xml:S1:12455:7	O
CD1	CIMZIA.xml:S1:12463:3	O
and	CIMZIA.xml:S1:12467:3	O
CD2	CIMZIA.xml:S1:12471:3	O
.	CIMZIA.xml:S1:12474:1	O

The	CIMZIA.xml:S1:12476:3	O
overall	CIMZIA.xml:S1:12480:7	O
percentage	CIMZIA.xml:S1:12488:10	O
of	CIMZIA.xml:S1:12499:2	O
antibody	CIMZIA.xml:S1:12502:8	O
positive	CIMZIA.xml:S1:12511:8	O
patients	CIMZIA.xml:S1:12520:8	O
was	CIMZIA.xml:S1:12529:3	O
8%	CIMZIA.xml:S1:12533:2	O
in	CIMZIA.xml:S1:12536:2	O
patients	CIMZIA.xml:S1:12539:8	O
continuously	CIMZIA.xml:S1:12548:12	O
exposed	CIMZIA.xml:S1:12561:7	O
to	CIMZIA.xml:S1:12569:2	O
CIMZIA	CIMZIA.xml:S1:12572:6	O
,	CIMZIA.xml:S1:12578:1	O
approximately	CIMZIA.xml:S1:12580:13	O
6%	CIMZIA.xml:S1:12594:2	O
were	CIMZIA.xml:S1:12597:4	O
neutralizing	CIMZIA.xml:S1:12602:12	O
in	CIMZIA.xml:S1:12616:2	O
vitro	CIMZIA.xml:S1:12619:5	O
.	CIMZIA.xml:S1:12626:1	O

No	CIMZIA.xml:S1:12628:2	O
apparent	CIMZIA.xml:S1:12631:8	O
correlation	CIMZIA.xml:S1:12640:11	O
of	CIMZIA.xml:S1:12652:2	O
antibody	CIMZIA.xml:S1:12655:8	O
development	CIMZIA.xml:S1:12664:11	O
to	CIMZIA.xml:S1:12676:2	O
adverse	CIMZIA.xml:S1:12679:7	O
events	CIMZIA.xml:S1:12687:6	O
or	CIMZIA.xml:S1:12694:2	O
efficacy	CIMZIA.xml:S1:12697:8	O
was	CIMZIA.xml:S1:12706:3	O
observed	CIMZIA.xml:S1:12710:8	O
.	CIMZIA.xml:S1:12718:1	O

Patients	CIMZIA.xml:S1:12720:8	O
treated	CIMZIA.xml:S1:12729:7	O
with	CIMZIA.xml:S1:12737:4	O
concomitant	CIMZIA.xml:S1:12742:11	O
immunosuppressants	CIMZIA.xml:S1:12754:18	O
had	CIMZIA.xml:S1:12773:3	O
a	CIMZIA.xml:S1:12777:1	O
lower	CIMZIA.xml:S1:12779:5	O
rate	CIMZIA.xml:S1:12785:4	O
of	CIMZIA.xml:S1:12790:2	O
antibody	CIMZIA.xml:S1:12793:8	O
development	CIMZIA.xml:S1:12802:11	O
than	CIMZIA.xml:S1:12814:4	O
patients	CIMZIA.xml:S1:12819:8	O
not	CIMZIA.xml:S1:12828:3	O
taking	CIMZIA.xml:S1:12832:6	O
immunosuppressants	CIMZIA.xml:S1:12839:18	O
at	CIMZIA.xml:S1:12858:2	O
baseline	CIMZIA.xml:S1:12861:8	O
(	CIMZIA.xml:S1:12870:1	O
3%	CIMZIA.xml:S1:12871:2	O
and	CIMZIA.xml:S1:12874:3	O
11%	CIMZIA.xml:S1:12878:3	O
,	CIMZIA.xml:S1:12881:1	O
respectively	CIMZIA.xml:S1:12883:12	O
)	CIMZIA.xml:S1:12895:1	O
.	CIMZIA.xml:S1:12896:1	O

The	CIMZIA.xml:S1:12898:3	O
following	CIMZIA.xml:S1:12902:9	O
adverse	CIMZIA.xml:S1:12912:7	O
events	CIMZIA.xml:S1:12920:6	O
were	CIMZIA.xml:S1:12927:4	O
reported	CIMZIA.xml:S1:12932:8	O
in	CIMZIA.xml:S1:12941:2	O
Crohn	CIMZIA.xml:S1:12944:5	O
's	CIMZIA.xml:S1:12949:2	O
disease	CIMZIA.xml:S1:12952:7	O
patients	CIMZIA.xml:S1:12960:8	O
who	CIMZIA.xml:S1:12969:3	O
were	CIMZIA.xml:S1:12973:4	O
antibody	CIMZIA.xml:S1:12978:8	O
-	CIMZIA.xml:S1:12986:1	O
positive	CIMZIA.xml:S1:12987:8	O
(	CIMZIA.xml:S1:12996:1	O
N	CIMZIA.xml:S1:12997:1	O
100	CIMZIA.xml:S1:13001:3	O
)	CIMZIA.xml:S1:13004:1	O
at	CIMZIA.xml:S1:13006:2	O
an	CIMZIA.xml:S1:13009:2	O
incidence	CIMZIA.xml:S1:13012:9	O
at	CIMZIA.xml:S1:13022:2	O
least	CIMZIA.xml:S1:13025:5	O
3%	CIMZIA.xml:S1:13031:2	O
higher	CIMZIA.xml:S1:13034:6	O
compared	CIMZIA.xml:S1:13041:8	O
to	CIMZIA.xml:S1:13050:2	O
antibody	CIMZIA.xml:S1:13053:8	O
-	CIMZIA.xml:S1:13061:1	O
negative	CIMZIA.xml:S1:13062:8	O
patients	CIMZIA.xml:S1:13071:8	O
(	CIMZIA.xml:S1:13080:1	O
N	CIMZIA.xml:S1:13081:1	O
1	CIMZIA.xml:S1:13085:1	O
,	CIMZIA.xml:S1:13086:1	O
242	CIMZIA.xml:S1:13087:3	O
)	CIMZIA.xml:S1:13090:1	O
:	CIMZIA.xml:S1:13091:1	O
abdominal	CIMZIA.xml:S1:13093:9	B-AdverseReaction
pain	CIMZIA.xml:S1:13103:4	I-AdverseReaction
,	CIMZIA.xml:S1:13107:1	O
arthralgia	CIMZIA.xml:S1:13109:10	B-AdverseReaction
,	CIMZIA.xml:S1:13119:1	O
edema	CIMZIA.xml:S1:13121:5	B-AdverseReaction
peripheral	CIMZIA.xml:S1:13127:10	I-AdverseReaction
,	CIMZIA.xml:S1:13137:1	O
erythema	CIMZIA.xml:S1:13139:8	B-AdverseReaction
nodosum	CIMZIA.xml:S1:13148:7	I-AdverseReaction
,	CIMZIA.xml:S1:13155:1	O
injection	CIMZIA.xml:S1:13157:9	B-AdverseReaction
site	CIMZIA.xml:S1:13167:4	I-AdverseReaction
erythema	CIMZIA.xml:S1:13172:8	I-AdverseReaction
,	CIMZIA.xml:S1:13180:1	O
injection	CIMZIA.xml:S1:13182:9	B-AdverseReaction
site	CIMZIA.xml:S1:13192:4	I-AdverseReaction
pain	CIMZIA.xml:S1:13197:4	I-AdverseReaction
,	CIMZIA.xml:S1:13201:1	O
pain	CIMZIA.xml:S1:13203:4	B-AdverseReaction
in	CIMZIA.xml:S1:13208:2	I-AdverseReaction
extremity	CIMZIA.xml:S1:13211:9	I-AdverseReaction
,	CIMZIA.xml:S1:13220:1	O
and	CIMZIA.xml:S1:13222:3	O
upper	CIMZIA.xml:S1:13226:5	B-AdverseReaction
respiratory	CIMZIA.xml:S1:13232:11	I-AdverseReaction
tract	CIMZIA.xml:S1:13244:5	I-AdverseReaction
infection	CIMZIA.xml:S1:13250:9	I-AdverseReaction
.	CIMZIA.xml:S1:13259:1	O

The	CIMZIA.xml:S1:13265:3	O
overall	CIMZIA.xml:S1:13269:7	O
percentage	CIMZIA.xml:S1:13277:10	O
of	CIMZIA.xml:S1:13288:2	O
patients	CIMZIA.xml:S1:13291:8	O
with	CIMZIA.xml:S1:13300:4	O
antibodies	CIMZIA.xml:S1:13305:10	O
to	CIMZIA.xml:S1:13316:2	O
certolizumab	CIMZIA.xml:S1:13319:12	O
pegol	CIMZIA.xml:S1:13332:5	O
detectable	CIMZIA.xml:S1:13338:10	O
on	CIMZIA.xml:S1:13349:2	O
at	CIMZIA.xml:S1:13352:2	O
least	CIMZIA.xml:S1:13355:5	O
one	CIMZIA.xml:S1:13361:3	O
occasion	CIMZIA.xml:S1:13365:8	O
was	CIMZIA.xml:S1:13374:3	O
7%	CIMZIA.xml:S1:13378:2	O
(	CIMZIA.xml:S1:13381:1	O
105	CIMZIA.xml:S1:13382:3	O
of	CIMZIA.xml:S1:13386:2	O
1	CIMZIA.xml:S1:13389:1	O
,	CIMZIA.xml:S1:13390:1	O
509	CIMZIA.xml:S1:13391:3	O
)	CIMZIA.xml:S1:13394:1	O
in	CIMZIA.xml:S1:13396:2	O
the	CIMZIA.xml:S1:13399:3	O
rheumatoid	CIMZIA.xml:S1:13403:10	O
arthritis	CIMZIA.xml:S1:13414:9	O
placebo	CIMZIA.xml:S1:13424:7	O
-	CIMZIA.xml:S1:13431:1	O
controlled	CIMZIA.xml:S1:13432:10	O
trials	CIMZIA.xml:S1:13443:6	O
.	CIMZIA.xml:S1:13449:1	O

Approximately	CIMZIA.xml:S1:13451:13	O
one	CIMZIA.xml:S1:13465:3	O
third	CIMZIA.xml:S1:13469:5	O
(	CIMZIA.xml:S1:13475:1	O
3%	CIMZIA.xml:S1:13476:2	O
,	CIMZIA.xml:S1:13478:1	O
39	CIMZIA.xml:S1:13480:2	O
of	CIMZIA.xml:S1:13483:2	O
1	CIMZIA.xml:S1:13486:1	O
,	CIMZIA.xml:S1:13487:1	O
509	CIMZIA.xml:S1:13488:3	O
)	CIMZIA.xml:S1:13491:1	O
of	CIMZIA.xml:S1:13493:2	O
these	CIMZIA.xml:S1:13496:5	O
patients	CIMZIA.xml:S1:13502:8	O
had	CIMZIA.xml:S1:13511:3	O
antibodies	CIMZIA.xml:S1:13515:10	O
with	CIMZIA.xml:S1:13526:4	O
neutralizing	CIMZIA.xml:S1:13531:12	O
activity	CIMZIA.xml:S1:13544:8	O
in	CIMZIA.xml:S1:13554:2	O
vitro	CIMZIA.xml:S1:13557:5	O
.	CIMZIA.xml:S1:13564:1	O

Patients	CIMZIA.xml:S1:13566:8	O
treated	CIMZIA.xml:S1:13575:7	O
with	CIMZIA.xml:S1:13583:4	O
concomitant	CIMZIA.xml:S1:13588:11	O
immunosuppressants	CIMZIA.xml:S1:13600:18	O
(	CIMZIA.xml:S1:13619:1	O
MTX	CIMZIA.xml:S1:13620:3	O
)	CIMZIA.xml:S1:13623:1	O
had	CIMZIA.xml:S1:13625:3	O
a	CIMZIA.xml:S1:13629:1	O
lower	CIMZIA.xml:S1:13631:5	O
rate	CIMZIA.xml:S1:13637:4	O
of	CIMZIA.xml:S1:13642:2	O
antibody	CIMZIA.xml:S1:13645:8	O
development	CIMZIA.xml:S1:13654:11	O
than	CIMZIA.xml:S1:13666:4	O
patients	CIMZIA.xml:S1:13671:8	O
not	CIMZIA.xml:S1:13680:3	O
taking	CIMZIA.xml:S1:13684:6	O
immunosuppressants	CIMZIA.xml:S1:13691:18	O
at	CIMZIA.xml:S1:13710:2	O
baseline	CIMZIA.xml:S1:13713:8	O
.	CIMZIA.xml:S1:13721:1	O

Patients	CIMZIA.xml:S1:13723:8	O
treated	CIMZIA.xml:S1:13732:7	O
with	CIMZIA.xml:S1:13740:4	O
concomitant	CIMZIA.xml:S1:13745:11	O
immunosuppressant	CIMZIA.xml:S1:13757:17	O
therapy	CIMZIA.xml:S1:13775:7	O
(	CIMZIA.xml:S1:13783:1	O
MTX	CIMZIA.xml:S1:13784:3	O
)	CIMZIA.xml:S1:13787:1	O
in	CIMZIA.xml:S1:13789:2	O
RA	CIMZIA.xml:S1:13792:2	O
-	CIMZIA.xml:S1:13794:1	O
I	CIMZIA.xml:S1:13795:1	O
,	CIMZIA.xml:S1:13796:1	O
RA	CIMZIA.xml:S1:13798:2	O
-	CIMZIA.xml:S1:13800:1	O
II	CIMZIA.xml:S1:13801:2	O
,	CIMZIA.xml:S1:13803:1	O
RA	CIMZIA.xml:S1:13805:2	O
-	CIMZIA.xml:S1:13807:1	O
III	CIMZIA.xml:S1:13808:3	O
had	CIMZIA.xml:S1:13812:3	O
a	CIMZIA.xml:S1:13816:1	O
lower	CIMZIA.xml:S1:13818:5	O
rate	CIMZIA.xml:S1:13824:4	O
of	CIMZIA.xml:S1:13829:2	O
neutralizing	CIMZIA.xml:S1:13832:12	O
antibody	CIMZIA.xml:S1:13845:8	O
formation	CIMZIA.xml:S1:13854:9	O
overall	CIMZIA.xml:S1:13864:7	O
than	CIMZIA.xml:S1:13872:4	O
patients	CIMZIA.xml:S1:13877:8	O
treated	CIMZIA.xml:S1:13886:7	O
with	CIMZIA.xml:S1:13894:4	O
CIMZIA	CIMZIA.xml:S1:13899:6	O
monotherapy	CIMZIA.xml:S1:13906:11	O
in	CIMZIA.xml:S1:13918:2	O
RA	CIMZIA.xml:S1:13921:2	O
-	CIMZIA.xml:S1:13923:1	O
IV	CIMZIA.xml:S1:13924:2	O
(	CIMZIA.xml:S1:13927:1	O
2%	CIMZIA.xml:S1:13928:2	O
vs	CIMZIA.xml:S1:13931:2	O
.	CIMZIA.xml:S1:13933:1	O

8%	CIMZIA.xml:S1:13935:2	O
)	CIMZIA.xml:S1:13937:1	O
.	CIMZIA.xml:S1:13938:1	O

Both	CIMZIA.xml:S1:13940:4	O
the	CIMZIA.xml:S1:13945:3	O
loading	CIMZIA.xml:S1:13949:7	O
dose	CIMZIA.xml:S1:13957:4	O
of	CIMZIA.xml:S1:13962:2	O
400	CIMZIA.xml:S1:13965:3	O
mg	CIMZIA.xml:S1:13969:2	O
every	CIMZIA.xml:S1:13972:5	O
other	CIMZIA.xml:S1:13978:5	O
week	CIMZIA.xml:S1:13984:4	O
at	CIMZIA.xml:S1:13989:2	O
Weeks	CIMZIA.xml:S1:13992:5	O
0	CIMZIA.xml:S1:13998:1	O
,	CIMZIA.xml:S1:13999:1	O
2	CIMZIA.xml:S1:14001:1	O
and	CIMZIA.xml:S1:14003:3	O
4	CIMZIA.xml:S1:14007:1	O
and	CIMZIA.xml:S1:14009:3	O
concomitant	CIMZIA.xml:S1:14013:11	O
use	CIMZIA.xml:S1:14025:3	O
of	CIMZIA.xml:S1:14029:2	O
MTX	CIMZIA.xml:S1:14032:3	O
were	CIMZIA.xml:S1:14036:4	O
associated	CIMZIA.xml:S1:14041:10	O
with	CIMZIA.xml:S1:14052:4	O
reduced	CIMZIA.xml:S1:14057:7	O
immunogenicity	CIMZIA.xml:S1:14065:14	O
.	CIMZIA.xml:S1:14079:1	O

Antibody	CIMZIA.xml:S1:14085:8	O
formation	CIMZIA.xml:S1:14094:9	O
was	CIMZIA.xml:S1:14104:3	O
associated	CIMZIA.xml:S1:14108:10	O
with	CIMZIA.xml:S1:14119:4	O
lowered	CIMZIA.xml:S1:14124:7	O
drug	CIMZIA.xml:S1:14132:4	O
plasma	CIMZIA.xml:S1:14137:6	O
concentration	CIMZIA.xml:S1:14144:13	O
and	CIMZIA.xml:S1:14158:3	O
reduced	CIMZIA.xml:S1:14162:7	O
efficacy	CIMZIA.xml:S1:14170:8	O
.	CIMZIA.xml:S1:14178:1	O

In	CIMZIA.xml:S1:14180:2	O
patients	CIMZIA.xml:S1:14183:8	O
receiving	CIMZIA.xml:S1:14192:9	O
the	CIMZIA.xml:S1:14202:3	O
recommended	CIMZIA.xml:S1:14206:11	O
CIMZIA	CIMZIA.xml:S1:14218:6	O
dosage	CIMZIA.xml:S1:14225:6	O
of	CIMZIA.xml:S1:14232:2	O
200	CIMZIA.xml:S1:14235:3	O
mg	CIMZIA.xml:S1:14239:2	O
every	CIMZIA.xml:S1:14242:5	O
other	CIMZIA.xml:S1:14248:5	O
week	CIMZIA.xml:S1:14254:4	O
with	CIMZIA.xml:S1:14259:4	O
concomitant	CIMZIA.xml:S1:14264:11	O
MTX	CIMZIA.xml:S1:14276:3	O
,	CIMZIA.xml:S1:14279:1	O
the	CIMZIA.xml:S1:14281:3	O
ACR20	CIMZIA.xml:S1:14285:5	O
response	CIMZIA.xml:S1:14291:8	O
was	CIMZIA.xml:S1:14300:3	O
lower	CIMZIA.xml:S1:14304:5	O
among	CIMZIA.xml:S1:14310:5	O
antibody	CIMZIA.xml:S1:14316:8	O
positive	CIMZIA.xml:S1:14325:8	O
patients	CIMZIA.xml:S1:14334:8	O
than	CIMZIA.xml:S1:14343:4	O
among	CIMZIA.xml:S1:14348:5	O
antibody	CIMZIA.xml:S1:14354:8	O
-	CIMZIA.xml:S1:14362:1	O
negative	CIMZIA.xml:S1:14363:8	O
patients	CIMZIA.xml:S1:14372:8	O
(	CIMZIA.xml:S1:14381:1	O
Study	CIMZIA.xml:S1:14382:5	O
RA	CIMZIA.xml:S1:14388:2	O
-	CIMZIA.xml:S1:14390:1	O
I	CIMZIA.xml:S1:14391:1	O
,	CIMZIA.xml:S1:14392:1	O
48%	CIMZIA.xml:S1:14394:3	O
versus	CIMZIA.xml:S1:14398:6	O
60%	CIMZIA.xml:S1:14405:3	O
;	CIMZIA.xml:S1:14408:1	O
Study	CIMZIA.xml:S1:14410:5	O
RA	CIMZIA.xml:S1:14416:2	O
-	CIMZIA.xml:S1:14418:1	O
II	CIMZIA.xml:S1:14419:2	O
35%	CIMZIA.xml:S1:14422:3	O
versus	CIMZIA.xml:S1:14426:6	O
59%	CIMZIA.xml:S1:14433:3	O
,	CIMZIA.xml:S1:14436:1	O
respectively	CIMZIA.xml:S1:14438:12	O
)	CIMZIA.xml:S1:14450:1	O
.	CIMZIA.xml:S1:14451:1	O

In	CIMZIA.xml:S1:14453:2	O
Study	CIMZIA.xml:S1:14456:5	O
RA	CIMZIA.xml:S1:14462:2	O
-	CIMZIA.xml:S1:14464:1	O
III	CIMZIA.xml:S1:14465:3	O
,	CIMZIA.xml:S1:14468:1	O
too	CIMZIA.xml:S1:14470:3	O
few	CIMZIA.xml:S1:14474:3	O
patients	CIMZIA.xml:S1:14478:8	O
developed	CIMZIA.xml:S1:14487:9	O
antibodies	CIMZIA.xml:S1:14497:10	O
to	CIMZIA.xml:S1:14508:2	O
allow	CIMZIA.xml:S1:14511:5	O
for	CIMZIA.xml:S1:14517:3	O
meaningful	CIMZIA.xml:S1:14521:10	O
analysis	CIMZIA.xml:S1:14532:8	O
of	CIMZIA.xml:S1:14541:2	O
ACR20	CIMZIA.xml:S1:14544:5	O
response	CIMZIA.xml:S1:14550:8	O
by	CIMZIA.xml:S1:14559:2	O
antibody	CIMZIA.xml:S1:14562:8	O
status	CIMZIA.xml:S1:14571:6	O
.	CIMZIA.xml:S1:14577:1	O

In	CIMZIA.xml:S1:14579:2	O
Study	CIMZIA.xml:S1:14582:5	O
RA	CIMZIA.xml:S1:14588:2	O
-	CIMZIA.xml:S1:14590:1	O
IV	CIMZIA.xml:S1:14591:2	O
(	CIMZIA.xml:S1:14594:1	O
monotherapy	CIMZIA.xml:S1:14595:11	O
)	CIMZIA.xml:S1:14606:1	O
,	CIMZIA.xml:S1:14607:1	O
the	CIMZIA.xml:S1:14609:3	O
ACR20	CIMZIA.xml:S1:14613:5	O
response	CIMZIA.xml:S1:14619:8	O
was	CIMZIA.xml:S1:14628:3	O
33%	CIMZIA.xml:S1:14632:3	O
versus	CIMZIA.xml:S1:14636:6	O
56%	CIMZIA.xml:S1:14643:3	O
,	CIMZIA.xml:S1:14646:1	O
antibody	CIMZIA.xml:S1:14648:8	O
-	CIMZIA.xml:S1:14656:1	O
positive	CIMZIA.xml:S1:14657:8	O
versus	CIMZIA.xml:S1:14666:6	O
antibody	CIMZIA.xml:S1:14673:8	O
-	CIMZIA.xml:S1:14681:1	O
negative	CIMZIA.xml:S1:14682:8	O
status	CIMZIA.xml:S1:14691:6	O
,	CIMZIA.xml:S1:14697:1	O
respectively	CIMZIA.xml:S1:14699:12	O
.	CIMZIA.xml:S1:14711:1	O

[	CIMZIA.xml:S1:14714:1	O
see	CIMZIA.xml:S1:14715:3	O
Clinical	CIMZIA.xml:S1:14720:8	O
Pharmacology	CIMZIA.xml:S1:14729:12	O
(	CIMZIA.xml:S1:14742:1	O
12.3	CIMZIA.xml:S1:14743:4	O
)	CIMZIA.xml:S1:14747:1	O
]	CIMZIA.xml:S1:14750:1	O
.	CIMZIA.xml:S1:14751:1	O

No	CIMZIA.xml:S1:14754:2	O
association	CIMZIA.xml:S1:14757:11	O
was	CIMZIA.xml:S1:14769:3	O
seen	CIMZIA.xml:S1:14773:4	O
between	CIMZIA.xml:S1:14778:7	O
antibody	CIMZIA.xml:S1:14786:8	O
development	CIMZIA.xml:S1:14795:11	O
and	CIMZIA.xml:S1:14807:3	O
the	CIMZIA.xml:S1:14811:3	O
development	CIMZIA.xml:S1:14815:11	O
of	CIMZIA.xml:S1:14827:2	O
adverse	CIMZIA.xml:S1:14830:7	O
events	CIMZIA.xml:S1:14838:6	O
.	CIMZIA.xml:S1:14844:1	O

The	CIMZIA.xml:S1:14850:3	O
data	CIMZIA.xml:S1:14854:4	O
reflect	CIMZIA.xml:S1:14859:7	O
the	CIMZIA.xml:S1:14867:3	O
percentage	CIMZIA.xml:S1:14871:10	O
of	CIMZIA.xml:S1:14882:2	O
patients	CIMZIA.xml:S1:14885:8	O
whose	CIMZIA.xml:S1:14894:5	O
test	CIMZIA.xml:S1:14900:4	O
results	CIMZIA.xml:S1:14905:7	O
were	CIMZIA.xml:S1:14913:4	O
considered	CIMZIA.xml:S1:14918:10	O
positive	CIMZIA.xml:S1:14929:8	O
for	CIMZIA.xml:S1:14938:3	O
antibodies	CIMZIA.xml:S1:14942:10	O
to	CIMZIA.xml:S1:14953:2	O
certolizumab	CIMZIA.xml:S1:14956:12	O
pegol	CIMZIA.xml:S1:14969:5	O
in	CIMZIA.xml:S1:14975:2	O
an	CIMZIA.xml:S1:14978:2	O
ELISA	CIMZIA.xml:S1:14981:5	O
,	CIMZIA.xml:S1:14986:1	O
and	CIMZIA.xml:S1:14988:3	O
are	CIMZIA.xml:S1:14992:3	O
highly	CIMZIA.xml:S1:14996:6	O
dependent	CIMZIA.xml:S1:15003:9	O
on	CIMZIA.xml:S1:15013:2	O
the	CIMZIA.xml:S1:15016:3	O
sensitivity	CIMZIA.xml:S1:15020:11	O
and	CIMZIA.xml:S1:15032:3	O
specificity	CIMZIA.xml:S1:15036:11	O
of	CIMZIA.xml:S1:15048:2	O
the	CIMZIA.xml:S1:15051:3	O
assay	CIMZIA.xml:S1:15055:5	O
.	CIMZIA.xml:S1:15060:1	O

The	CIMZIA.xml:S1:15062:3	O
observed	CIMZIA.xml:S1:15066:8	O
incidence	CIMZIA.xml:S1:15075:9	O
of	CIMZIA.xml:S1:15085:2	O
antibody	CIMZIA.xml:S1:15088:8	O
(	CIMZIA.xml:S1:15097:1	O
including	CIMZIA.xml:S1:15098:9	O
neutralizing	CIMZIA.xml:S1:15108:12	O
antibody	CIMZIA.xml:S1:15121:8	O
)	CIMZIA.xml:S1:15129:1	O
positivity	CIMZIA.xml:S1:15131:10	O
in	CIMZIA.xml:S1:15142:2	O
an	CIMZIA.xml:S1:15145:2	O
assay	CIMZIA.xml:S1:15148:5	O
is	CIMZIA.xml:S1:15154:2	O
highly	CIMZIA.xml:S1:15157:6	O
dependent	CIMZIA.xml:S1:15164:9	O
on	CIMZIA.xml:S1:15174:2	O
several	CIMZIA.xml:S1:15177:7	O
factors	CIMZIA.xml:S1:15185:7	O
,	CIMZIA.xml:S1:15192:1	O
including	CIMZIA.xml:S1:15194:9	O
assay	CIMZIA.xml:S1:15204:5	O
sensitivity	CIMZIA.xml:S1:15210:11	O
and	CIMZIA.xml:S1:15222:3	O
specificity	CIMZIA.xml:S1:15226:11	O
,	CIMZIA.xml:S1:15237:1	O
assay	CIMZIA.xml:S1:15239:5	O
methodology	CIMZIA.xml:S1:15245:11	O
,	CIMZIA.xml:S1:15256:1	O
sample	CIMZIA.xml:S1:15258:6	O
handling	CIMZIA.xml:S1:15265:8	O
,	CIMZIA.xml:S1:15273:1	O
timing	CIMZIA.xml:S1:15275:6	O
of	CIMZIA.xml:S1:15282:2	O
sample	CIMZIA.xml:S1:15285:6	O
collection	CIMZIA.xml:S1:15292:10	O
,	CIMZIA.xml:S1:15302:1	O
concomitant	CIMZIA.xml:S1:15304:11	O
medications	CIMZIA.xml:S1:15316:11	O
,	CIMZIA.xml:S1:15327:1	O
and	CIMZIA.xml:S1:15329:3	O
underlying	CIMZIA.xml:S1:15333:10	O
disease	CIMZIA.xml:S1:15344:7	O
.	CIMZIA.xml:S1:15351:1	O

For	CIMZIA.xml:S1:15353:3	O
these	CIMZIA.xml:S1:15357:5	O
reasons	CIMZIA.xml:S1:15363:7	O
,	CIMZIA.xml:S1:15370:1	O
comparison	CIMZIA.xml:S1:15372:10	O
of	CIMZIA.xml:S1:15383:2	O
the	CIMZIA.xml:S1:15386:3	O
incidence	CIMZIA.xml:S1:15390:9	O
of	CIMZIA.xml:S1:15400:2	O
antibodies	CIMZIA.xml:S1:15403:10	O
to	CIMZIA.xml:S1:15414:2	O
certolizumab	CIMZIA.xml:S1:15417:12	O
pegol	CIMZIA.xml:S1:15430:5	O
with	CIMZIA.xml:S1:15436:4	O
the	CIMZIA.xml:S1:15441:3	O
incidence	CIMZIA.xml:S1:15445:9	O
of	CIMZIA.xml:S1:15455:2	O
antibodies	CIMZIA.xml:S1:15458:10	O
to	CIMZIA.xml:S1:15469:2	O
other	CIMZIA.xml:S1:15472:5	O
products	CIMZIA.xml:S1:15478:8	O
may	CIMZIA.xml:S1:15487:3	O
be	CIMZIA.xml:S1:15491:2	O
misleading	CIMZIA.xml:S1:15494:10	O
.	CIMZIA.xml:S1:15504:1	O

Hypersensitivity	CIMZIA.xml:S1:15516:16	O
Reactions	CIMZIA.xml:S1:15533:9	O

The	CIMZIA.xml:S1:15551:3	O
following	CIMZIA.xml:S1:15555:9	O
symptoms	CIMZIA.xml:S1:15565:8	O
that	CIMZIA.xml:S1:15574:4	O
could	CIMZIA.xml:S1:15579:5	O
be	CIMZIA.xml:S1:15585:2	O
compatible	CIMZIA.xml:S1:15588:10	O
with	CIMZIA.xml:S1:15599:4	O
hypersensitivity	CIMZIA.xml:S1:15604:16	B-AdverseReaction
reactions	CIMZIA.xml:S1:15621:9	I-AdverseReaction
have	CIMZIA.xml:S1:15631:4	O
been	CIMZIA.xml:S1:15636:4	O
reported	CIMZIA.xml:S1:15641:8	O
rarely	CIMZIA.xml:S1:15650:6	O
following	CIMZIA.xml:S1:15657:9	O
CIMZIA	CIMZIA.xml:S1:15667:6	O
administration	CIMZIA.xml:S1:15674:14	O
to	CIMZIA.xml:S1:15689:2	O
patients	CIMZIA.xml:S1:15692:8	O
:	CIMZIA.xml:S1:15700:1	O
angioedema	CIMZIA.xml:S1:15702:10	B-AdverseReaction
,	CIMZIA.xml:S1:15712:1	O
dermatitis	CIMZIA.xml:S1:15714:10	B-AdverseReaction
allergic	CIMZIA.xml:S1:15725:8	I-AdverseReaction
,	CIMZIA.xml:S1:15733:1	O
dizziness	CIMZIA.xml:S1:15735:9	B-AdverseReaction
(	CIMZIA.xml:S1:15745:1	O
postural	CIMZIA.xml:S1:15746:8	I-AdverseReaction
)	CIMZIA.xml:S1:15754:1	O
,	CIMZIA.xml:S1:15755:1	O
dyspnea	CIMZIA.xml:S1:15757:7	B-AdverseReaction
,	CIMZIA.xml:S1:15764:1	O
hot	CIMZIA.xml:S1:15766:3	B-AdverseReaction
flush	CIMZIA.xml:S1:15770:5	I-AdverseReaction
,	CIMZIA.xml:S1:15775:1	O
hypotension	CIMZIA.xml:S1:15777:11	B-AdverseReaction
,	CIMZIA.xml:S1:15788:1	O
injection	CIMZIA.xml:S1:15790:9	B-AdverseReaction
site	CIMZIA.xml:S1:15800:4	I-AdverseReaction
reactions	CIMZIA.xml:S1:15805:9	I-AdverseReaction
,	CIMZIA.xml:S1:15814:1	O
malaise	CIMZIA.xml:S1:15816:7	B-AdverseReaction
,	CIMZIA.xml:S1:15823:1	O
pyrexia	CIMZIA.xml:S1:15825:7	B-AdverseReaction
,	CIMZIA.xml:S1:15832:1	O
rash	CIMZIA.xml:S1:15834:4	B-AdverseReaction
,	CIMZIA.xml:S1:15838:1	O
serum	CIMZIA.xml:S1:15840:5	B-AdverseReaction
sickness	CIMZIA.xml:S1:15846:8	I-AdverseReaction
,	CIMZIA.xml:S1:15854:1	O
and	CIMZIA.xml:S1:15856:3	O
(	CIMZIA.xml:S1:15860:1	O
vasovagal	CIMZIA.xml:S1:15861:9	B-AdverseReaction
)	CIMZIA.xml:S1:15870:1	O
syncope	CIMZIA.xml:S1:15872:7	I-AdverseReaction
[	CIMZIA.xml:S1:15881:1	O
see	CIMZIA.xml:S1:15882:3	O
Warnings	CIMZIA.xml:S1:15887:8	O
and	CIMZIA.xml:S1:15896:3	O
Precautions	CIMZIA.xml:S1:15900:11	O
(	CIMZIA.xml:S1:15912:1	O
5.4	CIMZIA.xml:S1:15913:3	O
)	CIMZIA.xml:S1:15916:1	O
]	CIMZIA.xml:S1:15919:1	O
.	CIMZIA.xml:S1:15922:1	O

6.2	CIMZIA.xml:S1:15930:3	O
Postmarketing	CIMZIA.xml:S1:15934:13	O
Experience	CIMZIA.xml:S1:15948:10	O

The	CIMZIA.xml:S1:15962:3	O
following	CIMZIA.xml:S1:15966:9	O
adverse	CIMZIA.xml:S1:15976:7	O
reactions	CIMZIA.xml:S1:15984:9	O
have	CIMZIA.xml:S1:15994:4	O
been	CIMZIA.xml:S1:15999:4	O
identified	CIMZIA.xml:S1:16004:10	O
during	CIMZIA.xml:S1:16015:6	O
post	CIMZIA.xml:S1:16022:4	O
-	CIMZIA.xml:S1:16026:1	O
approval	CIMZIA.xml:S1:16027:8	O
use	CIMZIA.xml:S1:16036:3	O
of	CIMZIA.xml:S1:16040:2	O
CIMZIA	CIMZIA.xml:S1:16043:6	O
.	CIMZIA.xml:S1:16049:1	O

Because	CIMZIA.xml:S1:16051:7	O
these	CIMZIA.xml:S1:16059:5	O
reactions	CIMZIA.xml:S1:16065:9	O
are	CIMZIA.xml:S1:16075:3	O
reported	CIMZIA.xml:S1:16079:8	O
voluntarily	CIMZIA.xml:S1:16088:11	O
from	CIMZIA.xml:S1:16100:4	O
a	CIMZIA.xml:S1:16105:1	O
population	CIMZIA.xml:S1:16107:10	O
of	CIMZIA.xml:S1:16118:2	O
uncertain	CIMZIA.xml:S1:16121:9	O
size	CIMZIA.xml:S1:16131:4	O
,	CIMZIA.xml:S1:16135:1	O
it	CIMZIA.xml:S1:16137:2	O
is	CIMZIA.xml:S1:16140:2	O
not	CIMZIA.xml:S1:16143:3	O
always	CIMZIA.xml:S1:16147:6	O
possible	CIMZIA.xml:S1:16154:8	O
to	CIMZIA.xml:S1:16163:2	O
estimate	CIMZIA.xml:S1:16166:8	O
reliably	CIMZIA.xml:S1:16175:8	O
their	CIMZIA.xml:S1:16184:5	O
frequency	CIMZIA.xml:S1:16190:9	O
or	CIMZIA.xml:S1:16200:2	O
establish	CIMZIA.xml:S1:16203:9	O
a	CIMZIA.xml:S1:16213:1	O
causal	CIMZIA.xml:S1:16215:6	O
relationship	CIMZIA.xml:S1:16222:12	O
to	CIMZIA.xml:S1:16235:2	O
drug	CIMZIA.xml:S1:16238:4	O
exposure	CIMZIA.xml:S1:16243:8	O
.	CIMZIA.xml:S1:16251:1	O

Vascular	CIMZIA.xml:S1:16257:8	O
disorder	CIMZIA.xml:S1:16266:8	O
:	CIMZIA.xml:S1:16274:1	O
systemic	CIMZIA.xml:S1:16276:8	B-AdverseReaction
vasculitis	CIMZIA.xml:S1:16285:10	I-AdverseReaction
has	CIMZIA.xml:S1:16296:3	O
been	CIMZIA.xml:S1:16300:4	O
identified	CIMZIA.xml:S1:16305:10	O
during	CIMZIA.xml:S1:16316:6	O
post	CIMZIA.xml:S1:16323:4	O
-	CIMZIA.xml:S1:16327:1	O
approval	CIMZIA.xml:S1:16328:8	O
use	CIMZIA.xml:S1:16337:3	O
of	CIMZIA.xml:S1:16341:2	O
TNF	CIMZIA.xml:S1:16344:3	B-DrugClass
blockers	CIMZIA.xml:S1:16348:8	I-DrugClass
.	CIMZIA.xml:S1:16356:1	O

Skin	CIMZIA.xml:S1:16362:4	O
:	CIMZIA.xml:S1:16366:1	O
case	CIMZIA.xml:S1:16368:4	O
of	CIMZIA.xml:S1:16373:2	O
severe	CIMZIA.xml:S1:16376:6	B-Severity
skin	CIMZIA.xml:S1:16383:4	B-AdverseReaction
reactions	CIMZIA.xml:S1:16388:9	I-AdverseReaction
,	CIMZIA.xml:S1:16397:1	O
including	CIMZIA.xml:S1:16399:9	O
Stevens	CIMZIA.xml:S1:16409:7	B-AdverseReaction
-	CIMZIA.xml:S1:16416:1	I-AdverseReaction
Johnson	CIMZIA.xml:S1:16417:7	I-AdverseReaction
syndrome	CIMZIA.xml:S1:16425:8	I-AdverseReaction
,	CIMZIA.xml:S1:16433:1	O
toxic	CIMZIA.xml:S1:16435:5	B-AdverseReaction
epidermal	CIMZIA.xml:S1:16441:9	I-AdverseReaction
necrolysis	CIMZIA.xml:S1:16451:10	I-AdverseReaction
,	CIMZIA.xml:S1:16461:1	O
erythema	CIMZIA.xml:S1:16463:8	B-AdverseReaction
multiforme	CIMZIA.xml:S1:16472:10	I-AdverseReaction
,	CIMZIA.xml:S1:16482:1	O
and	CIMZIA.xml:S1:16484:3	O
new	CIMZIA.xml:S1:16488:3	O
or	CIMZIA.xml:S1:16492:2	O
worsening	CIMZIA.xml:S1:16495:9	O
psoriasis	CIMZIA.xml:S1:16505:9	B-AdverseReaction
(	CIMZIA.xml:S1:16515:1	O
all	CIMZIA.xml:S1:16516:3	O
sub	CIMZIA.xml:S1:16520:3	O
-	CIMZIA.xml:S1:16523:1	O
types	CIMZIA.xml:S1:16524:5	O
including	CIMZIA.xml:S1:16530:9	O
pustular	CIMZIA.xml:S1:16540:8	I-AdverseReaction
and	CIMZIA.xml:S1:16549:3	O
palmoplantar	CIMZIA.xml:S1:16553:12	I-AdverseReaction
)	CIMZIA.xml:S1:16565:1	O
have	CIMZIA.xml:S1:16567:4	O
been	CIMZIA.xml:S1:16572:4	O
identified	CIMZIA.xml:S1:16577:10	O
during	CIMZIA.xml:S1:16588:6	O
post	CIMZIA.xml:S1:16595:4	O
-	CIMZIA.xml:S1:16599:1	O
approval	CIMZIA.xml:S1:16600:8	O
use	CIMZIA.xml:S1:16609:3	O
of	CIMZIA.xml:S1:16613:2	O
TNF	CIMZIA.xml:S1:16616:3	B-DrugClass
blockers	CIMZIA.xml:S1:16620:8	I-DrugClass
.	CIMZIA.xml:S1:16628:1	O

Immune	CIMZIA.xml:S1:16634:6	O
System	CIMZIA.xml:S1:16641:6	O
Disorders	CIMZIA.xml:S1:16648:9	O
:	CIMZIA.xml:S1:16657:1	O
sarcoidosis	CIMZIA.xml:S1:16659:11	B-AdverseReaction
\n\n	CIMZIA.xml:S2:0:2	O
BOXED	CIMZIA.xml:S2:6:5	O
WARNING	CIMZIA.xml:S2:12:7	O
:	CIMZIA.xml:S2:19:1	O
WARNING	CIMZIA.xml:S2:21:7	O
:	CIMZIA.xml:S2:28:1	O
SERIOUS	CIMZIA.xml:S2:30:7	B-Severity
INFECTIONS	CIMZIA.xml:S2:38:10	B-AdverseReaction
AND	CIMZIA.xml:S2:49:3	O
MALIGNANCY	CIMZIA.xml:S2:53:10	B-AdverseReaction
\n\n	CIMZIA.xml:S2:63:2	O
WARNING	CIMZIA.xml:S2:69:7	O
:	CIMZIA.xml:S2:76:1	O
SERIOUS	CIMZIA.xml:S2:78:7	B-Severity
INFECTIONS	CIMZIA.xml:S2:86:10	B-AdverseReaction
AND	CIMZIA.xml:S2:97:3	O
MALIGNANCY	CIMZIA.xml:S2:101:10	B-AdverseReaction
\n\n	CIMZIA.xml:S2:113:2	O
SERIOUS	CIMZIA.xml:S2:119:7	O
INFECTIONS	CIMZIA.xml:S2:127:10	O
\n\n\n\n	CIMZIA.xml:S2:139:4	O
Patients	CIMZIA.xml:S2:146:8	O
treated	CIMZIA.xml:S2:155:7	O
with	CIMZIA.xml:S2:163:4	O
CIMZIA	CIMZIA.xml:S2:168:6	O
are	CIMZIA.xml:S2:175:3	O
at	CIMZIA.xml:S2:179:2	O
increased	CIMZIA.xml:S2:182:9	O
risk	CIMZIA.xml:S2:192:4	B-Factor
for	CIMZIA.xml:S2:197:3	O
developing	CIMZIA.xml:S2:201:10	O
serious	CIMZIA.xml:S2:212:7	B-Severity
infections	CIMZIA.xml:S2:220:10	B-AdverseReaction
that	CIMZIA.xml:S2:231:4	O
may	CIMZIA.xml:S2:236:3	B-Factor
lead	CIMZIA.xml:S2:240:4	O
to	CIMZIA.xml:S2:245:2	O
hospitalization	CIMZIA.xml:S2:248:15	O
or	CIMZIA.xml:S2:264:2	O
death	CIMZIA.xml:S2:267:5	B-AdverseReaction
[	CIMZIA.xml:S2:275:1	O
see	CIMZIA.xml:S2:276:3	O
Warnings	CIMZIA.xml:S2:282:8	O
and	CIMZIA.xml:S2:291:3	O
Precautions	CIMZIA.xml:S2:295:11	O
(	CIMZIA.xml:S2:307:1	O
5.1	CIMZIA.xml:S2:308:3	O
)	CIMZIA.xml:S2:311:1	O
and	CIMZIA.xml:S2:315:3	O
Adverse	CIMZIA.xml:S2:321:7	O
Reactions	CIMZIA.xml:S2:329:9	O
(	CIMZIA.xml:S2:339:1	O
6.1	CIMZIA.xml:S2:340:3	O
)	CIMZIA.xml:S2:343:1	O
]	CIMZIA.xml:S2:346:1	O
.	CIMZIA.xml:S2:349:1	O

Most	CIMZIA.xml:S2:351:4	O
patients	CIMZIA.xml:S2:356:8	O
who	CIMZIA.xml:S2:365:3	O
developed	CIMZIA.xml:S2:369:9	O
these	CIMZIA.xml:S2:379:5	O
infections	CIMZIA.xml:S2:385:10	B-AdverseReaction
were	CIMZIA.xml:S2:396:4	O
taking	CIMZIA.xml:S2:401:6	O
concomitant	CIMZIA.xml:S2:408:11	O
immunosuppressants	CIMZIA.xml:S2:420:18	O
such	CIMZIA.xml:S2:439:4	O
as	CIMZIA.xml:S2:444:2	O
methotrexate	CIMZIA.xml:S2:447:12	O
or	CIMZIA.xml:S2:460:2	O
corticosteroids	CIMZIA.xml:S2:463:15	O
.	CIMZIA.xml:S2:478:1	O

CIMZIA	CIMZIA.xml:S2:488:6	O
should	CIMZIA.xml:S2:495:6	O
be	CIMZIA.xml:S2:502:2	O
discontinued	CIMZIA.xml:S2:505:12	O
if	CIMZIA.xml:S2:518:2	O
a	CIMZIA.xml:S2:521:1	O
patient	CIMZIA.xml:S2:523:7	O
develops	CIMZIA.xml:S2:531:8	O
a	CIMZIA.xml:S2:540:1	O
serious	CIMZIA.xml:S2:542:7	O
infection	CIMZIA.xml:S2:550:9	O
or	CIMZIA.xml:S2:560:2	O
sepsis	CIMZIA.xml:S2:563:6	O
.	CIMZIA.xml:S2:569:1	O

Reported	CIMZIA.xml:S2:579:8	O
infections	CIMZIA.xml:S2:588:10	O
include	CIMZIA.xml:S2:599:7	O
:	CIMZIA.xml:S2:606:1	O
\n\n\n\n	CIMZIA.xml:S2:609:4	O
Active	CIMZIA.xml:S2:617:6	B-AdverseReaction
tuberculosis	CIMZIA.xml:S2:624:12	I-AdverseReaction
,	CIMZIA.xml:S2:636:1	O
including	CIMZIA.xml:S2:638:9	O
reactivation	CIMZIA.xml:S2:648:12	B-AdverseReaction
of	CIMZIA.xml:S2:661:2	I-AdverseReaction
latent	CIMZIA.xml:S2:664:6	I-AdverseReaction
tuberculosis	CIMZIA.xml:S2:671:12	I-AdverseReaction
.	CIMZIA.xml:S2:683:1	O

Patients	CIMZIA.xml:S2:685:8	O
with	CIMZIA.xml:S2:694:4	O
tuberculosis	CIMZIA.xml:S2:699:12	B-AdverseReaction
have	CIMZIA.xml:S2:712:4	O
frequently	CIMZIA.xml:S2:717:10	O
presented	CIMZIA.xml:S2:728:9	O
with	CIMZIA.xml:S2:738:4	O
disseminated	CIMZIA.xml:S2:743:12	I-AdverseReaction
or	CIMZIA.xml:S2:756:2	O
extrapulmonary	CIMZIA.xml:S2:759:14	I-AdverseReaction
disease	CIMZIA.xml:S2:774:7	O
.	CIMZIA.xml:S2:781:1	O

Patients	CIMZIA.xml:S2:783:8	O
should	CIMZIA.xml:S2:792:6	O
be	CIMZIA.xml:S2:799:2	O
tested	CIMZIA.xml:S2:802:6	O
for	CIMZIA.xml:S2:809:3	O
latent	CIMZIA.xml:S2:813:6	O
tuberculosis	CIMZIA.xml:S2:820:12	O
before	CIMZIA.xml:S2:833:6	O
CIMZIA	CIMZIA.xml:S2:840:6	O
use	CIMZIA.xml:S2:847:3	O
and	CIMZIA.xml:S2:851:3	O
during	CIMZIA.xml:S2:855:6	O
therapy	CIMZIA.xml:S2:862:7	O
.	CIMZIA.xml:S2:869:1	O

Treatment	CIMZIA.xml:S2:871:9	O
for	CIMZIA.xml:S2:881:3	O
latent	CIMZIA.xml:S2:885:6	O
infection	CIMZIA.xml:S2:892:9	O
should	CIMZIA.xml:S2:902:6	O
be	CIMZIA.xml:S2:909:2	O
initiated	CIMZIA.xml:S2:912:9	O
prior	CIMZIA.xml:S2:922:5	O
to	CIMZIA.xml:S2:928:2	O
CIMZIA	CIMZIA.xml:S2:931:6	O
use	CIMZIA.xml:S2:938:3	O
.	CIMZIA.xml:S2:941:1	O

Invasive	CIMZIA.xml:S2:948:8	B-AdverseReaction
fungal	CIMZIA.xml:S2:957:6	I-AdverseReaction
infections	CIMZIA.xml:S2:964:10	I-AdverseReaction
,	CIMZIA.xml:S2:974:1	O
including	CIMZIA.xml:S2:976:9	O
histoplasmosis	CIMZIA.xml:S2:986:14	B-AdverseReaction
,	CIMZIA.xml:S2:1000:1	O
coccidioidomycosis	CIMZIA.xml:S2:1002:18	B-AdverseReaction
,	CIMZIA.xml:S2:1020:1	O
candidiasis	CIMZIA.xml:S2:1022:11	B-AdverseReaction
,	CIMZIA.xml:S2:1033:1	O
aspergillosis	CIMZIA.xml:S2:1035:13	B-AdverseReaction
,	CIMZIA.xml:S2:1048:1	O
blastomycosis	CIMZIA.xml:S2:1050:13	B-AdverseReaction
,	CIMZIA.xml:S2:1063:1	O
and	CIMZIA.xml:S2:1065:3	O
pneumocystosis	CIMZIA.xml:S2:1069:14	B-AdverseReaction
.	CIMZIA.xml:S2:1083:1	O

Patients	CIMZIA.xml:S2:1085:8	O
with	CIMZIA.xml:S2:1094:4	O
histoplasmosis	CIMZIA.xml:S2:1099:14	B-AdverseReaction
or	CIMZIA.xml:S2:1114:2	O
other	CIMZIA.xml:S2:1117:5	O
invasive	CIMZIA.xml:S2:1123:8	B-AdverseReaction
fungal	CIMZIA.xml:S2:1132:6	I-AdverseReaction
infections	CIMZIA.xml:S2:1139:10	I-AdverseReaction
may	CIMZIA.xml:S2:1150:3	B-Factor
present	CIMZIA.xml:S2:1154:7	O
with	CIMZIA.xml:S2:1162:4	O
disseminated	CIMZIA.xml:S2:1167:12	I-AdverseReaction
,	CIMZIA.xml:S2:1179:1	O
rather	CIMZIA.xml:S2:1181:6	O
than	CIMZIA.xml:S2:1188:4	O
localized	CIMZIA.xml:S2:1193:9	O
disease	CIMZIA.xml:S2:1203:7	O
.	CIMZIA.xml:S2:1210:1	O

Antigen	CIMZIA.xml:S2:1212:7	O
and	CIMZIA.xml:S2:1220:3	O
antibody	CIMZIA.xml:S2:1224:8	O
testing	CIMZIA.xml:S2:1233:7	O
for	CIMZIA.xml:S2:1241:3	O
histoplasmosis	CIMZIA.xml:S2:1245:14	O
may	CIMZIA.xml:S2:1260:3	O
be	CIMZIA.xml:S2:1264:2	O
negative	CIMZIA.xml:S2:1267:8	O
in	CIMZIA.xml:S2:1276:2	O
some	CIMZIA.xml:S2:1279:4	O
patients	CIMZIA.xml:S2:1284:8	O
with	CIMZIA.xml:S2:1293:4	O
active	CIMZIA.xml:S2:1298:6	O
infection	CIMZIA.xml:S2:1305:9	O
.	CIMZIA.xml:S2:1314:1	O

Empiric	CIMZIA.xml:S2:1316:7	O
anti	CIMZIA.xml:S2:1324:4	O
-	CIMZIA.xml:S2:1328:1	O
fungal	CIMZIA.xml:S2:1329:6	O
therapy	CIMZIA.xml:S2:1336:7	O
should	CIMZIA.xml:S2:1344:6	O
be	CIMZIA.xml:S2:1351:2	O
considered	CIMZIA.xml:S2:1354:10	O
in	CIMZIA.xml:S2:1365:2	O
patients	CIMZIA.xml:S2:1368:8	O
at	CIMZIA.xml:S2:1377:2	O
risk	CIMZIA.xml:S2:1380:4	O
for	CIMZIA.xml:S2:1385:3	O
invasive	CIMZIA.xml:S2:1389:8	O
fungal	CIMZIA.xml:S2:1398:6	O
infections	CIMZIA.xml:S2:1405:10	O
who	CIMZIA.xml:S2:1416:3	O
develop	CIMZIA.xml:S2:1420:7	O
severe	CIMZIA.xml:S2:1428:6	O
systemic	CIMZIA.xml:S2:1435:8	O
illness	CIMZIA.xml:S2:1444:7	O
.	CIMZIA.xml:S2:1451:1	O

Bacterial	CIMZIA.xml:S2:1458:9	B-AdverseReaction
,	CIMZIA.xml:S2:1467:1	O
viral	CIMZIA.xml:S2:1469:5	B-AdverseReaction
and	CIMZIA.xml:S2:1475:3	O
other	CIMZIA.xml:S2:1479:5	O
infections	CIMZIA.xml:S2:1485:10	I-AdverseReaction
due	CIMZIA.xml:S2:1496:3	O
to	CIMZIA.xml:S2:1500:2	O
opportunistic	CIMZIA.xml:S2:1503:13	O
pathogens	CIMZIA.xml:S2:1517:9	O
,	CIMZIA.xml:S2:1526:1	O
including	CIMZIA.xml:S2:1528:9	O
Legionella	CIMZIA.xml:S2:1538:10	I-AdverseReaction
and	CIMZIA.xml:S2:1549:3	O
Listeria	CIMZIA.xml:S2:1553:8	I-AdverseReaction
.	CIMZIA.xml:S2:1561:1	O

The	CIMZIA.xml:S2:1570:3	O
risks	CIMZIA.xml:S2:1574:5	O
and	CIMZIA.xml:S2:1580:3	O
benefits	CIMZIA.xml:S2:1584:8	O
of	CIMZIA.xml:S2:1593:2	O
treatment	CIMZIA.xml:S2:1596:9	O
with	CIMZIA.xml:S2:1606:4	O
CIMZIA	CIMZIA.xml:S2:1611:6	O
should	CIMZIA.xml:S2:1618:6	O
be	CIMZIA.xml:S2:1625:2	O
carefully	CIMZIA.xml:S2:1628:9	O
considered	CIMZIA.xml:S2:1638:10	O
prior	CIMZIA.xml:S2:1649:5	O
to	CIMZIA.xml:S2:1655:2	O
initiating	CIMZIA.xml:S2:1658:10	O
therapy	CIMZIA.xml:S2:1669:7	O
in	CIMZIA.xml:S2:1677:2	O
patients	CIMZIA.xml:S2:1680:8	O
with	CIMZIA.xml:S2:1689:4	O
chronic	CIMZIA.xml:S2:1694:7	O
or	CIMZIA.xml:S2:1702:2	O
recurrent	CIMZIA.xml:S2:1705:9	O
infection	CIMZIA.xml:S2:1715:9	O
.	CIMZIA.xml:S2:1724:1	O

Patients	CIMZIA.xml:S2:1734:8	O
should	CIMZIA.xml:S2:1743:6	O
be	CIMZIA.xml:S2:1750:2	O
closely	CIMZIA.xml:S2:1753:7	O
monitored	CIMZIA.xml:S2:1761:9	O
for	CIMZIA.xml:S2:1771:3	O
the	CIMZIA.xml:S2:1775:3	O
development	CIMZIA.xml:S2:1779:11	O
of	CIMZIA.xml:S2:1791:2	O
signs	CIMZIA.xml:S2:1794:5	O
and	CIMZIA.xml:S2:1800:3	O
symptoms	CIMZIA.xml:S2:1804:8	O
of	CIMZIA.xml:S2:1813:2	O
infection	CIMZIA.xml:S2:1816:9	O
during	CIMZIA.xml:S2:1826:6	O
and	CIMZIA.xml:S2:1833:3	O
after	CIMZIA.xml:S2:1837:5	O
treatment	CIMZIA.xml:S2:1843:9	O
with	CIMZIA.xml:S2:1853:4	O
CIMZIA	CIMZIA.xml:S2:1858:6	O
,	CIMZIA.xml:S2:1864:1	O
including	CIMZIA.xml:S2:1866:9	O
the	CIMZIA.xml:S2:1876:3	O
possible	CIMZIA.xml:S2:1880:8	O
development	CIMZIA.xml:S2:1889:11	O
of	CIMZIA.xml:S2:1901:2	O
tuberculosis	CIMZIA.xml:S2:1904:12	O
in	CIMZIA.xml:S2:1917:2	O
patients	CIMZIA.xml:S2:1920:8	O
who	CIMZIA.xml:S2:1929:3	O
tested	CIMZIA.xml:S2:1933:6	O
negative	CIMZIA.xml:S2:1940:8	O
for	CIMZIA.xml:S2:1949:3	O
latent	CIMZIA.xml:S2:1953:6	O
tuberculosis	CIMZIA.xml:S2:1960:12	O
infection	CIMZIA.xml:S2:1973:9	O
prior	CIMZIA.xml:S2:1983:5	O
to	CIMZIA.xml:S2:1989:2	O
initiating	CIMZIA.xml:S2:1992:10	O
therapy	CIMZIA.xml:S2:2003:7	O
.	CIMZIA.xml:S2:2010:1	O

[	CIMZIA.xml:S2:2014:1	O
see	CIMZIA.xml:S2:2015:3	O
Warnings	CIMZIA.xml:S2:2021:8	O
and	CIMZIA.xml:S2:2030:3	O
Precautions	CIMZIA.xml:S2:2034:11	O
(	CIMZIA.xml:S2:2046:1	O
5.1	CIMZIA.xml:S2:2047:3	O
)	CIMZIA.xml:S2:2050:1	O
and	CIMZIA.xml:S2:2054:3	O
Adverse	CIMZIA.xml:S2:2060:7	O
Reactions	CIMZIA.xml:S2:2068:9	O
(	CIMZIA.xml:S2:2078:1	O
6.1	CIMZIA.xml:S2:2079:3	O
)	CIMZIA.xml:S2:2082:1	O
]	CIMZIA.xml:S2:2085:1	O
.	CIMZIA.xml:S2:2086:1	O

MALIGNANCY	CIMZIA.xml:S2:2098:10	O
\n\n\n\n	CIMZIA.xml:S2:2110:4	O
Lymphoma	CIMZIA.xml:S2:2117:8	B-AdverseReaction
and	CIMZIA.xml:S2:2126:3	O
other	CIMZIA.xml:S2:2130:5	O
malignancies	CIMZIA.xml:S2:2136:12	B-AdverseReaction
,	CIMZIA.xml:S2:2148:1	O
some	CIMZIA.xml:S2:2150:4	O
fatal	CIMZIA.xml:S2:2155:5	B-AdverseReaction
,	CIMZIA.xml:S2:2160:1	O
have	CIMZIA.xml:S2:2162:4	O
been	CIMZIA.xml:S2:2167:4	O
reported	CIMZIA.xml:S2:2172:8	O
in	CIMZIA.xml:S2:2181:2	O
children	CIMZIA.xml:S2:2184:8	O
and	CIMZIA.xml:S2:2193:3	O
adolescent	CIMZIA.xml:S2:2197:10	O
patients	CIMZIA.xml:S2:2208:8	O
treated	CIMZIA.xml:S2:2217:7	O
with	CIMZIA.xml:S2:2225:4	O
TNF	CIMZIA.xml:S2:2230:3	B-DrugClass
blockers	CIMZIA.xml:S2:2234:8	I-DrugClass
,	CIMZIA.xml:S2:2242:1	O
of	CIMZIA.xml:S2:2244:2	O
which	CIMZIA.xml:S2:2247:5	O
CIMZIA	CIMZIA.xml:S2:2253:6	O
is	CIMZIA.xml:S2:2260:2	O
a	CIMZIA.xml:S2:2263:1	O
member	CIMZIA.xml:S2:2265:6	O
[	CIMZIA.xml:S2:2274:1	O
see	CIMZIA.xml:S2:2275:3	O
Warnings	CIMZIA.xml:S2:2281:8	O
and	CIMZIA.xml:S2:2290:3	O
Precautions	CIMZIA.xml:S2:2294:11	O
(	CIMZIA.xml:S2:2306:1	O
5.2	CIMZIA.xml:S2:2307:3	O
)	CIMZIA.xml:S2:2310:1	O
]	CIMZIA.xml:S2:2313:1	O
.	CIMZIA.xml:S2:2314:1	O

CIMZIA	CIMZIA.xml:S2:2318:6	O
is	CIMZIA.xml:S2:2325:2	O
not	CIMZIA.xml:S2:2328:3	O
indicated	CIMZIA.xml:S2:2332:9	O
for	CIMZIA.xml:S2:2342:3	O
use	CIMZIA.xml:S2:2346:3	O
in	CIMZIA.xml:S2:2350:2	O
pediatric	CIMZIA.xml:S2:2353:9	O
patients	CIMZIA.xml:S2:2363:8	O
.	CIMZIA.xml:S2:2371:1	O

EXCERPT	CIMZIA.xml:S2:2381:7	O
:	CIMZIA.xml:S2:2388:1	O
WARNING	CIMZIA.xml:S2:2394:7	O
:	CIMZIA.xml:S2:2401:1	O
SERIOUS	CIMZIA.xml:S2:2403:7	B-Severity
INFECTIONS	CIMZIA.xml:S2:2411:10	B-AdverseReaction
AND	CIMZIA.xml:S2:2422:3	O
MALIGNANCY	CIMZIA.xml:S2:2426:10	B-AdverseReaction
\n\n\n\n	CIMZIA.xml:S2:2438:4	O
See	CIMZIA.xml:S2:2445:3	O
full	CIMZIA.xml:S2:2449:4	O
prescribing	CIMZIA.xml:S2:2454:11	O
information	CIMZIA.xml:S2:2466:11	O
for	CIMZIA.xml:S2:2478:3	O
complete	CIMZIA.xml:S2:2482:8	O
boxed	CIMZIA.xml:S2:2491:5	O
warning	CIMZIA.xml:S2:2497:7	O
.	CIMZIA.xml:S2:2504:1	O

Increased	CIMZIA.xml:S2:2515:9	O
risk	CIMZIA.xml:S2:2525:4	B-Factor
of	CIMZIA.xml:S2:2530:2	O
serious	CIMZIA.xml:S2:2533:7	B-Severity
infections	CIMZIA.xml:S2:2541:10	B-AdverseReaction
leading	CIMZIA.xml:S2:2552:7	O
to	CIMZIA.xml:S2:2560:2	O
hospitalization	CIMZIA.xml:S2:2563:15	O
or	CIMZIA.xml:S2:2579:2	O
death	CIMZIA.xml:S2:2582:5	B-AdverseReaction
including	CIMZIA.xml:S2:2588:9	O
tuberculosis	CIMZIA.xml:S2:2598:12	B-AdverseReaction
(	CIMZIA.xml:S2:2611:1	O
TB	CIMZIA.xml:S2:2612:2	B-AdverseReaction
)	CIMZIA.xml:S2:2614:1	O
,	CIMZIA.xml:S2:2615:1	O
bacterial	CIMZIA.xml:S2:2617:9	B-AdverseReaction
sepsis	CIMZIA.xml:S2:2627:6	I-AdverseReaction
,	CIMZIA.xml:S2:2633:1	O
invasive	CIMZIA.xml:S2:2635:8	B-AdverseReaction
fungal	CIMZIA.xml:S2:2644:6	I-AdverseReaction
infections	CIMZIA.xml:S2:2651:10	I-AdverseReaction
(	CIMZIA.xml:S2:2662:1	O
such	CIMZIA.xml:S2:2663:4	O
as	CIMZIA.xml:S2:2668:2	O
histoplasmosis	CIMZIA.xml:S2:2671:14	B-AdverseReaction
)	CIMZIA.xml:S2:2685:1	O
,	CIMZIA.xml:S2:2686:1	O
and	CIMZIA.xml:S2:2688:3	O
infections	CIMZIA.xml:S2:2692:10	B-AdverseReaction
due	CIMZIA.xml:S2:2703:3	I-AdverseReaction
to	CIMZIA.xml:S2:2707:2	I-AdverseReaction
other	CIMZIA.xml:S2:2710:5	I-AdverseReaction
opportunistic	CIMZIA.xml:S2:2716:13	I-AdverseReaction
pathogens	CIMZIA.xml:S2:2730:9	I-AdverseReaction
(	CIMZIA.xml:S2:2740:1	O
5.1	CIMZIA.xml:S2:2741:3	O
)	CIMZIA.xml:S2:2744:1	O
.	CIMZIA.xml:S2:2745:1	O

CIMZIA	CIMZIA.xml:S2:2752:6	O
should	CIMZIA.xml:S2:2759:6	O
be	CIMZIA.xml:S2:2766:2	O
discontinued	CIMZIA.xml:S2:2769:12	O
if	CIMZIA.xml:S2:2782:2	O
a	CIMZIA.xml:S2:2785:1	O
patient	CIMZIA.xml:S2:2787:7	O
develops	CIMZIA.xml:S2:2795:8	O
a	CIMZIA.xml:S2:2804:1	O
serious	CIMZIA.xml:S2:2806:7	O
infection	CIMZIA.xml:S2:2814:9	O
or	CIMZIA.xml:S2:2824:2	O
sepsis	CIMZIA.xml:S2:2827:6	O
(	CIMZIA.xml:S2:2834:1	O
5.1	CIMZIA.xml:S2:2835:3	O
)	CIMZIA.xml:S2:2838:1	O
.	CIMZIA.xml:S2:2839:1	O

Perform	CIMZIA.xml:S2:2846:7	O
test	CIMZIA.xml:S2:2854:4	O
for	CIMZIA.xml:S2:2859:3	O
latent	CIMZIA.xml:S2:2863:6	O
TB	CIMZIA.xml:S2:2870:2	O
;	CIMZIA.xml:S2:2872:1	O
if	CIMZIA.xml:S2:2874:2	O
positive	CIMZIA.xml:S2:2877:8	O
,	CIMZIA.xml:S2:2885:1	O
start	CIMZIA.xml:S2:2887:5	O
treatment	CIMZIA.xml:S2:2893:9	O
for	CIMZIA.xml:S2:2903:3	O
TB	CIMZIA.xml:S2:2907:2	O
prior	CIMZIA.xml:S2:2910:5	O
to	CIMZIA.xml:S2:2916:2	O
starting	CIMZIA.xml:S2:2919:8	O
CIMZIA	CIMZIA.xml:S2:2928:6	O
(	CIMZIA.xml:S2:2935:1	O
5.1	CIMZIA.xml:S2:2936:3	O
)	CIMZIA.xml:S2:2939:1	O
.	CIMZIA.xml:S2:2940:1	O

Monitor	CIMZIA.xml:S2:2947:7	O
all	CIMZIA.xml:S2:2955:3	O
patients	CIMZIA.xml:S2:2959:8	O
for	CIMZIA.xml:S2:2968:3	O
active	CIMZIA.xml:S2:2972:6	O
TB	CIMZIA.xml:S2:2979:2	O
during	CIMZIA.xml:S2:2982:6	O
treatment	CIMZIA.xml:S2:2989:9	O
,	CIMZIA.xml:S2:2998:1	O
even	CIMZIA.xml:S2:3000:4	O
if	CIMZIA.xml:S2:3005:2	O
initial	CIMZIA.xml:S2:3008:7	O
latent	CIMZIA.xml:S2:3016:6	O
TB	CIMZIA.xml:S2:3023:2	O
test	CIMZIA.xml:S2:3026:4	O
is	CIMZIA.xml:S2:3031:2	O
negative	CIMZIA.xml:S2:3034:8	O
(	CIMZIA.xml:S2:3043:1	O
5.1	CIMZIA.xml:S2:3044:3	O
)	CIMZIA.xml:S2:3047:1	O
\n	CIMZIA.xml:S2:3049:1	O
Lymphoma	CIMZIA.xml:S2:3054:8	B-AdverseReaction
and	CIMZIA.xml:S2:3063:3	O
other	CIMZIA.xml:S2:3067:5	O
malignancies	CIMZIA.xml:S2:3073:12	B-AdverseReaction
,	CIMZIA.xml:S2:3085:1	O
some	CIMZIA.xml:S2:3087:4	O
fatal	CIMZIA.xml:S2:3092:5	B-AdverseReaction
,	CIMZIA.xml:S2:3097:1	O
have	CIMZIA.xml:S2:3099:4	O
been	CIMZIA.xml:S2:3104:4	O
reported	CIMZIA.xml:S2:3109:8	O
in	CIMZIA.xml:S2:3118:2	O
children	CIMZIA.xml:S2:3121:8	O
and	CIMZIA.xml:S2:3130:3	O
adolescent	CIMZIA.xml:S2:3134:10	O
patients	CIMZIA.xml:S2:3145:8	O
treated	CIMZIA.xml:S2:3154:7	O
with	CIMZIA.xml:S2:3162:4	O
TNF	CIMZIA.xml:S2:3167:3	B-DrugClass
blockers	CIMZIA.xml:S2:3171:8	I-DrugClass
,	CIMZIA.xml:S2:3179:1	O
of	CIMZIA.xml:S2:3181:2	O
which	CIMZIA.xml:S2:3184:5	O
CIMZIA	CIMZIA.xml:S2:3190:6	O
is	CIMZIA.xml:S2:3197:2	O
a	CIMZIA.xml:S2:3200:1	O
member	CIMZIA.xml:S2:3202:6	O
(	CIMZIA.xml:S2:3209:1	O
5.2	CIMZIA.xml:S2:3210:3	O
)	CIMZIA.xml:S2:3213:1	O
.	CIMZIA.xml:S2:3214:1	O

CIMZIA	CIMZIA.xml:S2:3216:6	O
is	CIMZIA.xml:S2:3223:2	O
not	CIMZIA.xml:S2:3226:3	O
indicated	CIMZIA.xml:S2:3230:9	O
for	CIMZIA.xml:S2:3240:3	O
use	CIMZIA.xml:S2:3244:3	O
in	CIMZIA.xml:S2:3248:2	O
pediatric	CIMZIA.xml:S2:3251:9	O
patients	CIMZIA.xml:S2:3261:8	O
.	CIMZIA.xml:S2:3269:1	O

(	CIMZIA.xml:S2:3271:1	O
8.4	CIMZIA.xml:S2:3272:3	O
)	CIMZIA.xml:S2:3275:1	O
\n	CIMZIA.xml:S2:3277:1	O
5	CIMZIA.xml:S3:4:1	O
WARNINGS	CIMZIA.xml:S3:6:8	O
AND	CIMZIA.xml:S3:15:3	O
PRECAUTIONS	CIMZIA.xml:S3:19:11	O

EXCERPT	CIMZIA.xml:S3:37:7	O
:	CIMZIA.xml:S3:44:1	O
Serious	CIMZIA.xml:S3:52:7	B-Severity
infections	CIMZIA.xml:S3:60:10	B-AdverseReaction
-	CIMZIA.xml:S3:71:1	O
do	CIMZIA.xml:S3:73:2	O
not	CIMZIA.xml:S3:76:3	O
start	CIMZIA.xml:S3:80:5	O
CIMZIA	CIMZIA.xml:S3:86:6	O
during	CIMZIA.xml:S3:93:6	O
an	CIMZIA.xml:S3:100:2	O
active	CIMZIA.xml:S3:103:6	O
infection	CIMZIA.xml:S3:110:9	O
.	CIMZIA.xml:S3:119:1	O

If	CIMZIA.xml:S3:121:2	O
an	CIMZIA.xml:S3:124:2	O
infection	CIMZIA.xml:S3:127:9	O
develops	CIMZIA.xml:S3:137:8	O
,	CIMZIA.xml:S3:145:1	O
monitor	CIMZIA.xml:S3:147:7	O
carefully	CIMZIA.xml:S3:155:9	O
,	CIMZIA.xml:S3:164:1	O
and	CIMZIA.xml:S3:166:3	O
stop	CIMZIA.xml:S3:170:4	O
CIMZIA	CIMZIA.xml:S3:175:6	O
if	CIMZIA.xml:S3:182:2	O
infection	CIMZIA.xml:S3:185:9	O
becomes	CIMZIA.xml:S3:195:7	O
serious	CIMZIA.xml:S3:203:7	O
(	CIMZIA.xml:S3:211:1	O
5.1	CIMZIA.xml:S3:214:3	O
)	CIMZIA.xml:S3:219:1	O

Invasive	CIMZIA.xml:S3:226:8	B-AdverseReaction
fungal	CIMZIA.xml:S3:235:6	I-AdverseReaction
infections	CIMZIA.xml:S3:242:10	I-AdverseReaction
-	CIMZIA.xml:S3:253:1	O
for	CIMZIA.xml:S3:255:3	O
patients	CIMZIA.xml:S3:259:8	O
who	CIMZIA.xml:S3:268:3	O
develop	CIMZIA.xml:S3:272:7	O
a	CIMZIA.xml:S3:280:1	O
systemic	CIMZIA.xml:S3:282:8	O
illness	CIMZIA.xml:S3:291:7	O
on	CIMZIA.xml:S3:299:2	O
CIMZIA	CIMZIA.xml:S3:302:6	O
,	CIMZIA.xml:S3:308:1	O
consider	CIMZIA.xml:S3:310:8	O
empiric	CIMZIA.xml:S3:319:7	O
antifungal	CIMZIA.xml:S3:327:10	O
therapy	CIMZIA.xml:S3:338:7	O
for	CIMZIA.xml:S3:346:3	O
those	CIMZIA.xml:S3:350:5	O
who	CIMZIA.xml:S3:356:3	O
reside	CIMZIA.xml:S3:360:6	O
or	CIMZIA.xml:S3:367:2	O
travel	CIMZIA.xml:S3:370:6	O
to	CIMZIA.xml:S3:377:2	O
regions	CIMZIA.xml:S3:380:7	O
where	CIMZIA.xml:S3:388:5	O
mycoses	CIMZIA.xml:S3:394:7	O
are	CIMZIA.xml:S3:402:3	O
endemic	CIMZIA.xml:S3:406:7	O
(	CIMZIA.xml:S3:414:1	O
5.1	CIMZIA.xml:S3:417:3	O
)	CIMZIA.xml:S3:422:1	O

Cases	CIMZIA.xml:S3:429:5	O
of	CIMZIA.xml:S3:435:2	O
lymphoma	CIMZIA.xml:S3:438:8	B-AdverseReaction
and	CIMZIA.xml:S3:447:3	O
other	CIMZIA.xml:S3:451:5	O
malignancies	CIMZIA.xml:S3:457:12	B-AdverseReaction
have	CIMZIA.xml:S3:470:4	O
been	CIMZIA.xml:S3:475:4	O
observed	CIMZIA.xml:S3:480:8	O
among	CIMZIA.xml:S3:489:5	O
patients	CIMZIA.xml:S3:495:8	O
receiving	CIMZIA.xml:S3:504:9	O
TNF	CIMZIA.xml:S3:514:3	B-DrugClass
blockers	CIMZIA.xml:S3:518:8	I-DrugClass
(	CIMZIA.xml:S3:527:1	O
5.2	CIMZIA.xml:S3:530:3	O
)	CIMZIA.xml:S3:535:1	O

Heart	CIMZIA.xml:S3:542:5	B-AdverseReaction
failure	CIMZIA.xml:S3:548:7	I-AdverseReaction
,	CIMZIA.xml:S3:555:1	I-AdverseReaction
worsening	CIMZIA.xml:S3:557:9	I-AdverseReaction
or	CIMZIA.xml:S3:567:2	O
new	CIMZIA.xml:S3:570:3	I-AdverseReaction
onset	CIMZIA.xml:S3:574:5	I-AdverseReaction
may	CIMZIA.xml:S3:580:3	B-Factor
occur	CIMZIA.xml:S3:584:5	O
(	CIMZIA.xml:S3:590:1	O
5.3	CIMZIA.xml:S3:593:3	O
)	CIMZIA.xml:S3:598:1	O

Anaphylaxis	CIMZIA.xml:S3:605:11	B-AdverseReaction
or	CIMZIA.xml:S3:617:2	O
serious	CIMZIA.xml:S3:620:7	B-Severity
allergic	CIMZIA.xml:S3:628:8	B-AdverseReaction
reactions	CIMZIA.xml:S3:637:9	I-AdverseReaction
may	CIMZIA.xml:S3:647:3	B-Factor
occur	CIMZIA.xml:S3:651:5	O
(	CIMZIA.xml:S3:657:1	O
5.4	CIMZIA.xml:S3:660:3	O
)	CIMZIA.xml:S3:665:1	O

Hepatitis	CIMZIA.xml:S3:672:9	B-AdverseReaction
B	CIMZIA.xml:S3:682:1	I-AdverseReaction
virus	CIMZIA.xml:S3:684:5	I-AdverseReaction
reactivation	CIMZIA.xml:S3:690:12	I-AdverseReaction
-	CIMZIA.xml:S3:703:1	O
test	CIMZIA.xml:S3:705:4	O
for	CIMZIA.xml:S3:710:3	O
HBV	CIMZIA.xml:S3:714:3	O
infection	CIMZIA.xml:S3:718:9	O
before	CIMZIA.xml:S3:728:6	O
starting	CIMZIA.xml:S3:735:8	O
CIMZIA	CIMZIA.xml:S3:744:6	O
.	CIMZIA.xml:S3:750:1	O

Monitor	CIMZIA.xml:S3:752:7	O
HBV	CIMZIA.xml:S3:760:3	O
carriers	CIMZIA.xml:S3:764:8	O
during	CIMZIA.xml:S3:773:6	O
and	CIMZIA.xml:S3:780:3	O
several	CIMZIA.xml:S3:784:7	O
months	CIMZIA.xml:S3:792:6	O
after	CIMZIA.xml:S3:799:5	O
therapy	CIMZIA.xml:S3:805:7	O
.	CIMZIA.xml:S3:812:1	O

If	CIMZIA.xml:S3:814:2	O
reactivation	CIMZIA.xml:S3:817:12	O
occurs	CIMZIA.xml:S3:830:6	O
,	CIMZIA.xml:S3:836:1	O
stop	CIMZIA.xml:S3:838:4	O
CIMZIA	CIMZIA.xml:S3:843:6	O
and	CIMZIA.xml:S3:850:3	O
begin	CIMZIA.xml:S3:854:5	O
anti	CIMZIA.xml:S3:860:4	O
-	CIMZIA.xml:S3:864:1	O
viral	CIMZIA.xml:S3:865:5	O
therapy	CIMZIA.xml:S3:871:7	O
(	CIMZIA.xml:S3:879:1	O
5.5	CIMZIA.xml:S3:882:3	O
)	CIMZIA.xml:S3:887:1	O

Demyelinating	CIMZIA.xml:S3:894:13	B-AdverseReaction
disease	CIMZIA.xml:S3:908:7	I-AdverseReaction
,	CIMZIA.xml:S3:915:1	O
exacerbation	CIMZIA.xml:S3:917:12	O
or	CIMZIA.xml:S3:930:2	O
new	CIMZIA.xml:S3:933:3	O
onset	CIMZIA.xml:S3:937:5	O
,	CIMZIA.xml:S3:942:1	O
may	CIMZIA.xml:S3:944:3	B-Factor
occur	CIMZIA.xml:S3:948:5	O
(	CIMZIA.xml:S3:954:1	O
5.6	CIMZIA.xml:S3:957:3	O
)	CIMZIA.xml:S3:962:1	O

Cytopenias	CIMZIA.xml:S3:969:10	B-AdverseReaction
,	CIMZIA.xml:S3:979:1	O
pancytopenia	CIMZIA.xml:S3:981:12	B-AdverseReaction
-	CIMZIA.xml:S3:994:1	O
advise	CIMZIA.xml:S3:996:6	O
patients	CIMZIA.xml:S3:1003:8	O
to	CIMZIA.xml:S3:1012:2	O
seek	CIMZIA.xml:S3:1015:4	O
immediate	CIMZIA.xml:S3:1020:9	O
medical	CIMZIA.xml:S3:1030:7	O
attention	CIMZIA.xml:S3:1038:9	O
if	CIMZIA.xml:S3:1048:2	O
symptoms	CIMZIA.xml:S3:1051:8	O
develop	CIMZIA.xml:S3:1060:7	O
,	CIMZIA.xml:S3:1067:1	O
and	CIMZIA.xml:S3:1069:3	O
consider	CIMZIA.xml:S3:1073:8	O
stopping	CIMZIA.xml:S3:1082:8	O
CIMZIA	CIMZIA.xml:S3:1091:6	O
(	CIMZIA.xml:S3:1098:1	O
5.7	CIMZIA.xml:S3:1101:3	O
)	CIMZIA.xml:S3:1106:1	O

Lupus	CIMZIA.xml:S3:1113:5	B-AdverseReaction
-	CIMZIA.xml:S3:1118:1	I-AdverseReaction
like	CIMZIA.xml:S3:1119:4	I-AdverseReaction
syndrome	CIMZIA.xml:S3:1124:8	I-AdverseReaction
-	CIMZIA.xml:S3:1133:1	O
stop	CIMZIA.xml:S3:1135:4	O
CIMZIA	CIMZIA.xml:S3:1140:6	O
if	CIMZIA.xml:S3:1147:2	O
syndrome	CIMZIA.xml:S3:1150:8	O
develops	CIMZIA.xml:S3:1159:8	O
(	CIMZIA.xml:S3:1168:1	O
5.9	CIMZIA.xml:S3:1171:3	O
)	CIMZIA.xml:S3:1176:1	O

5.1	CIMZIA.xml:S3:1190:3	O

Risk	CIMZIA.xml:S3:1194:4	O

of	CIMZIA.xml:S3:1199:2	O
Serious	CIMZIA.xml:S3:1202:7	O
Infections	CIMZIA.xml:S3:1210:10	O

[	CIMZIA.xml:S3:1227:1	O
see	CIMZIA.xml:S3:1228:3	O
Boxed	CIMZIA.xml:S3:1233:5	O
Warning	CIMZIA.xml:S3:1239:7	O
]	CIMZIA.xml:S3:1248:1	O

Patients	CIMZIA.xml:S3:1256:8	O
treated	CIMZIA.xml:S3:1265:7	O
with	CIMZIA.xml:S3:1273:4	O
CIMZIA	CIMZIA.xml:S3:1278:6	O
are	CIMZIA.xml:S3:1285:3	O
at	CIMZIA.xml:S3:1289:2	O
an	CIMZIA.xml:S3:1292:2	O
increased	CIMZIA.xml:S3:1295:9	O
risk	CIMZIA.xml:S3:1305:4	B-Factor
for	CIMZIA.xml:S3:1310:3	O
developing	CIMZIA.xml:S3:1314:10	O
serious	CIMZIA.xml:S3:1325:7	B-Severity
infections	CIMZIA.xml:S3:1333:10	B-AdverseReaction
involving	CIMZIA.xml:S3:1344:9	O
various	CIMZIA.xml:S3:1354:7	O
organ	CIMZIA.xml:S3:1362:5	O
systems	CIMZIA.xml:S3:1368:7	O
and	CIMZIA.xml:S3:1376:3	O
sites	CIMZIA.xml:S3:1380:5	O
that	CIMZIA.xml:S3:1386:4	O
may	CIMZIA.xml:S3:1391:3	B-Factor
lead	CIMZIA.xml:S3:1395:4	O
to	CIMZIA.xml:S3:1400:2	O
hospitalization	CIMZIA.xml:S3:1403:15	O
or	CIMZIA.xml:S3:1419:2	O
death	CIMZIA.xml:S3:1422:5	B-AdverseReaction
.	CIMZIA.xml:S3:1427:1	O

Opportunistic	CIMZIA.xml:S3:1433:13	B-AdverseReaction
infections	CIMZIA.xml:S3:1447:10	I-AdverseReaction
due	CIMZIA.xml:S3:1458:3	O
to	CIMZIA.xml:S3:1462:2	O
bacterial	CIMZIA.xml:S3:1465:9	I-AdverseReaction
,	CIMZIA.xml:S3:1474:1	O
mycobacterial	CIMZIA.xml:S3:1476:13	I-AdverseReaction
,	CIMZIA.xml:S3:1489:1	O
invasive	CIMZIA.xml:S3:1491:8	I-AdverseReaction
fungal	CIMZIA.xml:S3:1500:6	I-AdverseReaction
,	CIMZIA.xml:S3:1506:1	O
viral	CIMZIA.xml:S3:1508:5	I-AdverseReaction
,	CIMZIA.xml:S3:1513:1	O
parasitic	CIMZIA.xml:S3:1515:9	I-AdverseReaction
,	CIMZIA.xml:S3:1524:1	O
or	CIMZIA.xml:S3:1526:2	O
other	CIMZIA.xml:S3:1529:5	O
opportunistic	CIMZIA.xml:S3:1535:13	O
pathogens	CIMZIA.xml:S3:1549:9	O
including	CIMZIA.xml:S3:1559:9	O
aspergillosis	CIMZIA.xml:S3:1569:13	B-AdverseReaction
,	CIMZIA.xml:S3:1582:1	O
blastomycosis	CIMZIA.xml:S3:1584:13	B-AdverseReaction
,	CIMZIA.xml:S3:1597:1	O
candidiasis	CIMZIA.xml:S3:1599:11	B-AdverseReaction
,	CIMZIA.xml:S3:1610:1	O
coccidioidomycosis	CIMZIA.xml:S3:1612:18	B-AdverseReaction
,	CIMZIA.xml:S3:1630:1	O
histoplasmosis	CIMZIA.xml:S3:1632:14	B-AdverseReaction
,	CIMZIA.xml:S3:1646:1	O
legionellosis	CIMZIA.xml:S3:1648:13	B-AdverseReaction
,	CIMZIA.xml:S3:1661:1	O
listeriosis	CIMZIA.xml:S3:1663:11	B-AdverseReaction
,	CIMZIA.xml:S3:1674:1	O
pneumocystosis	CIMZIA.xml:S3:1676:14	B-AdverseReaction
and	CIMZIA.xml:S3:1691:3	O
tuberculosis	CIMZIA.xml:S3:1695:12	B-AdverseReaction
have	CIMZIA.xml:S3:1708:4	O
been	CIMZIA.xml:S3:1713:4	O
reported	CIMZIA.xml:S3:1718:8	O
with	CIMZIA.xml:S3:1727:4	O
TNF	CIMZIA.xml:S3:1732:3	B-DrugClass
blockers	CIMZIA.xml:S3:1736:8	I-DrugClass
.	CIMZIA.xml:S3:1744:1	O

Patients	CIMZIA.xml:S3:1746:8	O
have	CIMZIA.xml:S3:1755:4	O
frequently	CIMZIA.xml:S3:1760:10	O
presented	CIMZIA.xml:S3:1771:9	O
with	CIMZIA.xml:S3:1781:4	O
disseminated	CIMZIA.xml:S3:1786:12	O
rather	CIMZIA.xml:S3:1799:6	O
than	CIMZIA.xml:S3:1806:4	O
localized	CIMZIA.xml:S3:1811:9	O
disease	CIMZIA.xml:S3:1821:7	O
.	CIMZIA.xml:S3:1828:1	O

Treatment	CIMZIA.xml:S3:1834:9	O
with	CIMZIA.xml:S3:1844:4	O
CIMZIA	CIMZIA.xml:S3:1849:6	O
should	CIMZIA.xml:S3:1856:6	O
not	CIMZIA.xml:S3:1863:3	O
be	CIMZIA.xml:S3:1867:2	O
initiated	CIMZIA.xml:S3:1870:9	O
in	CIMZIA.xml:S3:1880:2	O
patients	CIMZIA.xml:S3:1883:8	O
with	CIMZIA.xml:S3:1892:4	O
an	CIMZIA.xml:S3:1897:2	O
active	CIMZIA.xml:S3:1900:6	O
infection	CIMZIA.xml:S3:1907:9	O
,	CIMZIA.xml:S3:1916:1	O
including	CIMZIA.xml:S3:1918:9	O
clinically	CIMZIA.xml:S3:1928:10	O
important	CIMZIA.xml:S3:1939:9	O
localized	CIMZIA.xml:S3:1949:9	O
infections	CIMZIA.xml:S3:1959:10	O
.	CIMZIA.xml:S3:1969:1	O

Patients	CIMZIA.xml:S3:1971:8	O
greater	CIMZIA.xml:S3:1980:7	O
than	CIMZIA.xml:S3:1988:4	O
65	CIMZIA.xml:S3:1993:2	O
years	CIMZIA.xml:S3:1996:5	O
of	CIMZIA.xml:S3:2002:2	O
age	CIMZIA.xml:S3:2005:3	O
,	CIMZIA.xml:S3:2008:1	O
patients	CIMZIA.xml:S3:2010:8	O
with	CIMZIA.xml:S3:2019:4	O
co	CIMZIA.xml:S3:2024:2	O
-	CIMZIA.xml:S3:2026:1	O
morbid	CIMZIA.xml:S3:2027:6	O
conditions	CIMZIA.xml:S3:2034:10	O
,	CIMZIA.xml:S3:2044:1	O
and	CIMZIA.xml:S3:2046:3	O
or	CIMZIA.xml:S3:2050:2	O
patients	CIMZIA.xml:S3:2053:8	O
taking	CIMZIA.xml:S3:2062:6	O
concomitant	CIMZIA.xml:S3:2069:11	O
immunosuppressants	CIMZIA.xml:S3:2081:18	O
(	CIMZIA.xml:S3:2100:1	O
e	CIMZIA.xml:S3:2101:1	O
.	CIMZIA.xml:S3:2102:1	O
g	CIMZIA.xml:S3:2103:1	O
.	CIMZIA.xml:S3:2104:1	O

corticosteroids	CIMZIA.xml:S3:2106:15	O
or	CIMZIA.xml:S3:2122:2	O
methotrexate	CIMZIA.xml:S3:2125:12	O
)	CIMZIA.xml:S3:2137:1	O
may	CIMZIA.xml:S3:2139:3	O
be	CIMZIA.xml:S3:2143:2	O
at	CIMZIA.xml:S3:2146:2	O
a	CIMZIA.xml:S3:2149:1	O
greater	CIMZIA.xml:S3:2151:7	O
risk	CIMZIA.xml:S3:2159:4	B-Factor
of	CIMZIA.xml:S3:2164:2	O
infection	CIMZIA.xml:S3:2167:9	B-AdverseReaction
.	CIMZIA.xml:S3:2176:1	O

The	CIMZIA.xml:S3:2178:3	O
risks	CIMZIA.xml:S3:2182:5	O
and	CIMZIA.xml:S3:2188:3	O
benefits	CIMZIA.xml:S3:2192:8	O
of	CIMZIA.xml:S3:2201:2	O
treatment	CIMZIA.xml:S3:2204:9	O
should	CIMZIA.xml:S3:2214:6	O
be	CIMZIA.xml:S3:2221:2	O
considered	CIMZIA.xml:S3:2224:10	O
prior	CIMZIA.xml:S3:2235:5	O
to	CIMZIA.xml:S3:2241:2	O
initiating	CIMZIA.xml:S3:2244:10	O
therapy	CIMZIA.xml:S3:2255:7	O
in	CIMZIA.xml:S3:2263:2	O
patients	CIMZIA.xml:S3:2266:8	O
:	CIMZIA.xml:S3:2274:1	O

with	CIMZIA.xml:S3:2283:4	O
chronic	CIMZIA.xml:S3:2288:7	O
or	CIMZIA.xml:S3:2296:2	O
recurrent	CIMZIA.xml:S3:2299:9	O
infection	CIMZIA.xml:S3:2309:9	O

who	CIMZIA.xml:S3:2324:3	O
have	CIMZIA.xml:S3:2328:4	O
been	CIMZIA.xml:S3:2333:4	O
exposed	CIMZIA.xml:S3:2338:7	O
to	CIMZIA.xml:S3:2346:2	O
tuberculosis	CIMZIA.xml:S3:2349:12	O

with	CIMZIA.xml:S3:2367:4	O
a	CIMZIA.xml:S3:2372:1	O
history	CIMZIA.xml:S3:2374:7	O
of	CIMZIA.xml:S3:2382:2	O
an	CIMZIA.xml:S3:2385:2	O
opportunistic	CIMZIA.xml:S3:2388:13	O
infection	CIMZIA.xml:S3:2402:9	O

who	CIMZIA.xml:S3:2417:3	O
have	CIMZIA.xml:S3:2421:4	O
resided	CIMZIA.xml:S3:2426:7	O
or	CIMZIA.xml:S3:2434:2	O
traveled	CIMZIA.xml:S3:2437:8	O
in	CIMZIA.xml:S3:2446:2	O
areas	CIMZIA.xml:S3:2449:5	O
of	CIMZIA.xml:S3:2455:2	O
endemic	CIMZIA.xml:S3:2458:7	O
tuberculosis	CIMZIA.xml:S3:2466:12	O
or	CIMZIA.xml:S3:2479:2	O
endemic	CIMZIA.xml:S3:2482:7	O
mycoses	CIMZIA.xml:S3:2490:7	O
,	CIMZIA.xml:S3:2497:1	O
such	CIMZIA.xml:S3:2499:4	O
as	CIMZIA.xml:S3:2504:2	O
histoplasmosis	CIMZIA.xml:S3:2507:14	O
,	CIMZIA.xml:S3:2521:1	O
coccidioidomycosis	CIMZIA.xml:S3:2523:18	O
,	CIMZIA.xml:S3:2541:1	O
or	CIMZIA.xml:S3:2543:2	O
blastomycosis	CIMZIA.xml:S3:2546:13	O

with	CIMZIA.xml:S3:2565:4	O
underlying	CIMZIA.xml:S3:2570:10	O
conditions	CIMZIA.xml:S3:2581:10	O
that	CIMZIA.xml:S3:2592:4	O
may	CIMZIA.xml:S3:2597:3	O
predispose	CIMZIA.xml:S3:2601:10	O
them	CIMZIA.xml:S3:2612:4	O
to	CIMZIA.xml:S3:2617:2	O
infection	CIMZIA.xml:S3:2620:9	O

Tuberculosis	CIMZIA.xml:S3:2638:12	O

Cases	CIMZIA.xml:S3:2657:5	O

of	CIMZIA.xml:S3:2663:2	O
reactivation	CIMZIA.xml:S3:2666:12	B-AdverseReaction
of	CIMZIA.xml:S3:2679:2	I-AdverseReaction
tuberculosis	CIMZIA.xml:S3:2682:12	I-AdverseReaction
or	CIMZIA.xml:S3:2695:2	O
new	CIMZIA.xml:S3:2698:3	O
tuberculosis	CIMZIA.xml:S3:2702:12	B-AdverseReaction
infections	CIMZIA.xml:S3:2715:10	I-AdverseReaction
have	CIMZIA.xml:S3:2726:4	O
been	CIMZIA.xml:S3:2731:4	O
observed	CIMZIA.xml:S3:2736:8	O
in	CIMZIA.xml:S3:2745:2	O
patients	CIMZIA.xml:S3:2748:8	O
receiving	CIMZIA.xml:S3:2757:9	O
CIMZIA	CIMZIA.xml:S3:2767:6	O
,	CIMZIA.xml:S3:2773:1	O
including	CIMZIA.xml:S3:2775:9	O
patients	CIMZIA.xml:S3:2785:8	O
who	CIMZIA.xml:S3:2794:3	O
have	CIMZIA.xml:S3:2798:4	O
previously	CIMZIA.xml:S3:2803:10	O
received	CIMZIA.xml:S3:2814:8	O
treatment	CIMZIA.xml:S3:2823:9	O
for	CIMZIA.xml:S3:2833:3	O
latent	CIMZIA.xml:S3:2837:6	O
or	CIMZIA.xml:S3:2844:2	O
active	CIMZIA.xml:S3:2847:6	O
tuberculosis	CIMZIA.xml:S3:2854:12	O
.	CIMZIA.xml:S3:2866:1	O

Patients	CIMZIA.xml:S3:2868:8	O
should	CIMZIA.xml:S3:2877:6	O
be	CIMZIA.xml:S3:2884:2	O
evaluated	CIMZIA.xml:S3:2887:9	O
for	CIMZIA.xml:S3:2897:3	O
tuberculosis	CIMZIA.xml:S3:2901:12	O
risk	CIMZIA.xml:S3:2914:4	O
factors	CIMZIA.xml:S3:2919:7	O
and	CIMZIA.xml:S3:2927:3	O
tested	CIMZIA.xml:S3:2931:6	O
for	CIMZIA.xml:S3:2938:3	O
latent	CIMZIA.xml:S3:2942:6	O
infection	CIMZIA.xml:S3:2949:9	O
prior	CIMZIA.xml:S3:2959:5	O
to	CIMZIA.xml:S3:2965:2	O
initiating	CIMZIA.xml:S3:2968:10	O
CIMZIA	CIMZIA.xml:S3:2979:6	O
and	CIMZIA.xml:S3:2986:3	O
periodically	CIMZIA.xml:S3:2990:12	O
during	CIMZIA.xml:S3:3003:6	O
therapy	CIMZIA.xml:S3:3010:7	O
.	CIMZIA.xml:S3:3017:1	O

Treatment	CIMZIA.xml:S3:3023:9	O
of	CIMZIA.xml:S3:3033:2	O
latent	CIMZIA.xml:S3:3036:6	O
tuberculosis	CIMZIA.xml:S3:3043:12	O
infection	CIMZIA.xml:S3:3056:9	O
prior	CIMZIA.xml:S3:3066:5	O
to	CIMZIA.xml:S3:3072:2	O
therapy	CIMZIA.xml:S3:3075:7	O
with	CIMZIA.xml:S3:3083:4	O
TNF	CIMZIA.xml:S3:3088:3	O
-	CIMZIA.xml:S3:3091:1	O
blocking	CIMZIA.xml:S3:3092:8	O
agents	CIMZIA.xml:S3:3101:6	O
has	CIMZIA.xml:S3:3108:3	O
been	CIMZIA.xml:S3:3112:4	O
shown	CIMZIA.xml:S3:3117:5	O
to	CIMZIA.xml:S3:3123:2	O
reduce	CIMZIA.xml:S3:3126:6	O
the	CIMZIA.xml:S3:3133:3	O
risk	CIMZIA.xml:S3:3137:4	O
of	CIMZIA.xml:S3:3142:2	O
tuberculosis	CIMZIA.xml:S3:3145:12	O
reactivation	CIMZIA.xml:S3:3158:12	O
during	CIMZIA.xml:S3:3171:6	O
therapy	CIMZIA.xml:S3:3178:7	O
.	CIMZIA.xml:S3:3185:1	O

Induration	CIMZIA.xml:S3:3187:10	O
of	CIMZIA.xml:S3:3198:2	O
5	CIMZIA.xml:S3:3201:1	O
mm	CIMZIA.xml:S3:3203:2	O
or	CIMZIA.xml:S3:3206:2	O
greater	CIMZIA.xml:S3:3209:7	O
with	CIMZIA.xml:S3:3217:4	O
tuberculin	CIMZIA.xml:S3:3222:10	O
skin	CIMZIA.xml:S3:3233:4	O
testing	CIMZIA.xml:S3:3238:7	O
should	CIMZIA.xml:S3:3246:6	O
be	CIMZIA.xml:S3:3253:2	O
considered	CIMZIA.xml:S3:3256:10	O
a	CIMZIA.xml:S3:3267:1	O
positive	CIMZIA.xml:S3:3269:8	O
test	CIMZIA.xml:S3:3278:4	O
result	CIMZIA.xml:S3:3283:6	O
when	CIMZIA.xml:S3:3290:4	O
assessing	CIMZIA.xml:S3:3295:9	O
if	CIMZIA.xml:S3:3305:2	O
treatment	CIMZIA.xml:S3:3308:9	O
for	CIMZIA.xml:S3:3318:3	O
latent	CIMZIA.xml:S3:3322:6	O
tuberculosis	CIMZIA.xml:S3:3329:12	O
is	CIMZIA.xml:S3:3342:2	O
needed	CIMZIA.xml:S3:3345:6	O
prior	CIMZIA.xml:S3:3352:5	O
to	CIMZIA.xml:S3:3358:2	O
initiating	CIMZIA.xml:S3:3361:10	O
CIMZIA	CIMZIA.xml:S3:3372:6	O
,	CIMZIA.xml:S3:3378:1	O
even	CIMZIA.xml:S3:3380:4	O
for	CIMZIA.xml:S3:3385:3	O
patients	CIMZIA.xml:S3:3389:8	O
previously	CIMZIA.xml:S3:3398:10	O
vaccinated	CIMZIA.xml:S3:3409:10	O
with	CIMZIA.xml:S3:3420:4	O
Bacille	CIMZIA.xml:S3:3425:7	O
Calmette	CIMZIA.xml:S3:3433:8	O
-	CIMZIA.xml:S3:3441:1	O
Guerin	CIMZIA.xml:S3:3442:6	O
(	CIMZIA.xml:S3:3449:1	O
BCG	CIMZIA.xml:S3:3450:3	O
)	CIMZIA.xml:S3:3453:1	O
.	CIMZIA.xml:S3:3454:1	O

Anti	CIMZIA.xml:S3:3460:4	O
-	CIMZIA.xml:S3:3464:1	O
tuberculosis	CIMZIA.xml:S3:3465:12	O
therapy	CIMZIA.xml:S3:3478:7	O
should	CIMZIA.xml:S3:3486:6	O
also	CIMZIA.xml:S3:3493:4	O
be	CIMZIA.xml:S3:3498:2	O
considered	CIMZIA.xml:S3:3501:10	O
prior	CIMZIA.xml:S3:3512:5	O
to	CIMZIA.xml:S3:3518:2	O
initiation	CIMZIA.xml:S3:3521:10	O
of	CIMZIA.xml:S3:3532:2	O
CIMZIA	CIMZIA.xml:S3:3535:6	O
in	CIMZIA.xml:S3:3542:2	O
patients	CIMZIA.xml:S3:3545:8	O
with	CIMZIA.xml:S3:3554:4	O
a	CIMZIA.xml:S3:3559:1	O
past	CIMZIA.xml:S3:3561:4	O
history	CIMZIA.xml:S3:3566:7	O
of	CIMZIA.xml:S3:3574:2	O
latent	CIMZIA.xml:S3:3577:6	O
or	CIMZIA.xml:S3:3584:2	O
active	CIMZIA.xml:S3:3587:6	O
tuberculosis	CIMZIA.xml:S3:3594:12	O
in	CIMZIA.xml:S3:3607:2	O
whom	CIMZIA.xml:S3:3610:4	O
an	CIMZIA.xml:S3:3615:2	O
adequate	CIMZIA.xml:S3:3618:8	O
course	CIMZIA.xml:S3:3627:6	O
of	CIMZIA.xml:S3:3634:2	O
treatment	CIMZIA.xml:S3:3637:9	O
cannot	CIMZIA.xml:S3:3647:6	O
be	CIMZIA.xml:S3:3654:2	O
confirmed	CIMZIA.xml:S3:3657:9	O
,	CIMZIA.xml:S3:3666:1	O
and	CIMZIA.xml:S3:3668:3	O
for	CIMZIA.xml:S3:3672:3	O
patients	CIMZIA.xml:S3:3676:8	O
with	CIMZIA.xml:S3:3685:4	O
a	CIMZIA.xml:S3:3690:1	O
negative	CIMZIA.xml:S3:3692:8	O
test	CIMZIA.xml:S3:3701:4	O
for	CIMZIA.xml:S3:3706:3	O
latent	CIMZIA.xml:S3:3710:6	O
tuberculosis	CIMZIA.xml:S3:3717:12	O
but	CIMZIA.xml:S3:3730:3	O
having	CIMZIA.xml:S3:3734:6	O
risk	CIMZIA.xml:S3:3741:4	O
factors	CIMZIA.xml:S3:3746:7	O
for	CIMZIA.xml:S3:3754:3	O
tuberculosis	CIMZIA.xml:S3:3758:12	O
infection	CIMZIA.xml:S3:3771:9	O
.	CIMZIA.xml:S3:3780:1	O

Consultation	CIMZIA.xml:S3:3782:12	O
with	CIMZIA.xml:S3:3795:4	O
a	CIMZIA.xml:S3:3800:1	O
physician	CIMZIA.xml:S3:3802:9	O
with	CIMZIA.xml:S3:3812:4	O
expertise	CIMZIA.xml:S3:3817:9	O
in	CIMZIA.xml:S3:3827:2	O
the	CIMZIA.xml:S3:3830:3	O
treatment	CIMZIA.xml:S3:3834:9	O
of	CIMZIA.xml:S3:3844:2	O
tuberculosis	CIMZIA.xml:S3:3847:12	O
is	CIMZIA.xml:S3:3860:2	O
recommended	CIMZIA.xml:S3:3863:11	O
to	CIMZIA.xml:S3:3875:2	O
aid	CIMZIA.xml:S3:3878:3	O
in	CIMZIA.xml:S3:3882:2	O
the	CIMZIA.xml:S3:3885:3	O
decision	CIMZIA.xml:S3:3889:8	O
of	CIMZIA.xml:S3:3898:2	O
whether	CIMZIA.xml:S3:3901:7	O
initiating	CIMZIA.xml:S3:3909:10	O
anti	CIMZIA.xml:S3:3920:4	O
-	CIMZIA.xml:S3:3924:1	O
tuberculosis	CIMZIA.xml:S3:3925:12	O
therapy	CIMZIA.xml:S3:3938:7	O
is	CIMZIA.xml:S3:3946:2	O
appropriate	CIMZIA.xml:S3:3949:11	O
for	CIMZIA.xml:S3:3961:3	O
an	CIMZIA.xml:S3:3965:2	O
individual	CIMZIA.xml:S3:3968:10	O
patient	CIMZIA.xml:S3:3979:7	O
.	CIMZIA.xml:S3:3986:1	O

Tuberculosis	CIMZIA.xml:S3:3992:12	O
should	CIMZIA.xml:S3:4005:6	O
be	CIMZIA.xml:S3:4012:2	O
strongly	CIMZIA.xml:S3:4015:8	O
considered	CIMZIA.xml:S3:4024:10	O
in	CIMZIA.xml:S3:4035:2	O
patients	CIMZIA.xml:S3:4038:8	O
who	CIMZIA.xml:S3:4047:3	O
develop	CIMZIA.xml:S3:4051:7	O
a	CIMZIA.xml:S3:4059:1	O
new	CIMZIA.xml:S3:4061:3	O
infection	CIMZIA.xml:S3:4065:9	O
during	CIMZIA.xml:S3:4075:6	O
CIMZIA	CIMZIA.xml:S3:4082:6	O
treatment	CIMZIA.xml:S3:4089:9	O
,	CIMZIA.xml:S3:4098:1	O
especially	CIMZIA.xml:S3:4100:10	O
in	CIMZIA.xml:S3:4111:2	O
patients	CIMZIA.xml:S3:4114:8	O
who	CIMZIA.xml:S3:4123:3	O
have	CIMZIA.xml:S3:4127:4	O
previously	CIMZIA.xml:S3:4132:10	O
or	CIMZIA.xml:S3:4143:2	O
recently	CIMZIA.xml:S3:4146:8	O
traveled	CIMZIA.xml:S3:4155:8	O
to	CIMZIA.xml:S3:4164:2	O
countries	CIMZIA.xml:S3:4167:9	O
with	CIMZIA.xml:S3:4177:4	O
a	CIMZIA.xml:S3:4182:1	O
high	CIMZIA.xml:S3:4184:4	O
prevalence	CIMZIA.xml:S3:4189:10	O
of	CIMZIA.xml:S3:4200:2	O
tuberculosis	CIMZIA.xml:S3:4203:12	O
,	CIMZIA.xml:S3:4215:1	O
or	CIMZIA.xml:S3:4217:2	O
who	CIMZIA.xml:S3:4220:3	O
have	CIMZIA.xml:S3:4224:4	O
had	CIMZIA.xml:S3:4229:3	O
close	CIMZIA.xml:S3:4233:5	O
contact	CIMZIA.xml:S3:4239:7	O
with	CIMZIA.xml:S3:4247:4	O
a	CIMZIA.xml:S3:4252:1	O
person	CIMZIA.xml:S3:4254:6	O
with	CIMZIA.xml:S3:4261:4	O
active	CIMZIA.xml:S3:4266:6	O
tuberculosis	CIMZIA.xml:S3:4273:12	O
.	CIMZIA.xml:S3:4285:1	O

Monitoring	CIMZIA.xml:S3:4294:10	O

Patients	CIMZIA.xml:S3:4311:8	O
should	CIMZIA.xml:S3:4320:6	O
be	CIMZIA.xml:S3:4327:2	O
closely	CIMZIA.xml:S3:4330:7	O
monitored	CIMZIA.xml:S3:4338:9	O
for	CIMZIA.xml:S3:4348:3	O
the	CIMZIA.xml:S3:4352:3	O
development	CIMZIA.xml:S3:4356:11	O
of	CIMZIA.xml:S3:4368:2	O
signs	CIMZIA.xml:S3:4371:5	O
and	CIMZIA.xml:S3:4377:3	O
symptoms	CIMZIA.xml:S3:4381:8	O
of	CIMZIA.xml:S3:4390:2	O
infection	CIMZIA.xml:S3:4393:9	O
during	CIMZIA.xml:S3:4403:6	O
and	CIMZIA.xml:S3:4410:3	O
after	CIMZIA.xml:S3:4414:5	O
treatment	CIMZIA.xml:S3:4420:9	O
with	CIMZIA.xml:S3:4430:4	O
CIMZIA	CIMZIA.xml:S3:4435:6	O
,	CIMZIA.xml:S3:4441:1	O
including	CIMZIA.xml:S3:4443:9	O
the	CIMZIA.xml:S3:4453:3	O
development	CIMZIA.xml:S3:4457:11	O
of	CIMZIA.xml:S3:4469:2	O
tuberculosis	CIMZIA.xml:S3:4472:12	O
in	CIMZIA.xml:S3:4485:2	O
patients	CIMZIA.xml:S3:4488:8	O
who	CIMZIA.xml:S3:4497:3	O
tested	CIMZIA.xml:S3:4501:6	O
negative	CIMZIA.xml:S3:4508:8	O
for	CIMZIA.xml:S3:4517:3	O
latent	CIMZIA.xml:S3:4521:6	O
tuberculosis	CIMZIA.xml:S3:4528:12	O
infection	CIMZIA.xml:S3:4541:9	O
prior	CIMZIA.xml:S3:4551:5	O
to	CIMZIA.xml:S3:4557:2	O
initiating	CIMZIA.xml:S3:4560:10	O
therapy	CIMZIA.xml:S3:4571:7	O
.	CIMZIA.xml:S3:4578:1	O

Tests	CIMZIA.xml:S3:4580:5	O
for	CIMZIA.xml:S3:4586:3	O
latent	CIMZIA.xml:S3:4590:6	O
tuberculosis	CIMZIA.xml:S3:4597:12	O
infection	CIMZIA.xml:S3:4610:9	O
may	CIMZIA.xml:S3:4620:3	O
also	CIMZIA.xml:S3:4624:4	O
be	CIMZIA.xml:S3:4629:2	O
falsely	CIMZIA.xml:S3:4632:7	O
negative	CIMZIA.xml:S3:4640:8	O
while	CIMZIA.xml:S3:4649:5	O
on	CIMZIA.xml:S3:4655:2	O
therapy	CIMZIA.xml:S3:4658:7	O
with	CIMZIA.xml:S3:4666:4	O
CIMZIA	CIMZIA.xml:S3:4671:6	O
.	CIMZIA.xml:S3:4677:1	O

CIMZIA	CIMZIA.xml:S3:4683:6	O
should	CIMZIA.xml:S3:4690:6	O
be	CIMZIA.xml:S3:4697:2	O
discontinued	CIMZIA.xml:S3:4700:12	O
if	CIMZIA.xml:S3:4713:2	O
a	CIMZIA.xml:S3:4716:1	O
patient	CIMZIA.xml:S3:4718:7	O
develops	CIMZIA.xml:S3:4726:8	O
a	CIMZIA.xml:S3:4735:1	O
serious	CIMZIA.xml:S3:4737:7	O
infection	CIMZIA.xml:S3:4745:9	O
or	CIMZIA.xml:S3:4755:2	O
sepsis	CIMZIA.xml:S3:4758:6	O
.	CIMZIA.xml:S3:4764:1	O

A	CIMZIA.xml:S3:4766:1	O
patient	CIMZIA.xml:S3:4768:7	O
who	CIMZIA.xml:S3:4776:3	O
develops	CIMZIA.xml:S3:4780:8	O
a	CIMZIA.xml:S3:4789:1	O
new	CIMZIA.xml:S3:4791:3	O
infection	CIMZIA.xml:S3:4795:9	O
during	CIMZIA.xml:S3:4805:6	O
treatment	CIMZIA.xml:S3:4812:9	O
with	CIMZIA.xml:S3:4822:4	O
CIMZIA	CIMZIA.xml:S3:4827:6	O
should	CIMZIA.xml:S3:4834:6	O
be	CIMZIA.xml:S3:4841:2	O
closely	CIMZIA.xml:S3:4844:7	O
monitored	CIMZIA.xml:S3:4852:9	O
,	CIMZIA.xml:S3:4861:1	O
undergo	CIMZIA.xml:S3:4863:7	O
a	CIMZIA.xml:S3:4871:1	O
prompt	CIMZIA.xml:S3:4873:6	O
and	CIMZIA.xml:S3:4880:3	O
complete	CIMZIA.xml:S3:4884:8	O
diagnostic	CIMZIA.xml:S3:4893:10	O
workup	CIMZIA.xml:S3:4904:6	O
appropriate	CIMZIA.xml:S3:4911:11	O
for	CIMZIA.xml:S3:4923:3	O
an	CIMZIA.xml:S3:4927:2	O
immunocompromised	CIMZIA.xml:S3:4930:17	O
patient	CIMZIA.xml:S3:4948:7	O
,	CIMZIA.xml:S3:4955:1	O
and	CIMZIA.xml:S3:4957:3	O
appropriate	CIMZIA.xml:S3:4961:11	O
antimicrobial	CIMZIA.xml:S3:4973:13	O
therapy	CIMZIA.xml:S3:4987:7	O
should	CIMZIA.xml:S3:4995:6	O
be	CIMZIA.xml:S3:5002:2	O
initiated	CIMZIA.xml:S3:5005:9	O
.	CIMZIA.xml:S3:5014:1	O

Invasive	CIMZIA.xml:S3:5023:8	O
Fungal	CIMZIA.xml:S3:5032:6	O
Infections	CIMZIA.xml:S3:5039:10	O

For	CIMZIA.xml:S3:5056:3	O
patients	CIMZIA.xml:S3:5060:8	O
who	CIMZIA.xml:S3:5069:3	O
reside	CIMZIA.xml:S3:5073:6	O
or	CIMZIA.xml:S3:5080:2	O
travel	CIMZIA.xml:S3:5083:6	O
in	CIMZIA.xml:S3:5090:2	O
regions	CIMZIA.xml:S3:5093:7	O
where	CIMZIA.xml:S3:5101:5	O
mycoses	CIMZIA.xml:S3:5107:7	O
are	CIMZIA.xml:S3:5115:3	O
endemic	CIMZIA.xml:S3:5119:7	O
,	CIMZIA.xml:S3:5126:1	O
invasive	CIMZIA.xml:S3:5128:8	O
fungal	CIMZIA.xml:S3:5137:6	O
infection	CIMZIA.xml:S3:5144:9	O
should	CIMZIA.xml:S3:5154:6	O
be	CIMZIA.xml:S3:5161:2	O
suspected	CIMZIA.xml:S3:5164:9	O
if	CIMZIA.xml:S3:5174:2	O
they	CIMZIA.xml:S3:5177:4	O
develop	CIMZIA.xml:S3:5182:7	O
a	CIMZIA.xml:S3:5190:1	O
serious	CIMZIA.xml:S3:5192:7	O
systemic	CIMZIA.xml:S3:5200:8	O
illness	CIMZIA.xml:S3:5209:7	O
.	CIMZIA.xml:S3:5216:1	O

Appropriate	CIMZIA.xml:S3:5218:11	O
empiric	CIMZIA.xml:S3:5230:7	O
antifungal	CIMZIA.xml:S3:5238:10	O
therapy	CIMZIA.xml:S3:5249:7	O
should	CIMZIA.xml:S3:5257:6	O
be	CIMZIA.xml:S3:5264:2	O
considered	CIMZIA.xml:S3:5267:10	O
while	CIMZIA.xml:S3:5278:5	O
a	CIMZIA.xml:S3:5284:1	O
diagnostic	CIMZIA.xml:S3:5286:10	O
workup	CIMZIA.xml:S3:5297:6	O
is	CIMZIA.xml:S3:5304:2	O
being	CIMZIA.xml:S3:5307:5	O
performed	CIMZIA.xml:S3:5313:9	O
.	CIMZIA.xml:S3:5322:1	O

Antigen	CIMZIA.xml:S3:5324:7	O
and	CIMZIA.xml:S3:5332:3	O
antibody	CIMZIA.xml:S3:5336:8	O
testing	CIMZIA.xml:S3:5345:7	O
for	CIMZIA.xml:S3:5353:3	O
histoplasmosis	CIMZIA.xml:S3:5357:14	O
may	CIMZIA.xml:S3:5372:3	O
be	CIMZIA.xml:S3:5376:2	O
negative	CIMZIA.xml:S3:5379:8	O
in	CIMZIA.xml:S3:5388:2	O
some	CIMZIA.xml:S3:5391:4	O
patients	CIMZIA.xml:S3:5396:8	O
with	CIMZIA.xml:S3:5405:4	O
active	CIMZIA.xml:S3:5410:6	O
infection	CIMZIA.xml:S3:5417:9	O
.	CIMZIA.xml:S3:5426:1	O

When	CIMZIA.xml:S3:5428:4	O
feasible	CIMZIA.xml:S3:5433:8	O
,	CIMZIA.xml:S3:5441:1	O
the	CIMZIA.xml:S3:5443:3	O
decision	CIMZIA.xml:S3:5447:8	O
to	CIMZIA.xml:S3:5456:2	O
administer	CIMZIA.xml:S3:5459:10	O
empiric	CIMZIA.xml:S3:5470:7	O
antifungal	CIMZIA.xml:S3:5478:10	O
therapy	CIMZIA.xml:S3:5489:7	O
in	CIMZIA.xml:S3:5497:2	O
these	CIMZIA.xml:S3:5500:5	O
patients	CIMZIA.xml:S3:5506:8	O
should	CIMZIA.xml:S3:5515:6	O
be	CIMZIA.xml:S3:5522:2	O
made	CIMZIA.xml:S3:5525:4	O
in	CIMZIA.xml:S3:5530:2	O
consultation	CIMZIA.xml:S3:5533:12	O
with	CIMZIA.xml:S3:5546:4	O
a	CIMZIA.xml:S3:5551:1	O
physician	CIMZIA.xml:S3:5553:9	O
with	CIMZIA.xml:S3:5563:4	O
expertise	CIMZIA.xml:S3:5568:9	O
in	CIMZIA.xml:S3:5578:2	O
the	CIMZIA.xml:S3:5581:3	O
diagnosis	CIMZIA.xml:S3:5585:9	O
and	CIMZIA.xml:S3:5595:3	O
treatment	CIMZIA.xml:S3:5599:9	O
of	CIMZIA.xml:S3:5609:2	O
invasive	CIMZIA.xml:S3:5612:8	O
fungal	CIMZIA.xml:S3:5621:6	O
infections	CIMZIA.xml:S3:5628:10	O
and	CIMZIA.xml:S3:5639:3	O
should	CIMZIA.xml:S3:5643:6	O
take	CIMZIA.xml:S3:5650:4	O
into	CIMZIA.xml:S3:5655:4	O
account	CIMZIA.xml:S3:5660:7	O
both	CIMZIA.xml:S3:5668:4	O
the	CIMZIA.xml:S3:5673:3	O
risk	CIMZIA.xml:S3:5677:4	O
for	CIMZIA.xml:S3:5682:3	O
severe	CIMZIA.xml:S3:5686:6	O
fungal	CIMZIA.xml:S3:5693:6	O
infection	CIMZIA.xml:S3:5700:9	O
and	CIMZIA.xml:S3:5710:3	O
risks	CIMZIA.xml:S3:5714:5	O
of	CIMZIA.xml:S3:5720:2	O
antifungal	CIMZIA.xml:S3:5723:10	O
therapy	CIMZIA.xml:S3:5734:7	O
.	CIMZIA.xml:S3:5741:1	O

5.2	CIMZIA.xml:S3:5750:3	O
Malignancies	CIMZIA.xml:S3:5754:12	O

In	CIMZIA.xml:S3:5772:2	O
the	CIMZIA.xml:S3:5775:3	O
controlled	CIMZIA.xml:S3:5779:10	O
portions	CIMZIA.xml:S3:5790:8	O
of	CIMZIA.xml:S3:5799:2	O
clinical	CIMZIA.xml:S3:5802:8	O
studies	CIMZIA.xml:S3:5811:7	O
of	CIMZIA.xml:S3:5819:2	O
some	CIMZIA.xml:S3:5822:4	O
TNF	CIMZIA.xml:S3:5827:3	O
blockers	CIMZIA.xml:S3:5831:8	O
,	CIMZIA.xml:S3:5839:1	O
more	CIMZIA.xml:S3:5841:4	O
cases	CIMZIA.xml:S3:5846:5	O
of	CIMZIA.xml:S3:5852:2	O
malignancies	CIMZIA.xml:S3:5855:12	B-AdverseReaction
have	CIMZIA.xml:S3:5868:4	O
been	CIMZIA.xml:S3:5873:4	O
observed	CIMZIA.xml:S3:5878:8	O
among	CIMZIA.xml:S3:5887:5	O
patients	CIMZIA.xml:S3:5893:8	O
receiving	CIMZIA.xml:S3:5902:9	O
TNF	CIMZIA.xml:S3:5912:3	B-DrugClass
blockers	CIMZIA.xml:S3:5916:8	I-DrugClass
compared	CIMZIA.xml:S3:5925:8	O
to	CIMZIA.xml:S3:5934:2	O
control	CIMZIA.xml:S3:5937:7	O
patients	CIMZIA.xml:S3:5945:8	O
.	CIMZIA.xml:S3:5953:1	O

During	CIMZIA.xml:S3:5955:6	O
controlled	CIMZIA.xml:S3:5962:10	O
and	CIMZIA.xml:S3:5973:3	O
open	CIMZIA.xml:S3:5977:4	O
-	CIMZIA.xml:S3:5981:1	O
labeled	CIMZIA.xml:S3:5982:7	O
portions	CIMZIA.xml:S3:5990:8	O
of	CIMZIA.xml:S3:5999:2	O
CIMZIA	CIMZIA.xml:S3:6002:6	O
studies	CIMZIA.xml:S3:6009:7	O
of	CIMZIA.xml:S3:6017:2	O
Crohn	CIMZIA.xml:S3:6020:5	O
's	CIMZIA.xml:S3:6025:2	O
disease	CIMZIA.xml:S3:6028:7	O
and	CIMZIA.xml:S3:6036:3	O
other	CIMZIA.xml:S3:6040:5	O
diseases	CIMZIA.xml:S3:6046:8	O
,	CIMZIA.xml:S3:6054:1	O
malignancies	CIMZIA.xml:S3:6056:12	B-AdverseReaction
(	CIMZIA.xml:S3:6069:1	O
excluding	CIMZIA.xml:S3:6070:9	B-Negation
non	CIMZIA.xml:S3:6080:3	B-AdverseReaction
-	CIMZIA.xml:S3:6083:1	I-AdverseReaction
melanoma	CIMZIA.xml:S3:6084:8	I-AdverseReaction
skin	CIMZIA.xml:S3:6093:4	I-AdverseReaction
cancer	CIMZIA.xml:S3:6098:6	I-AdverseReaction
)	CIMZIA.xml:S3:6104:1	O
were	CIMZIA.xml:S3:6106:4	O
observed	CIMZIA.xml:S3:6111:8	O
at	CIMZIA.xml:S3:6120:2	O
a	CIMZIA.xml:S3:6123:1	O
rate	CIMZIA.xml:S3:6125:4	O
(	CIMZIA.xml:S3:6130:1	O
95%	CIMZIA.xml:S3:6131:3	O
confidence	CIMZIA.xml:S3:6135:10	O
interval	CIMZIA.xml:S3:6146:8	O
)	CIMZIA.xml:S3:6154:1	O
of	CIMZIA.xml:S3:6156:2	O
0.5	CIMZIA.xml:S3:6159:3	O
(	CIMZIA.xml:S3:6163:1	O
0.4	CIMZIA.xml:S3:6164:3	O
,	CIMZIA.xml:S3:6167:1	O
0.7	CIMZIA.xml:S3:6169:3	O
)	CIMZIA.xml:S3:6172:1	O
per	CIMZIA.xml:S3:6174:3	O
100	CIMZIA.xml:S3:6178:3	O
patient	CIMZIA.xml:S3:6182:7	O
-	CIMZIA.xml:S3:6189:1	O
years	CIMZIA.xml:S3:6190:5	O
among	CIMZIA.xml:S3:6196:5	O
4	CIMZIA.xml:S3:6202:1	O
,	CIMZIA.xml:S3:6203:1	O
650	CIMZIA.xml:S3:6204:3	O
CIMZIA	CIMZIA.xml:S3:6208:6	O
-	CIMZIA.xml:S3:6214:1	O
treated	CIMZIA.xml:S3:6215:7	O
patients	CIMZIA.xml:S3:6223:8	O
versus	CIMZIA.xml:S3:6232:6	O
a	CIMZIA.xml:S3:6239:1	O
rate	CIMZIA.xml:S3:6241:4	O
of	CIMZIA.xml:S3:6246:2	O
0.6	CIMZIA.xml:S3:6249:3	O
(	CIMZIA.xml:S3:6253:1	O
0.1	CIMZIA.xml:S3:6254:3	O
,	CIMZIA.xml:S3:6257:1	O
1.7	CIMZIA.xml:S3:6259:3	O
)	CIMZIA.xml:S3:6262:1	O
per	CIMZIA.xml:S3:6264:3	O
100	CIMZIA.xml:S3:6268:3	O
patient	CIMZIA.xml:S3:6272:7	O
-	CIMZIA.xml:S3:6279:1	O
years	CIMZIA.xml:S3:6280:5	O
among	CIMZIA.xml:S3:6286:5	O
1	CIMZIA.xml:S3:6292:1	O
,	CIMZIA.xml:S3:6293:1	O
319	CIMZIA.xml:S3:6294:3	O
placebo	CIMZIA.xml:S3:6298:7	O
-	CIMZIA.xml:S3:6305:1	O
treated	CIMZIA.xml:S3:6306:7	O
patients	CIMZIA.xml:S3:6314:8	O
.	CIMZIA.xml:S3:6322:1	O

The	CIMZIA.xml:S3:6324:3	O
size	CIMZIA.xml:S3:6328:4	O
of	CIMZIA.xml:S3:6333:2	O
the	CIMZIA.xml:S3:6336:3	O
control	CIMZIA.xml:S3:6340:7	O
group	CIMZIA.xml:S3:6348:5	O
and	CIMZIA.xml:S3:6354:3	O
limited	CIMZIA.xml:S3:6358:7	O
duration	CIMZIA.xml:S3:6366:8	O
of	CIMZIA.xml:S3:6375:2	O
the	CIMZIA.xml:S3:6378:3	O
controlled	CIMZIA.xml:S3:6382:10	O
portions	CIMZIA.xml:S3:6393:8	O
of	CIMZIA.xml:S3:6402:2	O
the	CIMZIA.xml:S3:6405:3	O
studies	CIMZIA.xml:S3:6409:7	O
precludes	CIMZIA.xml:S3:6417:9	O
the	CIMZIA.xml:S3:6427:3	O
ability	CIMZIA.xml:S3:6431:7	O
to	CIMZIA.xml:S3:6439:2	O
draw	CIMZIA.xml:S3:6442:4	O
firm	CIMZIA.xml:S3:6447:4	O
conclusions	CIMZIA.xml:S3:6452:11	O
.	CIMZIA.xml:S3:6463:1	O

Malignancies	CIMZIA.xml:S3:6470:12	B-AdverseReaction
,	CIMZIA.xml:S3:6482:1	O
some	CIMZIA.xml:S3:6484:4	O
fatal	CIMZIA.xml:S3:6489:5	B-AdverseReaction
,	CIMZIA.xml:S3:6494:1	O
have	CIMZIA.xml:S3:6496:4	O
been	CIMZIA.xml:S3:6501:4	O
reported	CIMZIA.xml:S3:6506:8	O
among	CIMZIA.xml:S3:6515:5	O
children	CIMZIA.xml:S3:6521:8	O
,	CIMZIA.xml:S3:6529:1	O
adolescents	CIMZIA.xml:S3:6531:11	O
,	CIMZIA.xml:S3:6542:1	O
and	CIMZIA.xml:S3:6544:3	O
young	CIMZIA.xml:S3:6548:5	O
adults	CIMZIA.xml:S3:6554:6	O
who	CIMZIA.xml:S3:6561:3	O
received	CIMZIA.xml:S3:6565:8	O
treatment	CIMZIA.xml:S3:6574:9	O
with	CIMZIA.xml:S3:6584:4	O
TNF	CIMZIA.xml:S3:6589:3	B-DrugClass
-	CIMZIA.xml:S3:6592:1	I-DrugClass
blocking	CIMZIA.xml:S3:6593:8	I-DrugClass
agents	CIMZIA.xml:S3:6602:6	I-DrugClass
(	CIMZIA.xml:S3:6609:1	O
initiation	CIMZIA.xml:S3:6610:10	O
of	CIMZIA.xml:S3:6621:2	O
therapy	CIMZIA.xml:S3:6624:7	O
18	CIMZIA.xml:S3:6635:2	O
years	CIMZIA.xml:S3:6638:5	O
of	CIMZIA.xml:S3:6644:2	O
age	CIMZIA.xml:S3:6647:3	O
)	CIMZIA.xml:S3:6650:1	O
,	CIMZIA.xml:S3:6651:1	O
of	CIMZIA.xml:S3:6653:2	O
which	CIMZIA.xml:S3:6656:5	O
CIMZIA	CIMZIA.xml:S3:6662:6	O
is	CIMZIA.xml:S3:6669:2	O
a	CIMZIA.xml:S3:6672:1	O
member	CIMZIA.xml:S3:6674:6	O
.	CIMZIA.xml:S3:6680:1	O

Approximately	CIMZIA.xml:S3:6682:13	O
half	CIMZIA.xml:S3:6696:4	O
the	CIMZIA.xml:S3:6701:3	O
cases	CIMZIA.xml:S3:6705:5	O
were	CIMZIA.xml:S3:6711:4	O
lymphomas	CIMZIA.xml:S3:6716:9	B-AdverseReaction
,	CIMZIA.xml:S3:6725:1	O
including	CIMZIA.xml:S3:6727:9	O
Hodgkin	CIMZIA.xml:S3:6737:7	B-AdverseReaction
's	CIMZIA.xml:S3:6744:2	O
and	CIMZIA.xml:S3:6747:3	O
non	CIMZIA.xml:S3:6751:3	B-AdverseReaction
-	CIMZIA.xml:S3:6754:1	I-AdverseReaction
Hodgkin	CIMZIA.xml:S3:6755:7	I-AdverseReaction
's	CIMZIA.xml:S3:6762:2	I-AdverseReaction
lymphoma	CIMZIA.xml:S3:6765:8	I-AdverseReaction
.	CIMZIA.xml:S3:6773:1	O

The	CIMZIA.xml:S3:6775:3	O
other	CIMZIA.xml:S3:6779:5	O
cases	CIMZIA.xml:S3:6785:5	O
represented	CIMZIA.xml:S3:6791:11	O
a	CIMZIA.xml:S3:6803:1	O
variety	CIMZIA.xml:S3:6805:7	O
of	CIMZIA.xml:S3:6813:2	O
different	CIMZIA.xml:S3:6816:9	O
malignancies	CIMZIA.xml:S3:6826:12	B-AdverseReaction
and	CIMZIA.xml:S3:6839:3	O
included	CIMZIA.xml:S3:6843:8	O
rare	CIMZIA.xml:S3:6852:4	B-AdverseReaction
malignancies	CIMZIA.xml:S3:6857:12	I-AdverseReaction
usually	CIMZIA.xml:S3:6870:7	O
associated	CIMZIA.xml:S3:6878:10	O
with	CIMZIA.xml:S3:6889:4	O
immunosuppression	CIMZIA.xml:S3:6894:17	O
and	CIMZIA.xml:S3:6912:3	O
malignancies	CIMZIA.xml:S3:6916:12	B-AdverseReaction
that	CIMZIA.xml:S3:6929:4	O
are	CIMZIA.xml:S3:6934:3	O
not	CIMZIA.xml:S3:6938:3	O
usually	CIMZIA.xml:S3:6942:7	O
observed	CIMZIA.xml:S3:6950:8	O
in	CIMZIA.xml:S3:6959:2	O
children	CIMZIA.xml:S3:6962:8	O
and	CIMZIA.xml:S3:6971:3	O
adolescents	CIMZIA.xml:S3:6975:11	O
.	CIMZIA.xml:S3:6986:1	O

The	CIMZIA.xml:S3:6988:3	O
malignancies	CIMZIA.xml:S3:6992:12	B-AdverseReaction
occurred	CIMZIA.xml:S3:7005:8	O
after	CIMZIA.xml:S3:7014:5	O
a	CIMZIA.xml:S3:7020:1	O
median	CIMZIA.xml:S3:7022:6	O
of	CIMZIA.xml:S3:7029:2	O
30	CIMZIA.xml:S3:7032:2	O
months	CIMZIA.xml:S3:7035:6	O
of	CIMZIA.xml:S3:7042:2	O
therapy	CIMZIA.xml:S3:7045:7	O
(	CIMZIA.xml:S3:7053:1	O
range	CIMZIA.xml:S3:7054:5	O
1	CIMZIA.xml:S3:7060:1	O
to	CIMZIA.xml:S3:7062:2	O
84	CIMZIA.xml:S3:7065:2	O
months	CIMZIA.xml:S3:7068:6	O
)	CIMZIA.xml:S3:7074:1	O
.	CIMZIA.xml:S3:7075:1	O

Most	CIMZIA.xml:S3:7077:4	O
of	CIMZIA.xml:S3:7082:2	O
the	CIMZIA.xml:S3:7085:3	O
patients	CIMZIA.xml:S3:7089:8	O
were	CIMZIA.xml:S3:7098:4	O
receiving	CIMZIA.xml:S3:7103:9	O
concomitant	CIMZIA.xml:S3:7113:11	O
immunosuppressants	CIMZIA.xml:S3:7125:18	O
.	CIMZIA.xml:S3:7143:1	O

These	CIMZIA.xml:S3:7145:5	O
cases	CIMZIA.xml:S3:7151:5	O
were	CIMZIA.xml:S3:7157:4	O
reported	CIMZIA.xml:S3:7162:8	O
post	CIMZIA.xml:S3:7171:4	O
-	CIMZIA.xml:S3:7175:1	O
marketing	CIMZIA.xml:S3:7176:9	O
and	CIMZIA.xml:S3:7186:3	O
are	CIMZIA.xml:S3:7190:3	O
derived	CIMZIA.xml:S3:7194:7	O
from	CIMZIA.xml:S3:7202:4	O
a	CIMZIA.xml:S3:7207:1	O
variety	CIMZIA.xml:S3:7209:7	O
of	CIMZIA.xml:S3:7217:2	O
sources	CIMZIA.xml:S3:7220:7	O
including	CIMZIA.xml:S3:7228:9	O
registries	CIMZIA.xml:S3:7238:10	O
and	CIMZIA.xml:S3:7249:3	O
spontaneous	CIMZIA.xml:S3:7253:11	O
post	CIMZIA.xml:S3:7265:4	O
-	CIMZIA.xml:S3:7269:1	O
marketing	CIMZIA.xml:S3:7270:9	O
reports	CIMZIA.xml:S3:7280:7	O
.	CIMZIA.xml:S3:7287:1	O

CIMZIA	CIMZIA.xml:S3:7289:6	O
is	CIMZIA.xml:S3:7296:2	O
not	CIMZIA.xml:S3:7299:3	O
indicated	CIMZIA.xml:S3:7303:9	O
for	CIMZIA.xml:S3:7313:3	O
use	CIMZIA.xml:S3:7317:3	O
in	CIMZIA.xml:S3:7321:2	O
pediatric	CIMZIA.xml:S3:7324:9	O
patients	CIMZIA.xml:S3:7334:8	O
.	CIMZIA.xml:S3:7342:1	O

In	CIMZIA.xml:S3:7350:2	O
the	CIMZIA.xml:S3:7353:3	O
controlled	CIMZIA.xml:S3:7357:10	O
portions	CIMZIA.xml:S3:7368:8	O
of	CIMZIA.xml:S3:7377:2	O
clinical	CIMZIA.xml:S3:7380:8	O
trials	CIMZIA.xml:S3:7389:6	O
of	CIMZIA.xml:S3:7396:2	O
all	CIMZIA.xml:S3:7399:3	O
the	CIMZIA.xml:S3:7403:3	O
TNF	CIMZIA.xml:S3:7407:3	O
blockers	CIMZIA.xml:S3:7411:8	O
,	CIMZIA.xml:S3:7419:1	O
more	CIMZIA.xml:S3:7421:4	O
cases	CIMZIA.xml:S3:7426:5	O
of	CIMZIA.xml:S3:7432:2	O
lymphoma	CIMZIA.xml:S3:7435:8	B-AdverseReaction
have	CIMZIA.xml:S3:7444:4	O
been	CIMZIA.xml:S3:7449:4	O
observed	CIMZIA.xml:S3:7454:8	O
among	CIMZIA.xml:S3:7463:5	O
patients	CIMZIA.xml:S3:7469:8	O
receiving	CIMZIA.xml:S3:7478:9	O
TNF	CIMZIA.xml:S3:7488:3	B-DrugClass
blockers	CIMZIA.xml:S3:7492:8	I-DrugClass
compared	CIMZIA.xml:S3:7501:8	O
to	CIMZIA.xml:S3:7510:2	O
control	CIMZIA.xml:S3:7513:7	O
patients	CIMZIA.xml:S3:7521:8	O
.	CIMZIA.xml:S3:7529:1	O

In	CIMZIA.xml:S3:7531:2	O
controlled	CIMZIA.xml:S3:7534:10	O
studies	CIMZIA.xml:S3:7545:7	O
of	CIMZIA.xml:S3:7553:2	O
CIMZIA	CIMZIA.xml:S3:7556:6	O
for	CIMZIA.xml:S3:7563:3	O
Crohn	CIMZIA.xml:S3:7567:5	O
's	CIMZIA.xml:S3:7572:2	O
disease	CIMZIA.xml:S3:7575:7	O
and	CIMZIA.xml:S3:7583:3	O
other	CIMZIA.xml:S3:7587:5	O
investigational	CIMZIA.xml:S3:7593:15	O
uses	CIMZIA.xml:S3:7609:4	O
,	CIMZIA.xml:S3:7613:1	O
there	CIMZIA.xml:S3:7615:5	O
was	CIMZIA.xml:S3:7621:3	O
one	CIMZIA.xml:S3:7625:3	O
case	CIMZIA.xml:S3:7629:4	O
of	CIMZIA.xml:S3:7634:2	O
lymphoma	CIMZIA.xml:S3:7637:8	B-AdverseReaction
among	CIMZIA.xml:S3:7646:5	O
2	CIMZIA.xml:S3:7652:1	O
,	CIMZIA.xml:S3:7653:1	O
657	CIMZIA.xml:S3:7654:3	O
Cimzia	CIMZIA.xml:S3:7658:6	O
-	CIMZIA.xml:S3:7664:1	O
treated	CIMZIA.xml:S3:7665:7	O
patients	CIMZIA.xml:S3:7673:8	O
and	CIMZIA.xml:S3:7682:3	O
one	CIMZIA.xml:S3:7686:3	O
case	CIMZIA.xml:S3:7690:4	O
of	CIMZIA.xml:S3:7695:2	O
Hodgkin	CIMZIA.xml:S3:7698:7	B-AdverseReaction
's	CIMZIA.xml:S3:7705:2	I-AdverseReaction
lymphoma	CIMZIA.xml:S3:7708:8	I-AdverseReaction
among	CIMZIA.xml:S3:7717:5	O
1	CIMZIA.xml:S3:7723:1	O
,	CIMZIA.xml:S3:7724:1	O
319	CIMZIA.xml:S3:7725:3	O
placebo	CIMZIA.xml:S3:7729:7	B-Factor
-	CIMZIA.xml:S3:7736:1	O
treated	CIMZIA.xml:S3:7737:7	O
patients	CIMZIA.xml:S3:7745:8	O
.	CIMZIA.xml:S3:7753:1	O

In	CIMZIA.xml:S3:7759:2	O
the	CIMZIA.xml:S3:7762:3	O
CIMZIA	CIMZIA.xml:S3:7766:6	O
RA	CIMZIA.xml:S3:7773:2	O
clinical	CIMZIA.xml:S3:7776:8	O
trials	CIMZIA.xml:S3:7785:6	O
(	CIMZIA.xml:S3:7792:1	O
placebo	CIMZIA.xml:S3:7793:7	O
-	CIMZIA.xml:S3:7800:1	O
controlled	CIMZIA.xml:S3:7801:10	O
and	CIMZIA.xml:S3:7812:3	O
open	CIMZIA.xml:S3:7816:4	O
label	CIMZIA.xml:S3:7821:5	O
)	CIMZIA.xml:S3:7826:1	O
a	CIMZIA.xml:S3:7828:1	O
total	CIMZIA.xml:S3:7830:5	O
of	CIMZIA.xml:S3:7836:2	O
three	CIMZIA.xml:S3:7839:5	O
cases	CIMZIA.xml:S3:7845:5	O
of	CIMZIA.xml:S3:7851:2	O
lymphoma	CIMZIA.xml:S3:7854:8	B-AdverseReaction
were	CIMZIA.xml:S3:7863:4	O
observed	CIMZIA.xml:S3:7868:8	O
among	CIMZIA.xml:S3:7877:5	O
2	CIMZIA.xml:S3:7883:1	O
,	CIMZIA.xml:S3:7884:1	O
367	CIMZIA.xml:S3:7885:3	O
patients	CIMZIA.xml:S3:7889:8	O
.	CIMZIA.xml:S3:7897:1	O

This	CIMZIA.xml:S3:7899:4	O
is	CIMZIA.xml:S3:7904:2	O
approximately	CIMZIA.xml:S3:7907:13	O
2	CIMZIA.xml:S3:7921:1	O
-	CIMZIA.xml:S3:7922:1	O
fold	CIMZIA.xml:S3:7923:4	O
higher	CIMZIA.xml:S3:7928:6	O
than	CIMZIA.xml:S3:7935:4	O
expected	CIMZIA.xml:S3:7940:8	O
in	CIMZIA.xml:S3:7949:2	O
the	CIMZIA.xml:S3:7952:3	O
general	CIMZIA.xml:S3:7956:7	O
population	CIMZIA.xml:S3:7964:10	O
.	CIMZIA.xml:S3:7974:1	O

Patients	CIMZIA.xml:S3:7976:8	O
with	CIMZIA.xml:S3:7985:4	O
RA	CIMZIA.xml:S3:7990:2	O
,	CIMZIA.xml:S3:7992:1	O
particularly	CIMZIA.xml:S3:7994:12	O
those	CIMZIA.xml:S3:8007:5	O
with	CIMZIA.xml:S3:8013:4	O
highly	CIMZIA.xml:S3:8018:6	O
active	CIMZIA.xml:S3:8025:6	O
disease	CIMZIA.xml:S3:8032:7	O
,	CIMZIA.xml:S3:8039:1	O
are	CIMZIA.xml:S3:8041:3	O
at	CIMZIA.xml:S3:8045:2	O
a	CIMZIA.xml:S3:8048:1	O
higher	CIMZIA.xml:S3:8050:6	O
risk	CIMZIA.xml:S3:8057:4	O
for	CIMZIA.xml:S3:8062:3	O
the	CIMZIA.xml:S3:8066:3	O
development	CIMZIA.xml:S3:8070:11	O
of	CIMZIA.xml:S3:8082:2	O
lymphoma	CIMZIA.xml:S3:8085:8	O
.	CIMZIA.xml:S3:8093:1	O

Rates	CIMZIA.xml:S3:8099:5	O
in	CIMZIA.xml:S3:8105:2	O
clinical	CIMZIA.xml:S3:8108:8	O
studies	CIMZIA.xml:S3:8117:7	O
for	CIMZIA.xml:S3:8125:3	O
CIMZIA	CIMZIA.xml:S3:8129:6	O
cannot	CIMZIA.xml:S3:8136:6	O
be	CIMZIA.xml:S3:8143:2	O
compared	CIMZIA.xml:S3:8146:8	O
to	CIMZIA.xml:S3:8155:2	O
the	CIMZIA.xml:S3:8158:3	O
rates	CIMZIA.xml:S3:8162:5	O
of	CIMZIA.xml:S3:8168:2	O
clinical	CIMZIA.xml:S3:8171:8	O
trials	CIMZIA.xml:S3:8180:6	O
of	CIMZIA.xml:S3:8187:2	O
other	CIMZIA.xml:S3:8190:5	O
TNF	CIMZIA.xml:S3:8196:3	O
blockers	CIMZIA.xml:S3:8200:8	O
and	CIMZIA.xml:S3:8209:3	O
may	CIMZIA.xml:S3:8213:3	O
not	CIMZIA.xml:S3:8217:3	O
predict	CIMZIA.xml:S3:8221:7	O
the	CIMZIA.xml:S3:8229:3	O
rates	CIMZIA.xml:S3:8233:5	O
observed	CIMZIA.xml:S3:8239:8	O
when	CIMZIA.xml:S3:8248:4	O
CIMZIA	CIMZIA.xml:S3:8253:6	O
is	CIMZIA.xml:S3:8260:2	O
used	CIMZIA.xml:S3:8263:4	O
in	CIMZIA.xml:S3:8268:2	O
a	CIMZIA.xml:S3:8271:1	O
broader	CIMZIA.xml:S3:8273:7	O
patient	CIMZIA.xml:S3:8281:7	O
population	CIMZIA.xml:S3:8289:10	O
.	CIMZIA.xml:S3:8299:1	O

Patients	CIMZIA.xml:S3:8301:8	O
with	CIMZIA.xml:S3:8310:4	O
Crohn	CIMZIA.xml:S3:8315:5	O
's	CIMZIA.xml:S3:8320:2	O
disease	CIMZIA.xml:S3:8323:7	O
that	CIMZIA.xml:S3:8331:4	O
require	CIMZIA.xml:S3:8336:7	O
chronic	CIMZIA.xml:S3:8344:7	O
exposure	CIMZIA.xml:S3:8352:8	O
to	CIMZIA.xml:S3:8361:2	O
immunosuppressant	CIMZIA.xml:S3:8364:17	B-DrugClass
therapies	CIMZIA.xml:S3:8382:9	I-DrugClass
may	CIMZIA.xml:S3:8392:3	O
be	CIMZIA.xml:S3:8396:2	O
at	CIMZIA.xml:S3:8399:2	O
higher	CIMZIA.xml:S3:8402:6	O
risk	CIMZIA.xml:S3:8409:4	O
than	CIMZIA.xml:S3:8414:4	O
the	CIMZIA.xml:S3:8419:3	O
general	CIMZIA.xml:S3:8423:7	O
population	CIMZIA.xml:S3:8431:10	O
for	CIMZIA.xml:S3:8442:3	O
the	CIMZIA.xml:S3:8446:3	O
development	CIMZIA.xml:S3:8450:11	O
of	CIMZIA.xml:S3:8462:2	O
lymphoma	CIMZIA.xml:S3:8465:8	B-AdverseReaction
,	CIMZIA.xml:S3:8473:1	O
even	CIMZIA.xml:S3:8475:4	O
in	CIMZIA.xml:S3:8480:2	O
the	CIMZIA.xml:S3:8483:3	O
absence	CIMZIA.xml:S3:8487:7	O
of	CIMZIA.xml:S3:8495:2	O
TNF	CIMZIA.xml:S3:8498:3	O
blocker	CIMZIA.xml:S3:8502:7	O
therapy	CIMZIA.xml:S3:8510:7	O
[	CIMZIA.xml:S3:8518:1	O
see	CIMZIA.xml:S3:8519:3	O
Adverse	CIMZIA.xml:S3:8524:7	O
Reactions	CIMZIA.xml:S3:8532:9	O
(	CIMZIA.xml:S3:8542:1	O
6.1	CIMZIA.xml:S3:8543:3	O
)	CIMZIA.xml:S3:8546:1	O
]	CIMZIA.xml:S3:8549:1	O
.	CIMZIA.xml:S3:8552:1	O

The	CIMZIA.xml:S3:8554:3	O
potential	CIMZIA.xml:S3:8558:9	O
role	CIMZIA.xml:S3:8568:4	O
of	CIMZIA.xml:S3:8573:2	O
TNF	CIMZIA.xml:S3:8576:3	O
blocker	CIMZIA.xml:S3:8580:7	O
therapy	CIMZIA.xml:S3:8588:7	O
in	CIMZIA.xml:S3:8596:2	O
the	CIMZIA.xml:S3:8599:3	O
development	CIMZIA.xml:S3:8603:11	O
of	CIMZIA.xml:S3:8615:2	O
malignancies	CIMZIA.xml:S3:8618:12	O
in	CIMZIA.xml:S3:8631:2	O
adults	CIMZIA.xml:S3:8634:6	O
is	CIMZIA.xml:S3:8641:2	O
not	CIMZIA.xml:S3:8644:3	O
known	CIMZIA.xml:S3:8648:5	O
.	CIMZIA.xml:S3:8653:1	O

Postmarketing	CIMZIA.xml:S3:8660:13	O
cases	CIMZIA.xml:S3:8674:5	O
of	CIMZIA.xml:S3:8680:2	O
hepatosplenic	CIMZIA.xml:S3:8683:13	B-AdverseReaction
T	CIMZIA.xml:S3:8697:1	I-AdverseReaction
-	CIMZIA.xml:S3:8698:1	I-AdverseReaction
cell	CIMZIA.xml:S3:8699:4	I-AdverseReaction
lymphoma	CIMZIA.xml:S3:8704:8	I-AdverseReaction
(	CIMZIA.xml:S3:8713:1	O
HSTCL	CIMZIA.xml:S3:8714:5	B-AdverseReaction
)	CIMZIA.xml:S3:8719:1	O
,	CIMZIA.xml:S3:8720:1	O
a	CIMZIA.xml:S3:8722:1	O
rare	CIMZIA.xml:S3:8724:4	O
type	CIMZIA.xml:S3:8729:4	O
of	CIMZIA.xml:S3:8734:2	O
T	CIMZIA.xml:S3:8737:1	O
-	CIMZIA.xml:S3:8738:1	O
cell	CIMZIA.xml:S3:8739:4	O
lymphoma	CIMZIA.xml:S3:8744:8	O
that	CIMZIA.xml:S3:8753:4	O
has	CIMZIA.xml:S3:8758:3	O
a	CIMZIA.xml:S3:8762:1	O
very	CIMZIA.xml:S3:8764:4	O
aggressive	CIMZIA.xml:S3:8769:10	O
disease	CIMZIA.xml:S3:8780:7	O
course	CIMZIA.xml:S3:8788:6	O
and	CIMZIA.xml:S3:8795:3	O
is	CIMZIA.xml:S3:8799:2	O
usually	CIMZIA.xml:S3:8802:7	O
fatal	CIMZIA.xml:S3:8810:5	B-AdverseReaction
,	CIMZIA.xml:S3:8815:1	O
have	CIMZIA.xml:S3:8817:4	O
been	CIMZIA.xml:S3:8822:4	O
reported	CIMZIA.xml:S3:8827:8	O
in	CIMZIA.xml:S3:8836:2	O
patients	CIMZIA.xml:S3:8839:8	O
treated	CIMZIA.xml:S3:8848:7	O
with	CIMZIA.xml:S3:8856:4	O
TNF	CIMZIA.xml:S3:8861:3	O
blockers	CIMZIA.xml:S3:8865:8	O
,	CIMZIA.xml:S3:8873:1	O
including	CIMZIA.xml:S3:8875:9	O
CIMZIA	CIMZIA.xml:S3:8885:6	O
.	CIMZIA.xml:S3:8891:1	O

The	CIMZIA.xml:S3:8893:3	O
majority	CIMZIA.xml:S3:8897:8	O
of	CIMZIA.xml:S3:8906:2	O
reported	CIMZIA.xml:S3:8909:8	O
TNF	CIMZIA.xml:S3:8918:3	O
blocker	CIMZIA.xml:S3:8922:7	O
cases	CIMZIA.xml:S3:8930:5	O
occurred	CIMZIA.xml:S3:8936:8	O
in	CIMZIA.xml:S3:8945:2	O
adolescent	CIMZIA.xml:S3:8948:10	O
and	CIMZIA.xml:S3:8959:3	O
young	CIMZIA.xml:S3:8963:5	O
adult	CIMZIA.xml:S3:8969:5	O
males	CIMZIA.xml:S3:8975:5	O
with	CIMZIA.xml:S3:8981:4	O
Crohn	CIMZIA.xml:S3:8986:5	O
's	CIMZIA.xml:S3:8991:2	O
disease	CIMZIA.xml:S3:8994:7	O
or	CIMZIA.xml:S3:9002:2	O
ulcerative	CIMZIA.xml:S3:9005:10	O
colitis	CIMZIA.xml:S3:9016:7	O
.	CIMZIA.xml:S3:9023:1	O

Almost	CIMZIA.xml:S3:9025:6	O
all	CIMZIA.xml:S3:9032:3	O
of	CIMZIA.xml:S3:9036:2	O
these	CIMZIA.xml:S3:9039:5	O
patients	CIMZIA.xml:S3:9045:8	O
had	CIMZIA.xml:S3:9054:3	O
received	CIMZIA.xml:S3:9058:8	O
treatment	CIMZIA.xml:S3:9067:9	O
with	CIMZIA.xml:S3:9077:4	O
the	CIMZIA.xml:S3:9082:3	O
immunosuppressants	CIMZIA.xml:S3:9086:18	O
azathioprine	CIMZIA.xml:S3:9105:12	O
and	CIMZIA.xml:S3:9118:3	O
or	CIMZIA.xml:S3:9122:2	O
6	CIMZIA.xml:S3:9125:1	O
-	CIMZIA.xml:S3:9126:1	O
mercaptopurine	CIMZIA.xml:S3:9127:14	O
(	CIMZIA.xml:S3:9142:1	O
6	CIMZIA.xml:S3:9143:1	O
-	CIMZIA.xml:S3:9144:1	O
MP	CIMZIA.xml:S3:9145:2	O
)	CIMZIA.xml:S3:9147:1	O
concomitantly	CIMZIA.xml:S3:9149:13	O
with	CIMZIA.xml:S3:9163:4	O
a	CIMZIA.xml:S3:9168:1	O
TNF	CIMZIA.xml:S3:9170:3	O
blocker	CIMZIA.xml:S3:9174:7	O
at	CIMZIA.xml:S3:9182:2	O
or	CIMZIA.xml:S3:9185:2	O
prior	CIMZIA.xml:S3:9188:5	O
to	CIMZIA.xml:S3:9194:2	O
diagnosis	CIMZIA.xml:S3:9197:9	O
.	CIMZIA.xml:S3:9206:1	O

It	CIMZIA.xml:S3:9208:2	O
is	CIMZIA.xml:S3:9211:2	O
uncertain	CIMZIA.xml:S3:9214:9	O
whether	CIMZIA.xml:S3:9224:7	O
the	CIMZIA.xml:S3:9232:3	O
occurrence	CIMZIA.xml:S3:9236:10	O
of	CIMZIA.xml:S3:9247:2	O
HSTCL	CIMZIA.xml:S3:9250:5	O
is	CIMZIA.xml:S3:9256:2	O
related	CIMZIA.xml:S3:9259:7	O
to	CIMZIA.xml:S3:9267:2	O
use	CIMZIA.xml:S3:9270:3	O
of	CIMZIA.xml:S3:9274:2	O
a	CIMZIA.xml:S3:9277:1	O
TNF	CIMZIA.xml:S3:9279:3	O
blocker	CIMZIA.xml:S3:9283:7	O
or	CIMZIA.xml:S3:9291:2	O
a	CIMZIA.xml:S3:9294:1	O
TNF	CIMZIA.xml:S3:9296:3	O
blocker	CIMZIA.xml:S3:9300:7	O
in	CIMZIA.xml:S3:9308:2	O
combination	CIMZIA.xml:S3:9311:11	O
with	CIMZIA.xml:S3:9323:4	O
these	CIMZIA.xml:S3:9328:5	O
other	CIMZIA.xml:S3:9334:5	O
immunosuppressants	CIMZIA.xml:S3:9340:18	O
.	CIMZIA.xml:S3:9358:1	O

The	CIMZIA.xml:S3:9360:3	O
potential	CIMZIA.xml:S3:9364:9	O
risk	CIMZIA.xml:S3:9374:4	O
of	CIMZIA.xml:S3:9379:2	O
using	CIMZIA.xml:S3:9382:5	O
a	CIMZIA.xml:S3:9388:1	O
TNF	CIMZIA.xml:S3:9390:3	O
blocker	CIMZIA.xml:S3:9394:7	O
in	CIMZIA.xml:S3:9402:2	O
combination	CIMZIA.xml:S3:9405:11	O
with	CIMZIA.xml:S3:9417:4	O
azathioprine	CIMZIA.xml:S3:9422:12	O
or	CIMZIA.xml:S3:9435:2	O
6	CIMZIA.xml:S3:9438:1	O
-	CIMZIA.xml:S3:9439:1	O
MP	CIMZIA.xml:S3:9440:2	O
should	CIMZIA.xml:S3:9443:6	O
be	CIMZIA.xml:S3:9450:2	O
carefully	CIMZIA.xml:S3:9453:9	O
considered	CIMZIA.xml:S3:9463:10	O
.	CIMZIA.xml:S3:9473:1	O

Cases	CIMZIA.xml:S3:9481:5	O
of	CIMZIA.xml:S3:9487:2	O
acute	CIMZIA.xml:S3:9490:5	B-AdverseReaction
and	CIMZIA.xml:S3:9496:3	O
chronic	CIMZIA.xml:S3:9500:7	B-AdverseReaction
leukemia	CIMZIA.xml:S3:9508:8	I-AdverseReaction
have	CIMZIA.xml:S3:9517:4	O
been	CIMZIA.xml:S3:9522:4	O
reported	CIMZIA.xml:S3:9527:8	O
in	CIMZIA.xml:S3:9536:2	O
association	CIMZIA.xml:S3:9539:11	O
with	CIMZIA.xml:S3:9551:4	O
post	CIMZIA.xml:S3:9556:4	O
-	CIMZIA.xml:S3:9560:1	O
marketing	CIMZIA.xml:S3:9561:9	O
TNF	CIMZIA.xml:S3:9571:3	B-DrugClass
-	CIMZIA.xml:S3:9574:1	I-DrugClass
blocker	CIMZIA.xml:S3:9575:7	I-DrugClass
use	CIMZIA.xml:S3:9583:3	O
in	CIMZIA.xml:S3:9587:2	O
RA	CIMZIA.xml:S3:9590:2	O
and	CIMZIA.xml:S3:9593:3	O
other	CIMZIA.xml:S3:9597:5	O
indications	CIMZIA.xml:S3:9603:11	O
.	CIMZIA.xml:S3:9614:1	O

Even	CIMZIA.xml:S3:9616:4	O
in	CIMZIA.xml:S3:9621:2	O
the	CIMZIA.xml:S3:9624:3	O
absence	CIMZIA.xml:S3:9628:7	O
of	CIMZIA.xml:S3:9636:2	O
TNF	CIMZIA.xml:S3:9639:3	O
-	CIMZIA.xml:S3:9642:1	O
blocker	CIMZIA.xml:S3:9643:7	O
therapy	CIMZIA.xml:S3:9651:7	O
,	CIMZIA.xml:S3:9658:1	O
patients	CIMZIA.xml:S3:9660:8	O
with	CIMZIA.xml:S3:9669:4	O
RA	CIMZIA.xml:S3:9674:2	O
may	CIMZIA.xml:S3:9677:3	O
be	CIMZIA.xml:S3:9681:2	O
at	CIMZIA.xml:S3:9684:2	O
a	CIMZIA.xml:S3:9687:1	O
higher	CIMZIA.xml:S3:9689:6	O
risk	CIMZIA.xml:S3:9696:4	O
(	CIMZIA.xml:S3:9701:1	O
approximately	CIMZIA.xml:S3:9702:13	O
2	CIMZIA.xml:S3:9716:1	O
-	CIMZIA.xml:S3:9717:1	O
fold	CIMZIA.xml:S3:9718:4	O
)	CIMZIA.xml:S3:9722:1	O
than	CIMZIA.xml:S3:9724:4	O
the	CIMZIA.xml:S3:9729:3	O
general	CIMZIA.xml:S3:9733:7	O
population	CIMZIA.xml:S3:9741:10	O
for	CIMZIA.xml:S3:9752:3	O
the	CIMZIA.xml:S3:9756:3	O
development	CIMZIA.xml:S3:9760:11	O
of	CIMZIA.xml:S3:9772:2	O
leukemia	CIMZIA.xml:S3:9775:8	O
.	CIMZIA.xml:S3:9783:1	O

Periodic	CIMZIA.xml:S3:9790:8	O
skin	CIMZIA.xml:S3:9799:4	O
examinations	CIMZIA.xml:S3:9804:12	O
are	CIMZIA.xml:S3:9817:3	O
recommended	CIMZIA.xml:S3:9821:11	O
for	CIMZIA.xml:S3:9833:3	O
all	CIMZIA.xml:S3:9837:3	O
patients	CIMZIA.xml:S3:9841:8	O
,	CIMZIA.xml:S3:9849:1	O
particularly	CIMZIA.xml:S3:9851:12	O
those	CIMZIA.xml:S3:9864:5	O
with	CIMZIA.xml:S3:9870:4	O
risk	CIMZIA.xml:S3:9875:4	O
factors	CIMZIA.xml:S3:9880:7	O
for	CIMZIA.xml:S3:9888:3	O
skin	CIMZIA.xml:S3:9892:4	O
cancer	CIMZIA.xml:S3:9897:6	O
.	CIMZIA.xml:S3:9903:1	O

5.3	CIMZIA.xml:S3:9914:3	O
Heart	CIMZIA.xml:S3:9918:5	O
Failure	CIMZIA.xml:S3:9924:7	O

Cases	CIMZIA.xml:S3:9937:5	O
of	CIMZIA.xml:S3:9943:2	O
worsening	CIMZIA.xml:S3:9946:9	B-AdverseReaction
congestive	CIMZIA.xml:S3:9956:10	I-AdverseReaction
heart	CIMZIA.xml:S3:9967:5	I-AdverseReaction
failure	CIMZIA.xml:S3:9973:7	I-AdverseReaction
(	CIMZIA.xml:S3:9981:1	O
CHF	CIMZIA.xml:S3:9982:3	I-AdverseReaction
)	CIMZIA.xml:S3:9985:1	O
and	CIMZIA.xml:S3:9987:3	O
new	CIMZIA.xml:S3:9991:3	B-AdverseReaction
onset	CIMZIA.xml:S3:9995:5	I-AdverseReaction
CHF	CIMZIA.xml:S3:10001:3	I-AdverseReaction
have	CIMZIA.xml:S3:10005:4	O
been	CIMZIA.xml:S3:10010:4	O
reported	CIMZIA.xml:S3:10015:8	O
with	CIMZIA.xml:S3:10024:4	O
TNF	CIMZIA.xml:S3:10029:3	O
blockers	CIMZIA.xml:S3:10033:8	O
,	CIMZIA.xml:S3:10041:1	O
including	CIMZIA.xml:S3:10043:9	O
CIMZIA	CIMZIA.xml:S3:10053:6	O
.	CIMZIA.xml:S3:10059:1	O

CIMZIA	CIMZIA.xml:S3:10061:6	O
has	CIMZIA.xml:S3:10068:3	O
not	CIMZIA.xml:S3:10072:3	O
been	CIMZIA.xml:S3:10076:4	O
formally	CIMZIA.xml:S3:10081:8	O
studied	CIMZIA.xml:S3:10090:7	O
in	CIMZIA.xml:S3:10098:2	O
patients	CIMZIA.xml:S3:10101:8	O
with	CIMZIA.xml:S3:10110:4	O
CHF	CIMZIA.xml:S3:10115:3	O
;	CIMZIA.xml:S3:10118:1	O
however	CIMZIA.xml:S3:10120:7	O
,	CIMZIA.xml:S3:10127:1	O
in	CIMZIA.xml:S3:10129:2	O
clinical	CIMZIA.xml:S3:10132:8	O
studies	CIMZIA.xml:S3:10141:7	O
in	CIMZIA.xml:S3:10149:2	O
patients	CIMZIA.xml:S3:10152:8	O
with	CIMZIA.xml:S3:10161:4	O
CHF	CIMZIA.xml:S3:10166:3	O
with	CIMZIA.xml:S3:10170:4	O
another	CIMZIA.xml:S3:10175:7	O
TNF	CIMZIA.xml:S3:10183:3	B-DrugClass
blocker	CIMZIA.xml:S3:10187:7	I-DrugClass
,	CIMZIA.xml:S3:10194:1	O
worsening	CIMZIA.xml:S3:10196:9	B-AdverseReaction
congestive	CIMZIA.xml:S3:10206:10	I-AdverseReaction
heart	CIMZIA.xml:S3:10217:5	I-AdverseReaction
failure	CIMZIA.xml:S3:10223:7	I-AdverseReaction
(	CIMZIA.xml:S3:10231:1	O
CHF	CIMZIA.xml:S3:10232:3	I-AdverseReaction
)	CIMZIA.xml:S3:10235:1	O
and	CIMZIA.xml:S3:10237:3	O
increased	CIMZIA.xml:S3:10241:9	B-AdverseReaction
mortality	CIMZIA.xml:S3:10251:9	I-AdverseReaction
due	CIMZIA.xml:S3:10261:3	O
to	CIMZIA.xml:S3:10265:2	O
CHF	CIMZIA.xml:S3:10268:3	B-AdverseReaction
were	CIMZIA.xml:S3:10272:4	O
observed	CIMZIA.xml:S3:10277:8	O
.	CIMZIA.xml:S3:10285:1	O

Exercise	CIMZIA.xml:S3:10287:8	O
caution	CIMZIA.xml:S3:10296:7	O
in	CIMZIA.xml:S3:10304:2	O
patients	CIMZIA.xml:S3:10307:8	O
with	CIMZIA.xml:S3:10316:4	O
heart	CIMZIA.xml:S3:10321:5	O
failure	CIMZIA.xml:S3:10327:7	O
and	CIMZIA.xml:S3:10335:3	O
monitor	CIMZIA.xml:S3:10339:7	O
them	CIMZIA.xml:S3:10347:4	O
carefully	CIMZIA.xml:S3:10352:9	O
[	CIMZIA.xml:S3:10362:1	O
see	CIMZIA.xml:S3:10363:3	O
Adverse	CIMZIA.xml:S3:10369:7	O
Reactions	CIMZIA.xml:S3:10377:9	O
(	CIMZIA.xml:S3:10387:1	O
6.1	CIMZIA.xml:S3:10388:3	O
)	CIMZIA.xml:S3:10391:1	O
]	CIMZIA.xml:S3:10394:1	O
.	CIMZIA.xml:S3:10395:1	O

5.4	CIMZIA.xml:S3:10406:3	O
Hypersensitivity	CIMZIA.xml:S3:10410:16	O
Reactions	CIMZIA.xml:S3:10427:9	O

The	CIMZIA.xml:S3:10443:3	O
following	CIMZIA.xml:S3:10447:9	O
symptoms	CIMZIA.xml:S3:10457:8	O
that	CIMZIA.xml:S3:10466:4	O
could	CIMZIA.xml:S3:10471:5	B-Factor
be	CIMZIA.xml:S3:10477:2	O
compatible	CIMZIA.xml:S3:10480:10	O
with	CIMZIA.xml:S3:10491:4	O
hypersensitivity	CIMZIA.xml:S3:10496:16	B-AdverseReaction
reactions	CIMZIA.xml:S3:10513:9	I-AdverseReaction
have	CIMZIA.xml:S3:10523:4	O
been	CIMZIA.xml:S3:10528:4	O
reported	CIMZIA.xml:S3:10533:8	O
rarely	CIMZIA.xml:S3:10542:6	O
following	CIMZIA.xml:S3:10549:9	O
CIMZIA	CIMZIA.xml:S3:10559:6	O
administration	CIMZIA.xml:S3:10566:14	O
to	CIMZIA.xml:S3:10581:2	O
patients	CIMZIA.xml:S3:10584:8	O
:	CIMZIA.xml:S3:10592:1	O
angioedema	CIMZIA.xml:S3:10594:10	B-AdverseReaction
,	CIMZIA.xml:S3:10604:1	O
dyspnea	CIMZIA.xml:S3:10606:7	B-AdverseReaction
,	CIMZIA.xml:S3:10613:1	O
hypotension	CIMZIA.xml:S3:10615:11	B-AdverseReaction
,	CIMZIA.xml:S3:10626:1	O
rash	CIMZIA.xml:S3:10628:4	B-AdverseReaction
,	CIMZIA.xml:S3:10632:1	O
serum	CIMZIA.xml:S3:10634:5	B-AdverseReaction
sickness	CIMZIA.xml:S3:10640:8	I-AdverseReaction
,	CIMZIA.xml:S3:10648:1	O
and	CIMZIA.xml:S3:10650:3	O
urticaria	CIMZIA.xml:S3:10654:9	B-AdverseReaction
.	CIMZIA.xml:S3:10663:1	O

Some	CIMZIA.xml:S3:10665:4	O
of	CIMZIA.xml:S3:10670:2	O
these	CIMZIA.xml:S3:10673:5	O
reactions	CIMZIA.xml:S3:10679:9	O
occurred	CIMZIA.xml:S3:10689:8	O
after	CIMZIA.xml:S3:10698:5	O
the	CIMZIA.xml:S3:10704:3	O
first	CIMZIA.xml:S3:10708:5	O
administration	CIMZIA.xml:S3:10714:14	O
of	CIMZIA.xml:S3:10729:2	O
CIMZIA	CIMZIA.xml:S3:10732:6	O
.	CIMZIA.xml:S3:10738:1	O

If	CIMZIA.xml:S3:10740:2	O
such	CIMZIA.xml:S3:10743:4	O
reactions	CIMZIA.xml:S3:10748:9	O
occur	CIMZIA.xml:S3:10758:5	O
,	CIMZIA.xml:S3:10763:1	O
discontinue	CIMZIA.xml:S3:10765:11	O
further	CIMZIA.xml:S3:10777:7	O
administration	CIMZIA.xml:S3:10785:14	O
of	CIMZIA.xml:S3:10800:2	O
CIMZIA	CIMZIA.xml:S3:10803:6	O
and	CIMZIA.xml:S3:10810:3	O
institute	CIMZIA.xml:S3:10814:9	O
appropriate	CIMZIA.xml:S3:10824:11	O
therapy	CIMZIA.xml:S3:10836:7	O
.	CIMZIA.xml:S3:10843:1	O

There	CIMZIA.xml:S3:10845:5	O
are	CIMZIA.xml:S3:10851:3	O
no	CIMZIA.xml:S3:10855:2	O
data	CIMZIA.xml:S3:10858:4	O
on	CIMZIA.xml:S3:10863:2	O
the	CIMZIA.xml:S3:10866:3	O
risks	CIMZIA.xml:S3:10870:5	O
of	CIMZIA.xml:S3:10876:2	O
using	CIMZIA.xml:S3:10879:5	O
CIMZIA	CIMZIA.xml:S3:10885:6	O
in	CIMZIA.xml:S3:10892:2	O
patients	CIMZIA.xml:S3:10895:8	O
who	CIMZIA.xml:S3:10904:3	O
have	CIMZIA.xml:S3:10908:4	O
experienced	CIMZIA.xml:S3:10913:11	O
a	CIMZIA.xml:S3:10925:1	O
severe	CIMZIA.xml:S3:10927:6	O
hypersensitivity	CIMZIA.xml:S3:10934:16	O
reaction	CIMZIA.xml:S3:10951:8	O
towards	CIMZIA.xml:S3:10960:7	O
another	CIMZIA.xml:S3:10968:7	O
TNF	CIMZIA.xml:S3:10976:3	O
blocker	CIMZIA.xml:S3:10980:7	O
;	CIMZIA.xml:S3:10987:1	O
in	CIMZIA.xml:S3:10989:2	O
these	CIMZIA.xml:S3:10992:5	O
patients	CIMZIA.xml:S3:10998:8	O
caution	CIMZIA.xml:S3:11007:7	O
is	CIMZIA.xml:S3:11015:2	O
needed	CIMZIA.xml:S3:11018:6	O
[	CIMZIA.xml:S3:11025:1	O
see	CIMZIA.xml:S3:11026:3	O
Adverse	CIMZIA.xml:S3:11031:7	O
Reactions	CIMZIA.xml:S3:11039:9	O
(	CIMZIA.xml:S3:11049:1	O
6.1	CIMZIA.xml:S3:11050:3	O
)	CIMZIA.xml:S3:11053:1	O
]	CIMZIA.xml:S3:11056:1	O
.	CIMZIA.xml:S3:11059:1	O

5.5	CIMZIA.xml:S3:11070:3	O
Hepatitis	CIMZIA.xml:S3:11074:9	O
B	CIMZIA.xml:S3:11084:1	O
Virus	CIMZIA.xml:S3:11086:5	O
Reactivation	CIMZIA.xml:S3:11092:12	O

Use	CIMZIA.xml:S3:11110:3	O
of	CIMZIA.xml:S3:11114:2	O
TNF	CIMZIA.xml:S3:11117:3	O
blockers	CIMZIA.xml:S3:11121:8	O
,	CIMZIA.xml:S3:11129:1	O
including	CIMZIA.xml:S3:11131:9	O
CIMZIA	CIMZIA.xml:S3:11141:6	O
,	CIMZIA.xml:S3:11147:1	O
has	CIMZIA.xml:S3:11149:3	O
been	CIMZIA.xml:S3:11153:4	O
associated	CIMZIA.xml:S3:11158:10	O
with	CIMZIA.xml:S3:11169:4	O
reactivation	CIMZIA.xml:S3:11174:12	B-AdverseReaction
of	CIMZIA.xml:S3:11187:2	I-AdverseReaction
hepatitis	CIMZIA.xml:S3:11190:9	I-AdverseReaction
B	CIMZIA.xml:S3:11200:1	I-AdverseReaction
virus	CIMZIA.xml:S3:11202:5	I-AdverseReaction
(	CIMZIA.xml:S3:11208:1	O
HBV	CIMZIA.xml:S3:11209:3	I-AdverseReaction
)	CIMZIA.xml:S3:11212:1	O
in	CIMZIA.xml:S3:11214:2	O
patients	CIMZIA.xml:S3:11217:8	O
who	CIMZIA.xml:S3:11226:3	O
are	CIMZIA.xml:S3:11230:3	O
chronic	CIMZIA.xml:S3:11234:7	O
carriers	CIMZIA.xml:S3:11242:8	O
of	CIMZIA.xml:S3:11251:2	O
this	CIMZIA.xml:S3:11254:4	O
virus	CIMZIA.xml:S3:11259:5	O
.	CIMZIA.xml:S3:11264:1	O

In	CIMZIA.xml:S3:11266:2	O
some	CIMZIA.xml:S3:11269:4	O
instances	CIMZIA.xml:S3:11274:9	O
,	CIMZIA.xml:S3:11283:1	O
HBV	CIMZIA.xml:S3:11285:3	B-AdverseReaction
reactivation	CIMZIA.xml:S3:11289:12	I-AdverseReaction
occurring	CIMZIA.xml:S3:11302:9	O
in	CIMZIA.xml:S3:11312:2	O
conjunction	CIMZIA.xml:S3:11315:11	O
with	CIMZIA.xml:S3:11327:4	O
TNF	CIMZIA.xml:S3:11332:3	B-DrugClass
blocker	CIMZIA.xml:S3:11336:7	I-DrugClass
therapy	CIMZIA.xml:S3:11344:7	O
has	CIMZIA.xml:S3:11352:3	O
been	CIMZIA.xml:S3:11356:4	O
fatal	CIMZIA.xml:S3:11361:5	B-AdverseReaction
.	CIMZIA.xml:S3:11366:1	O

The	CIMZIA.xml:S3:11368:3	O
majority	CIMZIA.xml:S3:11372:8	O
of	CIMZIA.xml:S3:11381:2	O
reports	CIMZIA.xml:S3:11384:7	O
have	CIMZIA.xml:S3:11392:4	O
occurred	CIMZIA.xml:S3:11397:8	O
in	CIMZIA.xml:S3:11406:2	O
patients	CIMZIA.xml:S3:11409:8	O
concomitantly	CIMZIA.xml:S3:11418:13	O
receiving	CIMZIA.xml:S3:11432:9	O
other	CIMZIA.xml:S3:11442:5	O
medications	CIMZIA.xml:S3:11448:11	O
that	CIMZIA.xml:S3:11460:4	O
suppress	CIMZIA.xml:S3:11465:8	O
the	CIMZIA.xml:S3:11474:3	O
immune	CIMZIA.xml:S3:11478:6	O
system	CIMZIA.xml:S3:11485:6	O
,	CIMZIA.xml:S3:11491:1	O
which	CIMZIA.xml:S3:11493:5	O
may	CIMZIA.xml:S3:11499:3	O
also	CIMZIA.xml:S3:11503:4	O
contribute	CIMZIA.xml:S3:11508:10	O
to	CIMZIA.xml:S3:11519:2	O
HBV	CIMZIA.xml:S3:11522:3	B-AdverseReaction
reactivation	CIMZIA.xml:S3:11526:12	I-AdverseReaction
.	CIMZIA.xml:S3:11538:1	O

Test	CIMZIA.xml:S3:11544:4	O
patients	CIMZIA.xml:S3:11549:8	O
for	CIMZIA.xml:S3:11558:3	O
HBV	CIMZIA.xml:S3:11562:3	O
infection	CIMZIA.xml:S3:11566:9	O
before	CIMZIA.xml:S3:11576:6	O
initiating	CIMZIA.xml:S3:11583:10	O
treatment	CIMZIA.xml:S3:11594:9	O
with	CIMZIA.xml:S3:11604:4	O
CIMZIA	CIMZIA.xml:S3:11609:6	O
.	CIMZIA.xml:S3:11615:1	O

For	CIMZIA.xml:S3:11617:3	O
patients	CIMZIA.xml:S3:11621:8	O
who	CIMZIA.xml:S3:11630:3	O
test	CIMZIA.xml:S3:11634:4	O
positive	CIMZIA.xml:S3:11639:8	O
for	CIMZIA.xml:S3:11648:3	O
HBV	CIMZIA.xml:S3:11652:3	O
infection	CIMZIA.xml:S3:11656:9	O
,	CIMZIA.xml:S3:11665:1	O
consultation	CIMZIA.xml:S3:11667:12	O
with	CIMZIA.xml:S3:11680:4	O
a	CIMZIA.xml:S3:11685:1	O
physician	CIMZIA.xml:S3:11687:9	O
with	CIMZIA.xml:S3:11697:4	O
expertise	CIMZIA.xml:S3:11702:9	O
in	CIMZIA.xml:S3:11712:2	O
the	CIMZIA.xml:S3:11715:3	O
treatment	CIMZIA.xml:S3:11719:9	O
of	CIMZIA.xml:S3:11729:2	O
hepatitis	CIMZIA.xml:S3:11732:9	O
B	CIMZIA.xml:S3:11742:1	O
is	CIMZIA.xml:S3:11744:2	O
recommended	CIMZIA.xml:S3:11747:11	O
.	CIMZIA.xml:S3:11758:1	O

Adequate	CIMZIA.xml:S3:11760:8	O
data	CIMZIA.xml:S3:11769:4	O
are	CIMZIA.xml:S3:11774:3	O
not	CIMZIA.xml:S3:11778:3	O
available	CIMZIA.xml:S3:11782:9	O
on	CIMZIA.xml:S3:11792:2	O
the	CIMZIA.xml:S3:11795:3	O
safety	CIMZIA.xml:S3:11799:6	O
or	CIMZIA.xml:S3:11806:2	O
efficacy	CIMZIA.xml:S3:11809:8	O
of	CIMZIA.xml:S3:11818:2	O
treating	CIMZIA.xml:S3:11821:8	O
patients	CIMZIA.xml:S3:11830:8	O
who	CIMZIA.xml:S3:11839:3	O
are	CIMZIA.xml:S3:11843:3	O
carriers	CIMZIA.xml:S3:11847:8	O
of	CIMZIA.xml:S3:11856:2	O
HBV	CIMZIA.xml:S3:11859:3	O
with	CIMZIA.xml:S3:11863:4	O
anti	CIMZIA.xml:S3:11868:4	O
-	CIMZIA.xml:S3:11872:1	O
viral	CIMZIA.xml:S3:11873:5	O
therapy	CIMZIA.xml:S3:11879:7	O
in	CIMZIA.xml:S3:11887:2	O
conjunction	CIMZIA.xml:S3:11890:11	O
with	CIMZIA.xml:S3:11902:4	O
TNF	CIMZIA.xml:S3:11907:3	O
blocker	CIMZIA.xml:S3:11911:7	O
therapy	CIMZIA.xml:S3:11919:7	O
to	CIMZIA.xml:S3:11927:2	O
prevent	CIMZIA.xml:S3:11930:7	O
HBV	CIMZIA.xml:S3:11938:3	O
reactivation	CIMZIA.xml:S3:11942:12	O
.	CIMZIA.xml:S3:11954:1	O

Patients	CIMZIA.xml:S3:11956:8	O
who	CIMZIA.xml:S3:11965:3	O
are	CIMZIA.xml:S3:11969:3	O
carriers	CIMZIA.xml:S3:11973:8	O
of	CIMZIA.xml:S3:11982:2	O
HBV	CIMZIA.xml:S3:11985:3	O
and	CIMZIA.xml:S3:11989:3	O
require	CIMZIA.xml:S3:11993:7	O
treatment	CIMZIA.xml:S3:12001:9	O
with	CIMZIA.xml:S3:12011:4	O
CIMZIA	CIMZIA.xml:S3:12016:6	O
should	CIMZIA.xml:S3:12023:6	O
be	CIMZIA.xml:S3:12030:2	O
closely	CIMZIA.xml:S3:12033:7	O
monitored	CIMZIA.xml:S3:12041:9	O
for	CIMZIA.xml:S3:12051:3	O
clinical	CIMZIA.xml:S3:12055:8	O
and	CIMZIA.xml:S3:12064:3	O
laboratory	CIMZIA.xml:S3:12068:10	O
signs	CIMZIA.xml:S3:12079:5	O
of	CIMZIA.xml:S3:12085:2	O
active	CIMZIA.xml:S3:12088:6	O
HBV	CIMZIA.xml:S3:12095:3	O
infection	CIMZIA.xml:S3:12099:9	O
throughout	CIMZIA.xml:S3:12109:10	O
therapy	CIMZIA.xml:S3:12120:7	O
and	CIMZIA.xml:S3:12128:3	O
for	CIMZIA.xml:S3:12132:3	O
several	CIMZIA.xml:S3:12136:7	O
months	CIMZIA.xml:S3:12144:6	O
following	CIMZIA.xml:S3:12151:9	O
termination	CIMZIA.xml:S3:12161:11	O
of	CIMZIA.xml:S3:12173:2	O
therapy	CIMZIA.xml:S3:12176:7	O
.	CIMZIA.xml:S3:12183:1	O

In	CIMZIA.xml:S3:12189:2	O
patients	CIMZIA.xml:S3:12192:8	O
who	CIMZIA.xml:S3:12201:3	O
develop	CIMZIA.xml:S3:12205:7	O
HBV	CIMZIA.xml:S3:12213:3	O
reactivation	CIMZIA.xml:S3:12217:12	O
,	CIMZIA.xml:S3:12229:1	O
discontinue	CIMZIA.xml:S3:12231:11	O
CIMZIA	CIMZIA.xml:S3:12243:6	O
and	CIMZIA.xml:S3:12250:3	O
initiate	CIMZIA.xml:S3:12254:8	O
effective	CIMZIA.xml:S3:12263:9	O
anti	CIMZIA.xml:S3:12273:4	O
-	CIMZIA.xml:S3:12277:1	O
viral	CIMZIA.xml:S3:12278:5	O
therapy	CIMZIA.xml:S3:12284:7	O
with	CIMZIA.xml:S3:12292:4	O
appropriate	CIMZIA.xml:S3:12297:11	O
supportive	CIMZIA.xml:S3:12309:10	O
treatment	CIMZIA.xml:S3:12320:9	O
.	CIMZIA.xml:S3:12329:1	O

The	CIMZIA.xml:S3:12331:3	O
safety	CIMZIA.xml:S3:12335:6	O
of	CIMZIA.xml:S3:12342:2	O
resuming	CIMZIA.xml:S3:12345:8	O
TNF	CIMZIA.xml:S3:12354:3	O
blocker	CIMZIA.xml:S3:12358:7	O
therapy	CIMZIA.xml:S3:12366:7	O
after	CIMZIA.xml:S3:12374:5	O
HBV	CIMZIA.xml:S3:12380:3	O
reactivation	CIMZIA.xml:S3:12384:12	O
is	CIMZIA.xml:S3:12397:2	O
controlled	CIMZIA.xml:S3:12400:10	O
is	CIMZIA.xml:S3:12411:2	O
not	CIMZIA.xml:S3:12414:3	O
known	CIMZIA.xml:S3:12418:5	O
.	CIMZIA.xml:S3:12423:1	O

Therefore	CIMZIA.xml:S3:12425:9	O
,	CIMZIA.xml:S3:12434:1	O
exercise	CIMZIA.xml:S3:12436:8	O
caution	CIMZIA.xml:S3:12445:7	O
when	CIMZIA.xml:S3:12453:4	O
considering	CIMZIA.xml:S3:12458:11	O
resumption	CIMZIA.xml:S3:12470:10	O
of	CIMZIA.xml:S3:12481:2	O
CIMZIA	CIMZIA.xml:S3:12484:6	O
therapy	CIMZIA.xml:S3:12491:7	O
in	CIMZIA.xml:S3:12499:2	O
this	CIMZIA.xml:S3:12502:4	O
situation	CIMZIA.xml:S3:12507:9	O
and	CIMZIA.xml:S3:12517:3	O
monitor	CIMZIA.xml:S3:12521:7	O
patients	CIMZIA.xml:S3:12529:8	O
closely	CIMZIA.xml:S3:12538:7	O
.	CIMZIA.xml:S3:12545:1	O

5.6	CIMZIA.xml:S3:12554:3	O
Neurologic	CIMZIA.xml:S3:12558:10	O
Reactions	CIMZIA.xml:S3:12569:9	O

Use	CIMZIA.xml:S3:12584:3	O
of	CIMZIA.xml:S3:12588:2	O
TNF	CIMZIA.xml:S3:12591:3	B-DrugClass
blockers	CIMZIA.xml:S3:12595:8	I-DrugClass
,	CIMZIA.xml:S3:12603:1	O
of	CIMZIA.xml:S3:12605:2	O
which	CIMZIA.xml:S3:12608:5	O
CIMZIA	CIMZIA.xml:S3:12614:6	O
is	CIMZIA.xml:S3:12621:2	O
a	CIMZIA.xml:S3:12624:1	O
member	CIMZIA.xml:S3:12626:6	O
,	CIMZIA.xml:S3:12632:1	O
has	CIMZIA.xml:S3:12634:3	O
been	CIMZIA.xml:S3:12638:4	O
associated	CIMZIA.xml:S3:12643:10	O
with	CIMZIA.xml:S3:12654:4	O
rare	CIMZIA.xml:S3:12659:4	O
cases	CIMZIA.xml:S3:12664:5	O
of	CIMZIA.xml:S3:12670:2	O
new	CIMZIA.xml:S3:12673:3	O
onset	CIMZIA.xml:S3:12677:5	O
or	CIMZIA.xml:S3:12683:2	O
exacerbation	CIMZIA.xml:S3:12686:12	O
of	CIMZIA.xml:S3:12699:2	O
clinical	CIMZIA.xml:S3:12702:8	O
symptoms	CIMZIA.xml:S3:12711:8	O
and	CIMZIA.xml:S3:12720:3	O
or	CIMZIA.xml:S3:12724:2	O
radiographic	CIMZIA.xml:S3:12727:12	O
evidence	CIMZIA.xml:S3:12740:8	O
of	CIMZIA.xml:S3:12749:2	O
central	CIMZIA.xml:S3:12752:7	B-AdverseReaction
nervous	CIMZIA.xml:S3:12760:7	I-AdverseReaction
system	CIMZIA.xml:S3:12768:6	I-AdverseReaction
demyelinating	CIMZIA.xml:S3:12775:13	I-AdverseReaction
disease	CIMZIA.xml:S3:12789:7	I-AdverseReaction
,	CIMZIA.xml:S3:12796:1	O
including	CIMZIA.xml:S3:12798:9	O
multiple	CIMZIA.xml:S3:12808:8	B-AdverseReaction
sclerosis	CIMZIA.xml:S3:12817:9	I-AdverseReaction
,	CIMZIA.xml:S3:12826:1	O
and	CIMZIA.xml:S3:12828:3	O
with	CIMZIA.xml:S3:12832:4	O
peripheral	CIMZIA.xml:S3:12837:10	B-AdverseReaction
demyelinating	CIMZIA.xml:S3:12848:13	I-AdverseReaction
disease	CIMZIA.xml:S3:12862:7	I-AdverseReaction
,	CIMZIA.xml:S3:12869:1	O
including	CIMZIA.xml:S3:12871:9	O
Guillain	CIMZIA.xml:S3:12881:8	B-AdverseReaction
-	CIMZIA.xml:S3:12889:1	I-AdverseReaction
Barre	CIMZIA.xml:S3:12890:5	I-AdverseReaction
syndrome	CIMZIA.xml:S3:12896:8	I-AdverseReaction
.	CIMZIA.xml:S3:12905:1	O

Exercise	CIMZIA.xml:S3:12907:8	O
caution	CIMZIA.xml:S3:12916:7	O
in	CIMZIA.xml:S3:12924:2	O
considering	CIMZIA.xml:S3:12927:11	O
the	CIMZIA.xml:S3:12939:3	O
use	CIMZIA.xml:S3:12943:3	O
of	CIMZIA.xml:S3:12947:2	O
CIMZIA	CIMZIA.xml:S3:12950:6	O
in	CIMZIA.xml:S3:12957:2	O
patients	CIMZIA.xml:S3:12960:8	O
with	CIMZIA.xml:S3:12969:4	O
pre	CIMZIA.xml:S3:12974:3	O
-	CIMZIA.xml:S3:12977:1	O
existing	CIMZIA.xml:S3:12978:8	O
or	CIMZIA.xml:S3:12987:2	O
recent	CIMZIA.xml:S3:12990:6	O
-	CIMZIA.xml:S3:12996:1	O
onset	CIMZIA.xml:S3:12997:5	O
central	CIMZIA.xml:S3:13003:7	O
or	CIMZIA.xml:S3:13011:2	O
peripheral	CIMZIA.xml:S3:13014:10	O
nervous	CIMZIA.xml:S3:13025:7	O
system	CIMZIA.xml:S3:13033:6	O
demyelinating	CIMZIA.xml:S3:13040:13	O
disorders	CIMZIA.xml:S3:13054:9	O
.	CIMZIA.xml:S3:13063:1	O

Rare	CIMZIA.xml:S3:13065:4	O
cases	CIMZIA.xml:S3:13070:5	O
of	CIMZIA.xml:S3:13076:2	O
neurological	CIMZIA.xml:S3:13079:12	B-AdverseReaction
disorders	CIMZIA.xml:S3:13092:9	I-AdverseReaction
,	CIMZIA.xml:S3:13101:1	O
including	CIMZIA.xml:S3:13103:9	O
seizure	CIMZIA.xml:S3:13113:7	B-AdverseReaction
disorder	CIMZIA.xml:S3:13121:8	I-AdverseReaction
,	CIMZIA.xml:S3:13129:1	O
optic	CIMZIA.xml:S3:13131:5	B-AdverseReaction
neuritis	CIMZIA.xml:S3:13137:8	I-AdverseReaction
,	CIMZIA.xml:S3:13145:1	O
and	CIMZIA.xml:S3:13147:3	O
peripheral	CIMZIA.xml:S3:13151:10	B-AdverseReaction
neuropathy	CIMZIA.xml:S3:13162:10	I-AdverseReaction
have	CIMZIA.xml:S3:13173:4	O
been	CIMZIA.xml:S3:13178:4	O
reported	CIMZIA.xml:S3:13183:8	O
in	CIMZIA.xml:S3:13192:2	O
patients	CIMZIA.xml:S3:13195:8	O
treated	CIMZIA.xml:S3:13204:7	O
with	CIMZIA.xml:S3:13212:4	O
CIMZIA	CIMZIA.xml:S3:13217:6	O
[	CIMZIA.xml:S3:13224:1	O
see	CIMZIA.xml:S3:13225:3	O
Adverse	CIMZIA.xml:S3:13230:7	O
Reactions	CIMZIA.xml:S3:13238:9	O
(	CIMZIA.xml:S3:13248:1	O
6.1	CIMZIA.xml:S3:13249:3	O
)	CIMZIA.xml:S3:13252:1	O
]	CIMZIA.xml:S3:13255:1	O
.	CIMZIA.xml:S3:13258:1	O

5.7	CIMZIA.xml:S3:13267:3	O
Hematological	CIMZIA.xml:S3:13271:13	O
Reactions	CIMZIA.xml:S3:13285:9	O

Rare	CIMZIA.xml:S3:13300:4	O
reports	CIMZIA.xml:S3:13305:7	O
of	CIMZIA.xml:S3:13313:2	O
pancytopenia	CIMZIA.xml:S3:13316:12	B-AdverseReaction
,	CIMZIA.xml:S3:13328:1	O
including	CIMZIA.xml:S3:13330:9	O
aplastic	CIMZIA.xml:S3:13340:8	B-AdverseReaction
anemia	CIMZIA.xml:S3:13349:6	I-AdverseReaction
,	CIMZIA.xml:S3:13355:1	O
have	CIMZIA.xml:S3:13357:4	O
been	CIMZIA.xml:S3:13362:4	O
reported	CIMZIA.xml:S3:13367:8	O
with	CIMZIA.xml:S3:13376:4	O
TNF	CIMZIA.xml:S3:13381:3	B-DrugClass
blockers	CIMZIA.xml:S3:13385:8	I-DrugClass
.	CIMZIA.xml:S3:13393:1	O

Adverse	CIMZIA.xml:S3:13395:7	B-AdverseReaction
reactions	CIMZIA.xml:S3:13403:9	I-AdverseReaction
of	CIMZIA.xml:S3:13413:2	I-AdverseReaction
the	CIMZIA.xml:S3:13416:3	I-AdverseReaction
hematologic	CIMZIA.xml:S3:13420:11	I-AdverseReaction
system	CIMZIA.xml:S3:13432:6	I-AdverseReaction
,	CIMZIA.xml:S3:13438:1	O
including	CIMZIA.xml:S3:13440:9	O
medically	CIMZIA.xml:S3:13450:9	B-Severity
significant	CIMZIA.xml:S3:13460:11	I-Severity
cytopenia	CIMZIA.xml:S3:13472:9	B-AdverseReaction
(	CIMZIA.xml:S3:13482:1	O
e	CIMZIA.xml:S3:13483:1	O
.	CIMZIA.xml:S3:13484:1	O
g	CIMZIA.xml:S3:13485:1	O
.	CIMZIA.xml:S3:13486:1	O
,	CIMZIA.xml:S3:13487:1	O
leukopenia	CIMZIA.xml:S3:13489:10	B-AdverseReaction
,	CIMZIA.xml:S3:13499:1	O
pancytopenia	CIMZIA.xml:S3:13501:12	B-AdverseReaction
,	CIMZIA.xml:S3:13513:1	O
thrombocytopenia	CIMZIA.xml:S3:13515:16	B-AdverseReaction
)	CIMZIA.xml:S3:13531:1	O
have	CIMZIA.xml:S3:13533:4	O
been	CIMZIA.xml:S3:13538:4	O
infrequently	CIMZIA.xml:S3:13543:12	O
reported	CIMZIA.xml:S3:13556:8	O
with	CIMZIA.xml:S3:13565:4	O
CIMZIA	CIMZIA.xml:S3:13570:6	O
[	CIMZIA.xml:S3:13577:1	O
see	CIMZIA.xml:S3:13578:3	O
Adverse	CIMZIA.xml:S3:13583:7	O
Reactions	CIMZIA.xml:S3:13591:9	O
(	CIMZIA.xml:S3:13601:1	O
6.1	CIMZIA.xml:S3:13602:3	O
)	CIMZIA.xml:S3:13605:1	O
]	CIMZIA.xml:S3:13608:1	O
.	CIMZIA.xml:S3:13611:1	O

The	CIMZIA.xml:S3:13613:3	O
causal	CIMZIA.xml:S3:13617:6	O
relationship	CIMZIA.xml:S3:13624:12	O
of	CIMZIA.xml:S3:13637:2	O
these	CIMZIA.xml:S3:13640:5	O
events	CIMZIA.xml:S3:13646:6	O
to	CIMZIA.xml:S3:13653:2	O
CIMZIA	CIMZIA.xml:S3:13656:6	O
remains	CIMZIA.xml:S3:13663:7	O
unclear	CIMZIA.xml:S3:13671:7	O
.	CIMZIA.xml:S3:13678:1	O

Although	CIMZIA.xml:S3:13684:8	O
no	CIMZIA.xml:S3:13693:2	O
high	CIMZIA.xml:S3:13696:4	O
risk	CIMZIA.xml:S3:13701:4	O
group	CIMZIA.xml:S3:13706:5	O
has	CIMZIA.xml:S3:13712:3	O
been	CIMZIA.xml:S3:13716:4	O
identified	CIMZIA.xml:S3:13721:10	O
,	CIMZIA.xml:S3:13731:1	O
exercise	CIMZIA.xml:S3:13733:8	O
caution	CIMZIA.xml:S3:13742:7	O
in	CIMZIA.xml:S3:13750:2	O
patients	CIMZIA.xml:S3:13753:8	O
being	CIMZIA.xml:S3:13762:5	O
treated	CIMZIA.xml:S3:13768:7	O
with	CIMZIA.xml:S3:13776:4	O
CIMZIA	CIMZIA.xml:S3:13781:6	O
who	CIMZIA.xml:S3:13788:3	O
have	CIMZIA.xml:S3:13792:4	O
ongoing	CIMZIA.xml:S3:13797:7	O
,	CIMZIA.xml:S3:13804:1	O
or	CIMZIA.xml:S3:13806:2	O
a	CIMZIA.xml:S3:13809:1	O
history	CIMZIA.xml:S3:13811:7	O
of	CIMZIA.xml:S3:13819:2	O
,	CIMZIA.xml:S3:13821:1	O
significant	CIMZIA.xml:S3:13823:11	O
hematologic	CIMZIA.xml:S3:13835:11	O
abnormalities	CIMZIA.xml:S3:13847:13	O
.	CIMZIA.xml:S3:13860:1	O

Advise	CIMZIA.xml:S3:13862:6	O
all	CIMZIA.xml:S3:13869:3	O
patients	CIMZIA.xml:S3:13873:8	O
to	CIMZIA.xml:S3:13882:2	O
seek	CIMZIA.xml:S3:13885:4	O
immediate	CIMZIA.xml:S3:13890:9	O
medical	CIMZIA.xml:S3:13900:7	O
attention	CIMZIA.xml:S3:13908:9	O
if	CIMZIA.xml:S3:13918:2	O
they	CIMZIA.xml:S3:13921:4	O
develop	CIMZIA.xml:S3:13926:7	O
signs	CIMZIA.xml:S3:13934:5	O
and	CIMZIA.xml:S3:13940:3	O
symptoms	CIMZIA.xml:S3:13944:8	O
suggestive	CIMZIA.xml:S3:13953:10	O
of	CIMZIA.xml:S3:13964:2	O
blood	CIMZIA.xml:S3:13967:5	O
dyscrasias	CIMZIA.xml:S3:13973:10	O
or	CIMZIA.xml:S3:13984:2	O
infection	CIMZIA.xml:S3:13987:9	O
(	CIMZIA.xml:S3:13997:1	O
e	CIMZIA.xml:S3:13998:1	O
.	CIMZIA.xml:S3:13999:1	O
g	CIMZIA.xml:S3:14000:1	O
.	CIMZIA.xml:S3:14001:1	O
,	CIMZIA.xml:S3:14002:1	O
persistent	CIMZIA.xml:S3:14004:10	O
fever	CIMZIA.xml:S3:14015:5	O
,	CIMZIA.xml:S3:14020:1	O
bruising	CIMZIA.xml:S3:14022:8	O
,	CIMZIA.xml:S3:14030:1	O
bleeding	CIMZIA.xml:S3:14032:8	O
,	CIMZIA.xml:S3:14040:1	O
pallor	CIMZIA.xml:S3:14042:6	O
)	CIMZIA.xml:S3:14048:1	O
while	CIMZIA.xml:S3:14050:5	O
on	CIMZIA.xml:S3:14056:2	O
CIMZIA	CIMZIA.xml:S3:14059:6	O
.	CIMZIA.xml:S3:14065:1	O

Consider	CIMZIA.xml:S3:14067:8	O
discontinuation	CIMZIA.xml:S3:14076:15	O
of	CIMZIA.xml:S3:14092:2	O
CIMZIA	CIMZIA.xml:S3:14095:6	O
therapy	CIMZIA.xml:S3:14102:7	O
in	CIMZIA.xml:S3:14110:2	O
patients	CIMZIA.xml:S3:14113:8	O
with	CIMZIA.xml:S3:14122:4	O
confirmed	CIMZIA.xml:S3:14127:9	O
significant	CIMZIA.xml:S3:14137:11	O
hematologic	CIMZIA.xml:S3:14149:11	O
abnormalities	CIMZIA.xml:S3:14161:13	O
.	CIMZIA.xml:S3:14174:1	O

5.8	CIMZIA.xml:S3:14183:3	O
Use	CIMZIA.xml:S3:14187:3	O
with	CIMZIA.xml:S3:14191:4	O
Biological	CIMZIA.xml:S3:14196:10	O
Disease	CIMZIA.xml:S3:14207:7	O
-	CIMZIA.xml:S3:14214:1	O
Modifying	CIMZIA.xml:S3:14215:9	O
Antirheumatic	CIMZIA.xml:S3:14225:13	O
Drugs	CIMZIA.xml:S3:14239:5	O
(	CIMZIA.xml:S3:14245:1	O
Biological	CIMZIA.xml:S3:14246:10	O
DMARDs	CIMZIA.xml:S3:14257:6	O
)	CIMZIA.xml:S3:14263:1	O

Serious	CIMZIA.xml:S3:14270:7	B-Severity
infections	CIMZIA.xml:S3:14278:10	B-AdverseReaction
were	CIMZIA.xml:S3:14289:4	O
seen	CIMZIA.xml:S3:14294:4	O
in	CIMZIA.xml:S3:14299:2	O
clinical	CIMZIA.xml:S3:14302:8	O
studies	CIMZIA.xml:S3:14311:7	O
with	CIMZIA.xml:S3:14319:4	O
concurrent	CIMZIA.xml:S3:14324:10	O
use	CIMZIA.xml:S3:14335:3	O
of	CIMZIA.xml:S3:14339:2	O
anakinra	CIMZIA.xml:S3:14342:8	O
(	CIMZIA.xml:S3:14351:1	O
an	CIMZIA.xml:S3:14352:2	O
interleukin	CIMZIA.xml:S3:14355:11	O
-	CIMZIA.xml:S3:14366:1	O
1	CIMZIA.xml:S3:14367:1	O
antagonist	CIMZIA.xml:S3:14369:10	O
)	CIMZIA.xml:S3:14379:1	O
and	CIMZIA.xml:S3:14381:3	O
another	CIMZIA.xml:S3:14385:7	O
TNF	CIMZIA.xml:S3:14393:3	O
blocker	CIMZIA.xml:S3:14397:7	O
,	CIMZIA.xml:S3:14404:1	O
etanercept	CIMZIA.xml:S3:14406:10	B-DrugClass
,	CIMZIA.xml:S3:14416:1	O
with	CIMZIA.xml:S3:14418:4	O
no	CIMZIA.xml:S3:14423:2	O
added	CIMZIA.xml:S3:14426:5	O
benefit	CIMZIA.xml:S3:14432:7	O
compared	CIMZIA.xml:S3:14440:8	O
to	CIMZIA.xml:S3:14449:2	O
etanercept	CIMZIA.xml:S3:14452:10	O
alone	CIMZIA.xml:S3:14463:5	O
.	CIMZIA.xml:S3:14468:1	O

A	CIMZIA.xml:S3:14470:1	O
higher	CIMZIA.xml:S3:14472:6	O
risk	CIMZIA.xml:S3:14479:4	B-Factor
of	CIMZIA.xml:S3:14484:2	O
serious	CIMZIA.xml:S3:14487:7	B-Severity
infections	CIMZIA.xml:S3:14495:10	B-AdverseReaction
was	CIMZIA.xml:S3:14506:3	O
also	CIMZIA.xml:S3:14510:4	O
observed	CIMZIA.xml:S3:14515:8	O
in	CIMZIA.xml:S3:14524:2	O
combination	CIMZIA.xml:S3:14527:11	O
use	CIMZIA.xml:S3:14539:3	O
of	CIMZIA.xml:S3:14543:2	O
TNF	CIMZIA.xml:S3:14546:3	B-DrugClass
blockers	CIMZIA.xml:S3:14550:8	I-DrugClass
with	CIMZIA.xml:S3:14559:4	O
abatacept	CIMZIA.xml:S3:14564:9	O
and	CIMZIA.xml:S3:14574:3	O
rituximab	CIMZIA.xml:S3:14578:9	O
.	CIMZIA.xml:S3:14587:1	O

Because	CIMZIA.xml:S3:14589:7	O
of	CIMZIA.xml:S3:14597:2	O
the	CIMZIA.xml:S3:14600:3	O
nature	CIMZIA.xml:S3:14604:6	O
of	CIMZIA.xml:S3:14611:2	O
the	CIMZIA.xml:S3:14614:3	O
adverse	CIMZIA.xml:S3:14618:7	O
events	CIMZIA.xml:S3:14626:6	O
seen	CIMZIA.xml:S3:14633:4	O
with	CIMZIA.xml:S3:14638:4	O
this	CIMZIA.xml:S3:14643:4	O
combination	CIMZIA.xml:S3:14648:11	O
therapy	CIMZIA.xml:S3:14660:7	O
,	CIMZIA.xml:S3:14667:1	O
similar	CIMZIA.xml:S3:14669:7	O
toxicities	CIMZIA.xml:S3:14677:10	O
may	CIMZIA.xml:S3:14688:3	O
also	CIMZIA.xml:S3:14692:4	O
result	CIMZIA.xml:S3:14697:6	O
from	CIMZIA.xml:S3:14704:4	O
the	CIMZIA.xml:S3:14709:3	O
use	CIMZIA.xml:S3:14713:3	O
of	CIMZIA.xml:S3:14717:2	O
CIMZIA	CIMZIA.xml:S3:14720:6	O
in	CIMZIA.xml:S3:14727:2	O
this	CIMZIA.xml:S3:14730:4	O
combination	CIMZIA.xml:S3:14735:11	O
.	CIMZIA.xml:S3:14746:1	O

Therefore	CIMZIA.xml:S3:14748:9	O
,	CIMZIA.xml:S3:14757:1	O
the	CIMZIA.xml:S3:14759:3	O
use	CIMZIA.xml:S3:14763:3	O
of	CIMZIA.xml:S3:14767:2	O
CIMZIA	CIMZIA.xml:S3:14770:6	O
in	CIMZIA.xml:S3:14777:2	O
combination	CIMZIA.xml:S3:14780:11	O
with	CIMZIA.xml:S3:14792:4	O
other	CIMZIA.xml:S3:14797:5	O
biological	CIMZIA.xml:S3:14803:10	O
DMARDs	CIMZIA.xml:S3:14814:6	O
is	CIMZIA.xml:S3:14821:2	O
not	CIMZIA.xml:S3:14824:3	O
recommended	CIMZIA.xml:S3:14828:11	O
[	CIMZIA.xml:S3:14840:1	O
see	CIMZIA.xml:S3:14841:3	O
Drug	CIMZIA.xml:S3:14846:4	O
Interactions	CIMZIA.xml:S3:14851:12	O
(	CIMZIA.xml:S3:14864:1	O
7.1	CIMZIA.xml:S3:14865:3	O
)	CIMZIA.xml:S3:14868:1	O
]	CIMZIA.xml:S3:14871:1	O
.	CIMZIA.xml:S3:14872:1	O

5.9	CIMZIA.xml:S3:14883:3	O
Autoimmunity	CIMZIA.xml:S3:14887:12	O

Treatment	CIMZIA.xml:S3:14905:9	O
with	CIMZIA.xml:S3:14915:4	O
CIMZIA	CIMZIA.xml:S3:14920:6	O
may	CIMZIA.xml:S3:14927:3	B-Factor
result	CIMZIA.xml:S3:14931:6	O
in	CIMZIA.xml:S3:14938:2	O
the	CIMZIA.xml:S3:14941:3	O
formation	CIMZIA.xml:S3:14945:9	B-AdverseReaction
of	CIMZIA.xml:S3:14955:2	I-AdverseReaction
autoantibodies	CIMZIA.xml:S3:14958:14	I-AdverseReaction
and	CIMZIA.xml:S3:14973:3	O
rarely	CIMZIA.xml:S3:14977:6	O
,	CIMZIA.xml:S3:14983:1	O
in	CIMZIA.xml:S3:14985:2	O
the	CIMZIA.xml:S3:14988:3	O
development	CIMZIA.xml:S3:14992:11	O
of	CIMZIA.xml:S3:15004:2	O
a	CIMZIA.xml:S3:15007:1	O
lupus	CIMZIA.xml:S3:15009:5	B-AdverseReaction
-	CIMZIA.xml:S3:15014:1	I-AdverseReaction
like	CIMZIA.xml:S3:15015:4	I-AdverseReaction
syndrome	CIMZIA.xml:S3:15020:8	I-AdverseReaction
.	CIMZIA.xml:S3:15028:1	O

If	CIMZIA.xml:S3:15030:2	O
a	CIMZIA.xml:S3:15033:1	O
patient	CIMZIA.xml:S3:15035:7	O
develops	CIMZIA.xml:S3:15043:8	O
symptoms	CIMZIA.xml:S3:15052:8	O
suggestive	CIMZIA.xml:S3:15061:10	O
of	CIMZIA.xml:S3:15072:2	O
a	CIMZIA.xml:S3:15075:1	O
lupus	CIMZIA.xml:S3:15077:5	O
-	CIMZIA.xml:S3:15082:1	O
like	CIMZIA.xml:S3:15083:4	O
syndrome	CIMZIA.xml:S3:15088:8	O
following	CIMZIA.xml:S3:15097:9	O
treatment	CIMZIA.xml:S3:15107:9	O
with	CIMZIA.xml:S3:15117:4	O
CIMZIA	CIMZIA.xml:S3:15122:6	O
,	CIMZIA.xml:S3:15128:1	O
discontinue	CIMZIA.xml:S3:15130:11	O
treatment	CIMZIA.xml:S3:15142:9	O
[	CIMZIA.xml:S3:15152:1	O
see	CIMZIA.xml:S3:15153:3	O
Adverse	CIMZIA.xml:S3:15158:7	O
Reactions	CIMZIA.xml:S3:15166:9	O
(	CIMZIA.xml:S3:15176:1	O
6.1	CIMZIA.xml:S3:15177:3	O
)	CIMZIA.xml:S3:15180:1	O
]	CIMZIA.xml:S3:15183:1	O
.	CIMZIA.xml:S3:15186:1	O

5.10	CIMZIA.xml:S3:15195:4	O
Immunizations	CIMZIA.xml:S3:15200:13	O

Patients	CIMZIA.xml:S3:15219:8	O
treated	CIMZIA.xml:S3:15228:7	O
with	CIMZIA.xml:S3:15236:4	O
CIMZIA	CIMZIA.xml:S3:15241:6	O
may	CIMZIA.xml:S3:15248:3	O
receive	CIMZIA.xml:S3:15252:7	O
vaccinations	CIMZIA.xml:S3:15260:12	O
,	CIMZIA.xml:S3:15272:1	O
except	CIMZIA.xml:S3:15274:6	O
for	CIMZIA.xml:S3:15281:3	O
live	CIMZIA.xml:S3:15285:4	O
or	CIMZIA.xml:S3:15290:2	O
live	CIMZIA.xml:S3:15293:4	O
attenuated	CIMZIA.xml:S3:15298:10	O
vaccines	CIMZIA.xml:S3:15309:8	O
.	CIMZIA.xml:S3:15317:1	O

No	CIMZIA.xml:S3:15319:2	O
data	CIMZIA.xml:S3:15322:4	O
are	CIMZIA.xml:S3:15327:3	O
available	CIMZIA.xml:S3:15331:9	O
on	CIMZIA.xml:S3:15341:2	O
the	CIMZIA.xml:S3:15344:3	O
response	CIMZIA.xml:S3:15348:8	O
to	CIMZIA.xml:S3:15357:2	O
live	CIMZIA.xml:S3:15360:4	O
vaccinations	CIMZIA.xml:S3:15365:12	O
or	CIMZIA.xml:S3:15378:2	O
the	CIMZIA.xml:S3:15381:3	O
secondary	CIMZIA.xml:S3:15385:9	O
transmission	CIMZIA.xml:S3:15395:12	O
of	CIMZIA.xml:S3:15408:2	O
infection	CIMZIA.xml:S3:15411:9	O
by	CIMZIA.xml:S3:15421:2	O
live	CIMZIA.xml:S3:15424:4	O
vaccines	CIMZIA.xml:S3:15429:8	O
in	CIMZIA.xml:S3:15438:2	O
patients	CIMZIA.xml:S3:15441:8	O
receiving	CIMZIA.xml:S3:15450:9	O
CIMZIA	CIMZIA.xml:S3:15460:6	O
.	CIMZIA.xml:S3:15466:1	O

In	CIMZIA.xml:S3:15472:2	O
a	CIMZIA.xml:S3:15475:1	O
placebo	CIMZIA.xml:S3:15477:7	O
-	CIMZIA.xml:S3:15484:1	O
controlled	CIMZIA.xml:S3:15485:10	O
clinical	CIMZIA.xml:S3:15496:8	O
trial	CIMZIA.xml:S3:15505:5	O
of	CIMZIA.xml:S3:15511:2	O
patients	CIMZIA.xml:S3:15514:8	O
with	CIMZIA.xml:S3:15523:4	O
rheumatoid	CIMZIA.xml:S3:15528:10	O
arthritis	CIMZIA.xml:S3:15539:9	O
,	CIMZIA.xml:S3:15548:1	O
no	CIMZIA.xml:S3:15550:2	O
difference	CIMZIA.xml:S3:15553:10	O
was	CIMZIA.xml:S3:15564:3	O
detected	CIMZIA.xml:S3:15568:8	O
in	CIMZIA.xml:S3:15577:2	O
antibody	CIMZIA.xml:S3:15580:8	O
response	CIMZIA.xml:S3:15589:8	O
to	CIMZIA.xml:S3:15598:2	O
vaccine	CIMZIA.xml:S3:15601:7	O
between	CIMZIA.xml:S3:15609:7	O
CIMZIA	CIMZIA.xml:S3:15617:6	O
and	CIMZIA.xml:S3:15624:3	O
placebo	CIMZIA.xml:S3:15628:7	O
treatment	CIMZIA.xml:S3:15636:9	O
groups	CIMZIA.xml:S3:15646:6	O
when	CIMZIA.xml:S3:15653:4	O
the	CIMZIA.xml:S3:15658:3	O
pneumococcal	CIMZIA.xml:S3:15662:12	O
polysaccharide	CIMZIA.xml:S3:15675:14	O
vaccine	CIMZIA.xml:S3:15690:7	O
and	CIMZIA.xml:S3:15698:3	O
influenza	CIMZIA.xml:S3:15702:9	O
vaccine	CIMZIA.xml:S3:15712:7	O
were	CIMZIA.xml:S3:15720:4	O
administered	CIMZIA.xml:S3:15725:12	O
concurrently	CIMZIA.xml:S3:15738:12	O
with	CIMZIA.xml:S3:15751:4	O
CIMZIA	CIMZIA.xml:S3:15756:6	O
.	CIMZIA.xml:S3:15762:1	O

Similar	CIMZIA.xml:S3:15764:7	O
proportions	CIMZIA.xml:S3:15772:11	O
of	CIMZIA.xml:S3:15784:2	O
patients	CIMZIA.xml:S3:15787:8	O
developed	CIMZIA.xml:S3:15796:9	O
protective	CIMZIA.xml:S3:15806:10	O
levels	CIMZIA.xml:S3:15817:6	O
of	CIMZIA.xml:S3:15824:2	O
anti	CIMZIA.xml:S3:15827:4	O
-	CIMZIA.xml:S3:15831:1	O
vaccine	CIMZIA.xml:S3:15832:7	O
antibodies	CIMZIA.xml:S3:15840:10	O
between	CIMZIA.xml:S3:15851:7	O
CIMZIA	CIMZIA.xml:S3:15859:6	O
and	CIMZIA.xml:S3:15866:3	O
placebo	CIMZIA.xml:S3:15870:7	O
treatment	CIMZIA.xml:S3:15878:9	O
groups	CIMZIA.xml:S3:15888:6	O
;	CIMZIA.xml:S3:15894:1	O
however	CIMZIA.xml:S3:15896:7	O
patients	CIMZIA.xml:S3:15904:8	O
receiving	CIMZIA.xml:S3:15913:9	O
CIMZIA	CIMZIA.xml:S3:15923:6	O
and	CIMZIA.xml:S3:15930:3	O
concomitant	CIMZIA.xml:S3:15934:11	O
methotrexate	CIMZIA.xml:S3:15946:12	O
had	CIMZIA.xml:S3:15959:3	O
a	CIMZIA.xml:S3:15963:1	O
lower	CIMZIA.xml:S3:15965:5	O
humoral	CIMZIA.xml:S3:15971:7	O
response	CIMZIA.xml:S3:15979:8	O
compared	CIMZIA.xml:S3:15988:8	O
with	CIMZIA.xml:S3:15997:4	O
patients	CIMZIA.xml:S3:16002:8	O
receiving	CIMZIA.xml:S3:16011:9	O
CIMZIA	CIMZIA.xml:S3:16021:6	O
alone	CIMZIA.xml:S3:16028:5	O
.	CIMZIA.xml:S3:16033:1	O

The	CIMZIA.xml:S3:16035:3	O
clinical	CIMZIA.xml:S3:16039:8	O
significance	CIMZIA.xml:S3:16048:12	O
of	CIMZIA.xml:S3:16061:2	O
this	CIMZIA.xml:S3:16064:4	O
is	CIMZIA.xml:S3:16069:2	O
unknown	CIMZIA.xml:S3:16072:7	O
.	CIMZIA.xml:S3:16079:1	O

5.11	CIMZIA.xml:S3:16088:4	O
Immunosuppression	CIMZIA.xml:S3:16093:17	O

Since	CIMZIA.xml:S3:16116:5	O
TNF	CIMZIA.xml:S3:16122:3	O
mediates	CIMZIA.xml:S3:16126:8	O
inflammation	CIMZIA.xml:S3:16135:12	O
and	CIMZIA.xml:S3:16148:3	O
modulates	CIMZIA.xml:S3:16152:9	O
cellular	CIMZIA.xml:S3:16162:8	O
immune	CIMZIA.xml:S3:16171:6	O
responses	CIMZIA.xml:S3:16178:9	O
,	CIMZIA.xml:S3:16187:1	O
the	CIMZIA.xml:S3:16189:3	O
possibility	CIMZIA.xml:S3:16193:11	O
exists	CIMZIA.xml:S3:16205:6	O
for	CIMZIA.xml:S3:16212:3	O
TNF	CIMZIA.xml:S3:16216:3	O
blockers	CIMZIA.xml:S3:16220:8	O
,	CIMZIA.xml:S3:16228:1	O
including	CIMZIA.xml:S3:16230:9	O
CIMZIA	CIMZIA.xml:S3:16240:6	O
,	CIMZIA.xml:S3:16246:1	O
to	CIMZIA.xml:S3:16248:2	O
affect	CIMZIA.xml:S3:16251:6	O
host	CIMZIA.xml:S3:16258:4	O
defenses	CIMZIA.xml:S3:16263:8	O
against	CIMZIA.xml:S3:16272:7	O
infections	CIMZIA.xml:S3:16280:10	O
and	CIMZIA.xml:S3:16291:3	O
malignancies	CIMZIA.xml:S3:16295:12	O
.	CIMZIA.xml:S3:16307:1	O

The	CIMZIA.xml:S3:16309:3	O
impact	CIMZIA.xml:S3:16313:6	O
of	CIMZIA.xml:S3:16320:2	O
treatment	CIMZIA.xml:S3:16323:9	O
with	CIMZIA.xml:S3:16333:4	O
CIMZIA	CIMZIA.xml:S3:16338:6	O
on	CIMZIA.xml:S3:16345:2	O
the	CIMZIA.xml:S3:16348:3	O
development	CIMZIA.xml:S3:16352:11	O
and	CIMZIA.xml:S3:16364:3	O
course	CIMZIA.xml:S3:16368:6	O
of	CIMZIA.xml:S3:16375:2	O
malignancies	CIMZIA.xml:S3:16378:12	O
,	CIMZIA.xml:S3:16390:1	O
as	CIMZIA.xml:S3:16392:2	O
well	CIMZIA.xml:S3:16395:4	O
as	CIMZIA.xml:S3:16400:2	O
active	CIMZIA.xml:S3:16403:6	O
and	CIMZIA.xml:S3:16410:3	O
or	CIMZIA.xml:S3:16414:2	O
chronic	CIMZIA.xml:S3:16417:7	O
infections	CIMZIA.xml:S3:16425:10	O
,	CIMZIA.xml:S3:16435:1	O
is	CIMZIA.xml:S3:16437:2	O
not	CIMZIA.xml:S3:16440:3	O
fully	CIMZIA.xml:S3:16444:5	O
understood	CIMZIA.xml:S3:16450:10	O
[	CIMZIA.xml:S3:16461:1	O
see	CIMZIA.xml:S3:16462:3	O
Warnings	CIMZIA.xml:S3:16467:8	O
and	CIMZIA.xml:S3:16476:3	O
Precautions	CIMZIA.xml:S3:16480:11	O
(	CIMZIA.xml:S3:16492:1	O
5.1	CIMZIA.xml:S3:16493:3	O
,	CIMZIA.xml:S3:16498:1	O
5.2	CIMZIA.xml:S3:16501:3	O
,	CIMZIA.xml:S3:16506:1	O
5.5	CIMZIA.xml:S3:16509:3	O
)	CIMZIA.xml:S3:16512:1	O
and	CIMZIA.xml:S3:16515:3	O
Adverse	CIMZIA.xml:S3:16520:7	O
Reactions	CIMZIA.xml:S3:16528:9	O
(	CIMZIA.xml:S3:16538:1	O
6.1	CIMZIA.xml:S3:16539:3	O
)	CIMZIA.xml:S3:16542:1	O
]	CIMZIA.xml:S3:16545:1	O
.	CIMZIA.xml:S3:16548:1	O

The	CIMZIA.xml:S3:16550:3	O
safety	CIMZIA.xml:S3:16554:6	O
and	CIMZIA.xml:S3:16561:3	O
efficacy	CIMZIA.xml:S3:16565:8	O
of	CIMZIA.xml:S3:16574:2	O
CIMZIA	CIMZIA.xml:S3:16577:6	O
in	CIMZIA.xml:S3:16584:2	O
patients	CIMZIA.xml:S3:16587:8	O
with	CIMZIA.xml:S3:16596:4	O
immunosuppression	CIMZIA.xml:S3:16601:17	O
has	CIMZIA.xml:S3:16619:3	O
not	CIMZIA.xml:S3:16623:3	O
been	CIMZIA.xml:S3:16627:4	O
formally	CIMZIA.xml:S3:16632:8	O
evaluated	CIMZIA.xml:S3:16641:9	O
.	CIMZIA.xml:S3:16650:1	O
